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Summary
Point-of-care (POC) testing has great potential for the management and diagnosis
of disease. POC devices allow for testing close to the patient permitting rapid
diagnosis, prompt treatment initiation, and when needed, quick referral to other
health-care units. They have the potential to be lower-cost, more robust, and more
user-friendly than traditional medical devices. For these reasons, POC diagnostic
tests are a promising approach for the developing world, where there is also the
most urgent need for new health technologies. In this context, this thesis is focused
in the development of POC in vitro diagnostic tests for global health.
Considering that the resources for developing POC devices for low-resource set-
tings are limited, during Chapter 2 we focused on setting health research priorities
to aid test developers setting their targets to increase the impact of the technology.
The criteria for prioritization considered were very broad and took into account
the impact of a new test on the burden of disease, the availability and expense of
disease treatments, the technological investment to develop a new device, and the
bioethical principles.
Chapter 3 describes the development of a medical device that can be easily
manufactured in limited resources laboratories: paper diagnostic chemical dip-
sticks to detect biomarkers present in biological fluids produced with domestic
inkjet printers and simple ink preparation recipes. This fabrication technique for
diagnostic strips was tested for the detection of iodine deficiency, a severe global
health problem worldwide. In this chapter we present successful experiments for
chemical inks preparation, printing on paper, detection of iodine in the concen-
trations present in the urine, and guidelines for new ink development to target
other disease biomarkers. This simple and versatile manufacturing process for di-
agnostic tests would allow hospitals and laboratories with limited infrastructure to
design diagnostics for relevant diseases in a format and quantity adapted to each
community needs.
Unfortunately, not all diseases can be diagnosed using simple chemical dipstick
assays and more complex diagnostic devices are required. Chapter 4 is focused
on the development of a low-cost, real-time, point-of-care PCR and RT-PCR sys-
tems for quantitative detection of DNA and RNA-based pathogens. Our systems
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are based on continuous-flow PCR which maintains fixed temperatures zones and
pushes the PCR solution between heated areas allowing for faster heat transfer
and as a result, faster PCRs. Both PCR and RT-PCR systems were built around
disposable microfluidic chips designed to be economically produced industrially
by roll-to-roll embossing methods. The optical system allows for pathogen de-
tection via real-time fluorescence measurements. To demonstrate the function of
the chips, two infectious bacteria and one viral target were selected: Chlamydia
trachomatis, Escherichia coli O157:H7, and Ebola virus. For the three pathogens,
different flow velocities were tested, the limit of detection of the system was de-
termined, and PCR efficiencies were calculated. Our successful results, and the
versatility of our system, make it promising for the detection of other DNA and
RNA-based pathogens such as Zika or chikungunya, which constitute global health
threats worldwide.
The two in vitro diagnostic tests presented in this thesis are good examples of
promising POC diagnostic devices appropriate for global health.
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Resumen
Los test de tipo ‘point-of-care’ (POC) presentan un gran potencial para el manejo
y el diagno´stico de enfermedades. Los dispositivos POC permiten la realizacio´n
de pruebas cl´ınicas cerca del paciente, permitiendo as´ı un diagno´stico ra´pido, una
pronta iniciacio´n de tratamientos, y en caso necesario, una derivacio´n ra´pida a
otros centros me´dicos. Estos dispositivos tienen adema´s el potencial de ser ma´s
econo´micos, ma´s robustos, y ma´s fa´ciles de usar que los dispositivos me´dicos tradi-
cionales. Por estos motivos, los dispositivos me´dicos de tipo POC se consideran
prometedores para los pa´ıses en v´ıas de desarrollo, los cuales son tambie´n los que
necesitan de forma ma´s urgente nuevas tecnolog´ıas me´dicas. En este contexto, esta
tesis se centra en el desarrollo de dispositivos me´dicos de diagno´stico in vitro de
tipo POC para salud global.
Teniendo en cuenta que los recursos para el desarrollo de dispositivos POC para
pa´ıses con bajos recursos son limitados, el Cap´ıtulo 2 se enfoca en el desarrollo de
prioridades de investigacio´n en salud. Mediante el establecimiento de estas prior-
idades se pretende facilitar la seleccio´n de objetivos a fabricantes de dispositivos
me´dicos, as´ı como incrementar el impacto de las nuevas tecnolog´ıas desarrolladas.
Los criterios de priorizacio´n considerados son muy amplios e incluyen el impacto
de un nuevo test en la incidencia de una enfermedad, la disponibilidad y precio de
los tratamientos de las enfermedades, la inversio´n tecnolo´gica para el desarrollo de
un nuevo dispositivo, y los principios bioe´ticos.
El Cap´ıtulo 3 describe el desarrollo de un dispositivo me´dico sencillo que
puede ser fabricado fa´cilmente en laboratorios con escasos recursos: tiras reac-
tivas de diagno´stico de papel para la deteccio´n de biomarcadores presentes en
fluidos biolo´gicos fabricados con impresoras de chorro de tinta dome´sticas y con
recetas sencillas para la preparacio´n de las tintas. Esta te´cnica de fabricacio´n de
tiras reactivas de diagno´stico fue probada para la deteccio´n de deficiencia de yodo,
un problema severo de salud global en el mundo. En este cap´ıtulo se presentan
experimentos de preparacio´n de tintas qu´ımicas, impresio´n en papel, deteccio´n
de yodo en las concentraciones presentes en la orina, y directrices para el desar-
rollo de nuevas tintas para la deteccio´n de otros biomarcadores de enfermedades.
Este simple y versa´til proceso de fabricacio´n de tests de diagno´stico permitir´ıa a
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hospitales y laboratorios con pocos recursos disen˜ar sus propios diagno´sticos para
enfermedades relevantes, en una forma y cantidad adaptada a las necesidades de
cada comunidad.
Desafortunadamente, no todas las enfermedades pueden diagnosticarse usando
sencillas tiras reactivas de diagno´stico, y frecuentemente se necesitan dispositivos
ma´s complejos. El Cap´ıtulo 4 esta´ enfocado en el desarrollo de dispositivos de PCR
y RT-PCR de bajo coste, de tiempo-real, y de tipo POC que permiten detectar
cuantitativamente pato´genos basados en DNA y RNA respectivamente. Nuestro
sistema se basa en PCR de flujo continuo, el cual mantiene zonas de temperatura
fijas y empuja la solucio´n de PCR entre las a´reas calefactadas, permitiendo as´ı una
transferencia de calor ma´s ra´pida y consecuentemente, PCRs ma´s veloces. Ambos
sistemas de PCR y RT-PCR fueron fabricados en base a un chip microflu´ıdico
desechable disen˜ado para ser producido a bajo coste industrialmente mediante
me´todos de ‘roll-to-roll’. El sistema o´ptico permite la deteccio´n de pato´genos en
tiempo real mediante medidas de fluorescencia. Para demostrar la funcio´n del chip,
dos bacterias infecciosas y un virus fueron seleccionados: Chlamydia trachomatis,
Escherichia coli O157:H7, y Ebola virus. Para los tres pato´genos, se probaron
diferentes velocidades de flujo, se determino´ el l´ımite de deteccio´n del sistema, y
se calcularon las eficiencias de las PCRs. El e´xito de los resultados obtenidos y
la versatilidad del sistema, hace que estos dispositivos se consideren prometedores
para el diagno´stico de otros pato´genos como Zika o chikungunya, que constituyen
amenazas mundiales a la salud pu´blica.
Ambos dispositivos de diagno´stico in vitro presentados en esta tesis son buenos
ejemplos de dispositivos de diagno´stico prometedores apropiados para salud global.
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Resum
Els test de tipus ‘point-of-care’ (POC) presenten un gran potencial per al maneig
i el diagno`stic de malalties. Els dispositius POC permeten la realitzacio´ de proves
cl´ıniques prop del pacient, permetent aix´ı un diagno`stic ra`pid, una prompta ini-
ciacio´ de tractaments, i en cas necessari, una derivacio´ a`gil a altres centres me`dics.
Aquests dispositius tenen a me´s el potencial de ser me´s econo`mics, me´s robustos,
i me´s fa`cils d’usar que els dispositius me`dics tradicionals. Per aquests motius, els
dispositius me`dics de tipus POC es consideren prometedors per als pa¨ısos en vies
de desenvolupament, els quals so´n tambe´ els que necessiten de forma me´s urgent
noves tecnologies me`diques. En aquest context, aquesta tesi se centra en el desen-
volupament de dispositius me`dics de diagno`stic in vitro de tipus POC per salut
global.
Tenint en compte que els recursos per al desenvolupament i explotacio´ de dis-
positius POC per a pa¨ısos amb baixos recursos so´n limitats, el Cap´ıtol 2 s’enfoca en
el desenvolupament de prioritats d’investigacio´ en salut. Mitjanc¸ant l’establiment
d’aquestes prioritats es prete´n facilitar la seleccio´ d’objectius a fabricants d’instru-
ments me`dics, aix´ı com incrementar l’impacte de les noves tecnologies desenvolu-
pades. Els criteris de prioritzacio´ considerats so´n molt amplis i inclouen l’impacte
d’un nou test en la incide`ncia d’una malaltia, la disponibilitat i preu dels tracta-
ments de les malalties, la inversio´ tecnolo`gica per al desenvolupament d’un nou
dispositiu, i els principis bioe`tics.
El tercer cap´ıtol descriu el desenvolupament d’un dispositiu me`dic senzill que
pot ser fabricat fa`cilment en laboratoris amb escassos recursos: tires reactives de
diagno`stic de paper per a la deteccio´ de biomarcadors presents en fluids biolo`gics
fabricats amb impressores de raig de tinta dome`stiques i amb receptes senzilles
per la preparacio´ de les tintes. Aquesta te`cnica de fabricacio´ de tires reactives
de diagno`stic va ser provada per a la deteccio´ de deficie`ncia de iode, un prob-
lema sever de salut global al mo´n. En aquest cap´ıtol es presenten experiments de
preparacio´ de tintes qu´ımiques, impressio´ en paper, deteccio´ de iode en les concen-
tracions presents en l’orina, i consells per al desenvolupament de noves tintes per
a la deteccio´ d’altres biomarcadors de malalties. Aquest simple i versa`til proce´s
de fabricacio´ de tests de diagno`stic permetria a hospitals i laboratoris amb pocs
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recursos dissenyar els seus propis diagno`stics per a malalties rellevants, i en la
forma i quantitat adaptada a les necessitats de cada comunitat.
Desafortunadament, no totes les malalties es poden diagnosticar usant sen-
zilles tires reactives de diagno`stic, i frequ¨entment es necessiten dispositius me´s
complexos. El cap´ıtol 4 esta` enfocat en el desenvolupament de dispositius de PCR
i RT-PCR de baix cost, a temps real, i de tipus POC que permeten detectar quan-
titativament pato`gens basats en DNA i RNA respectivament. El nostre sistema es
basa en la utilitzacio´ de la te`cnica de PCR de flux continu. Aquest, mante´ zones
de temperatura fixes i empeny la solucio´ de PCR entre les a`rees calefactades, per-
metent aix´ı una transfere`ncia de calor me´s ra`pida i consequ¨entment, una PCR
me´s veloc¸. Tots dos sistemes de PCR i RT-PCR van ser fabricats a partir d’un xip
microflu´ıdic d’un sol u´s dissenyat per a ser produ¨ıt a baix cost industrialment mit-
janc¸ant me`todes de ‘roll-to-roll’. El sistema o`ptic permet la deteccio´ de pato`gens
en temps real mitjanc¸ant mesures de fluoresce`ncia. Per demostrar la funcio´ del
xip, es van seleccionar dos bacteris infecciosos i un virus: Chlamydia trachomatis,
Escherichia coli O157:H7, i virus de l’Ebola. Per als tres pato`gens, es van provar
diferents velocitats de flux, es va determinar el l´ımit de deteccio´ del sistema, i es
van calcular les eficie`ncies de les PCRs. L’e`xit dels resultats obtinguts i la ver-
satilitat del sistema, fa que aquests dispositius es considerin prometedors per al
diagno`stic d’altres pato`gens com Zika o chikungunya, que constitueixen amenaces
mundials a la salut pu´blica.
Tots dos dispositius de diagno`stic in vitro presentats en aquesta tesi so´n bons
exemples de dispositius de diagno`stic prometedors apropiats per a salut global.
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Chapter 1
Motivation and Aims
1.1 Motivation
Rapid and accurate diagnosis, in high- and low-income countries alike, is crucial to
deliver proper health care and improve the health of individuals and populations.1
Diagnostic medical devices play a key role for proper and successful diagnosis.
They are essential for identifying the presence and cause of a disease, selecting an
appropriate treatment, limiting the spread of a diseases in a population, avoiding
waste of resources in ineffective treatments, monitoring the evolution of a disease
or intervention, and determining drug resistances.1,2
In the early days of medicine, diagnosis was performed in the patients homes
through physician house visits, during which clinical decisions were immediately
made. As medical discoveries were made and new technologies were developed,
care then shifted to hospitals. Laboratory testing for diagnostic purposes was
performed in centralized laboratories with accurate and automated equipment that
allowed analysis of large number of samples accurately and at a relatively low-cost.3
This health provider-centered model, also known as ‘conventional diagnostics’ is
currently dominant around the world.3
The main drawback of conventional diagnostic laboratory-based is the long
turn-around time (days) from sample collection until the diagnosis is communi-
cated to the patient, mostly when testing is performed in remote areas.4 Samples
collected at rural clinics need to be transported to centralized laboratories, which
are usually located a significant distance away in large cities. At central labora-
25
tories, samples are processed in a batch manner, and then the diagnoses need to
be transmitted correctly to the health-care provider who should afterwards com-
municate it to the patient and manage clinical decisions.5 This long process line
makes challenging successful extension of centralized testing to remote settings.6
The long confirmatory diagnostic turn-arounds, and the fact that patients in rural
settings, who live far away from the clinic, are less prone to come back in a timely
manner for second medical appointments or confirmatory diagnosis, lead many
physicians to manage diseases during the first clinical encounter without waiting
for confirmatory diagnosis.5,6 Infectious diseases especially are routinely managed
with antibacterial therapy without confirmation of the causative pathogen or its
antibiotic-resistances, which lead to the overuse of antibiotics driving the increase
of antibiotic-resistant pathogens.5–9 Additionally, late diagnosis of infectious dis-
eases contributes to the spread the infection since precautions cannot be taken.10
In the case of non-communicable diseases, poor assessment of health status and
infrequent monitoring of risks factors usually implies worse disease management.10
These examples of disease mismanagement support the vital need for fast and
accurate disease diagnostic procedures.
In this context, during the last few decades, Point-Of-Care-Tests (POCT) have
arisen as rapid and accurate diagnostic devices, with the potential to combine the
accuracy and sensitivity of centralized laboratory equipment while being patient-
centered and allowing a more rapid management of clinical decisions.3,4 According
to Ehrmeyer et al. POCT can be defined as ‘patient specimens assayed at or
near the patient with the assumption that test results will be available instantly
or in a very short timeframe to assist caregivers with immediate diagnosis and/or
clinical intervention’.11 Although there is a large diversity of definitions of POC
testing, and no universal one, the characteristics that most definitions have in
common include testing close to the patient site and a short time-to-result to
allow rapid diagnosis and management of clinical decisions in the same clinical
encounter.4,5,12–14
The ability to diagnose and make clinical decisions in the same clinical en-
counter is undoubtedly the most significant characteristic of POC tests. Indeed,
it constitutes the main difference respect to traditional diagnostics.4 Figure 1.1
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shows the comparison of the process time line for conventional laboratory-based
diagnostics and POCT.
Figure 1.1: Comparison of the process time line from taking a clinical sample
until treatment initiation. A: Using conventional laboratory-based diagnostics:
which usually require several days from sample collection to treatment initiation.
B: Using POC diagnostic tests: which usually take less than 1 h from sample
collection to treatment initiation.13
Other important features of POCT are the high potential to be more simple and
cost effective than traditional medical devices.10,15 POC devices are less expensive
than equipment in centralized laboratories that perform an equivalent function.
Although the cost per test is usually lower in centralized laboratories (due to
the sample multiplexing), when considering the overall costs of sample shipping
and handling from rural or remote clinics and reporting the results back is often
comparable to the cost of a POCT.10 Other characteristics, such as user-friendly,
equipment-free and delivered to end user are also achievable for POC diagnostic
test.3,15
All these POCT features make them promising for places where timing is crit-
ical (e.g. emergency room), where laboratory facilities are nonexistent (e.g. mili-
tary or extraterrestrial), and where resources are low (e.g. developing countries).16
Diagnostics for global health are seen as the most promising users of POC and
where there is the most urgent need for new health technologies.1
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Along this line, although low- and middle-income countries account for approx-
imately 90 % of the global disease burdena, they lack essential medical devices and
almost all their available diagnostic devices were designed to be used in high-
income settings and are inappropriately complex and/or costly when considered
for international healthb applications.2,20 When these medical devices arrive to a
new setting with poor infrastructure often lacking stable sources of electricity or
clean water, they very frequently malfunction, are not properly exploited, or stay
unused, reducing and/or eliminating their intended benefit and impact.20 To max-
imize health benefits, diagnostic medical devices need to be appropriate for the
context or environment of intended use.1,16,20
Moreover, the international health community is increasingly appreciating the
pressing need for new health technologies, and especially new technologies for
health diagnostics.1 In a survey performed by internationally eminent scientists
with expertise in global health, the top-ranking overall priority was ‘modified
molecular technologies for affordable, simple diagnosis of infectious diseases’.21
Another study conducted by Bill and Melinda Gates Foundation and the United
States National Institutes of Health (NIH) identified 14 ‘Grand Challenges for
Global Health’, two of the 14 global health priorities involved diagnostics and
technologies to measure the health status of individual and populations (i.e. ‘de-
velop technologies that allow assessment of individuals for multiple conditions or
pathogens at point-of-care’, and ‘develop technologies that permit quantitative
assessment of population health status’).22
Similarly, international organizations and an increasing number of studies re-
quest new appropriate and accessible diagnostics devices designed for the unique
characteristics of developing countries.1,2 In 2006, the World Health Organization
(WHO) Sexually Transmitted Diseases Diagnostics Initiative has coined the term
‘ASSURED tests’ to describe the ideal features for diagnostic devices for develop-
ing countries. ASSURED accounts for Affordable, Sensitive (few false-negatives),
aDisease burden is defined as the impact of a health problem as measured by financial cost,
mortality, morbidity, or other indicators. It is here quantified in terms disability-adjusted life
years (DALYs). Disability-adjusted life years (DALYs) is calculated as the sum of years of
potential life lost due to premature death and the years of productive live lost due to disability.17
bInternational health is defined by Merson, Black, and Mills as ‘the application of the prin-
ciples of public health to problems and challenges that affect low and middle-income countries
and to the complex array of global and local forces that influence them’.18,19
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Specific (few false-positives), User-friendly, Rapid and Robust, Equipment-free and
Delivered to those who need it (end-users).23,24
POC diagnostics have the potential to fill the gap and fulfil most of the AS-
SURED criteria. However, nowadays the ASSURED criteria is considered too
restrictive, and fulfilling all ASSURED features might not be required for a suc-
cessful POCT. The desirable features for a POCT are highly dependent on the
specifics of the context of use. Five distinct contexts of use for POC use are gen-
erally considered: homes, communities, clinics, peripheral laboratories, hospitals.
The relative importance of each context varies from country to country and within
countries, where there may be significant differences in rural versus urban areas,
and/or public versus private sectors.4 For example, in most developing countries
with high percentage of people living in rural areas, POCT targeted to communi-
ties and clinics may have a higher impact.4
When designing diagnostic medical devices, it is beneficial for scientists and
engineers to be aware of the final targeted context of use of the device in the
early device development stages since there are different design constraints.1 For
example, within developing countries, different design criteria apply to diagnostic
devices used at reference laboratories, hospitals, rural health clinics, or at home and
also the purpose of the test may vary from referral, to monitoring, and treatment.1,4
In Table 1.1, the main design constraints of the different context of use within low-
resource countries are summarized.1
Test developers who aim to design high impact POC diagnostic tests for inter-
national health should take into account the disease prevalence and should focus
on those diseases which are in most need of diagnostic devices.16 It is remarkable
the large difference in the prevalence of the different types of diseases in high-,
middle-, and low-income countries as shown in Figure 1.2.25 While communicable
diseases, maternal and perinatal conditions, and nutritional deficiencies consti-
tute more than 55 % of the disease burden in developing countries; in high-income
countries, these diseases represent less than 6 % of the disease burden.25 New POC
diagnostic devices should focus on priority diseases in the intended place of use.
During the last decades, there has been abundant research in the area of
POC diagnostics for international health; however, readily available devices in
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Table 1.1: Design constraints for POC devices in different settings of developing
countries.1,4
Design constraints Hospital Ref. laboratory Clinic
Settings constraints
Lack of stable electricity U U S
Lack of well-equipped health infrastructure S S I
Lack of skilled personnel (end-users) U S S
Large temperature fluctuations S S I
Device constraints
Low cost of fixed instrument U S I
Low cost of disposables S I I
Rapid analysis U U I
High sensitivity and specificity I I I
Portability U S S
I: Important, S: Somewhat important, and U: Unimportant.
Figure 1.2: Distribution of disease burden (DALYs) in high-, middle-, and low-
income countries. Data from 2012.25
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the market are scarce.3,26,27 Even when the design is adequate for the context,
many promising POC devices fail when it comes to the implementation and/or
production steps.3 Devices designed and produced in developing countries have
more chances to succeed and be implemented since, among other reasons, they are
well adapted to the local conditions, can be maintained and repaired by the local
population, and count with availability of spare parts.20 However, in general, only
simple devices can be produced successfully at a low-cost in settings with scarce
infrastructure. Complex devices, such as nucleic acid or cells assays, require ma-
chines from industrialized countries for large-scale production in order to keep the
price of the device and disposables low. Many new promising devices are stuck in
the ‘R&D’ phase indefinitely because the device cannot be easily translated to the
industrial scale.
A ‘holistic approach’ to POC device design is one in which considerable at-
tention is given to the context, the end-users, the prevalent diseases, the end goal
of production and implementation of the device and which fulfills the bioethical
principles — beneficence, autonomy, justice, and no maleficence.
1.2 Aims
Given the need for fast and accurate diagnostics for international health purposes
and the importance of the holistic approach in the design of diagnostic devices,
the aim of this thesis was to apply such holistic approach to the development of
POC diagnostic devices appropriate for low-resource countries.
• Develop prioritization criteria for POC device development.
• Develop POC devices of different complexity that fulfill the holistic approach
to POC devices design that can be applied to prevalent diseases in developing
countries and are appropriate to be used at health clinics in the context of
low-resource countries.
• Characterize the POC diagnostic devices developed with diseases of high
prevalence in developing countries.
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1.3 Thesis Structure
According to these aims, the thesis is structured as follows.
In Chapter 2, several prioritization criteria for the development of POC diag-
nostic devices are described in detail. These criteria take into account the burden
of disease, disease treatments, the technologies of the devices, and the bioethical
principles. At the end of the chapter, POC devices in high need are described.
Chapter 3 is focused on the development of simple POC chemical tests in a
dipstick format that can be fully manufactured in developing countries. The assay
target are metabolites from body fluids and uses simple chemical reactions. The
characterization of the POC device developed is also presented in this chapter.
Chapter 4 is focused on the development of a more complex nucleic-acid based
device to overcome the limitations of chemical dipsticks and immunoassays and
allowing the diagnosis of diseases that cannot be detected with simpler assay for-
mats. This complex POC test was designed to be fabricated in industrialized
countries with mass production systems in order to keep low the price of the de-
vice and disposables. The POC device characterization is also presented in this
chapter.
Chapter 5 summarizes the conclusions of this thesis.
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Chapter 2
Prioritization criteria for the
development of diagnostic
medical devices
During the Motivation and Aims Chapter, the urgent need for diagnostic medical
devices was described and the characteristics of ideal POC devices for limited-
resource settings were analyzed. However, since the resources available for de-
signing and developing new POC devices are limited, there is a clear need for
prioritization.1 In this chapter, several criteria for the prioritization of diagnostic
medical devices are described in detail to aid in setting health research priori-
ties and assure optimal health intervention outputs for the available budget. The
criteria for prioritization are very broad and take into account the burden of dis-
ease, disease treatments, the technologies of the devices and bioethical principles.
A summary of the different criteria is shown in Table 2.1 followed by a detailed
description of each criterion.
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Table 2.1: Criteria for diagnostic POC medical devices prioritization.
Disease burden
1. Reducing the global disease burden
2. Expected impact of a new test on disease burden
3. Feasibility of global or local disease elimination
Treatment
4. Availability, expense and toxicity of treatment
Device
5. Feasibility of developing an appropriate test
6. Availability of tests in the market and their limitations
7. Resources and infrastructure required for POC device production
Bioethics
8. Fulfillment of the bioethical principles
2.1 Disease burden-related prioritization crite-
ria
Reducing the global disease burden is the first criterion of prioritization
according to Mabey et al.1 As a measure to estimate the importance of a disease,
Disease-Adjusted Life Years (DALYs) are used, which are defined as the sum of
years of potential life lost due to premature death and the years of productive live
lost due to disability.2 DALYs account for the years of life lost due to premature
mortality as well as disability (in order to take into account those diseases that
cause significant ill health but few direct deaths).2,3 The relative burden of disease
that most affect low-income countries is detailed in Table 2.2, where the DALYs
for diseases, conditions and injuries as grouped by the World Health Organization
(WHO) are shown. Data are presented for global, low-, middle- and high-income
groups as organized by the World Bank Group. Diseases are clustered in 3 groups.
Group 1, communicable, maternal, perinatal and nutritional conditions; group 2,
non-communicable diseases; and group 3, injuries.4
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As can be observed from Table 2.2, Group 1 of diseases represents a more
important burden of diseases in low-income countries than in high-income ones.
Those diseases have a greater potential for being eliminated when resources are
available.
The biggest percentage of DALYS within Group 1 corresponds to infectious
diseases.4 As expected, infectious diseases represent a large burden of disease in
developing countries (39.6 % total DALYs in low-income countries compared to
4.9 % total DALYs in high-income countries).4 Figure 2.1 shows the DALYS lost
due to different infectious diseases, as a proportion of the total caused by infection
for low-income countries. It is remarkable that only 3 diseases, the trifecta of
tuberculosis, HIV/AIDS, and malaria, represent 36.9 % of the disease burden
caused by infection and 12.6 % of the total disease burden in developing countries.4
Figure 2.1: DALYs lost due to different infectious diseases as a proportion of the
total caused by infection in low-income countries. Data from 2012.4
Other highly prevalent infectious diseases are respiratory infections, and di-
arrheal diseases, which account for 23.7 % and 16.7 % of the DALYs caused by
infection in low-income countries respectively.4 These diseases are also the most
important causes of death of post-neonatal children under the age of five globally.4
Most of child deaths were concentrated in developing regions, with African and
South Asian countries the most affected.4,5 Sexually-transmitted infections, other
than HIV/AIDS (such as hepatitis B and C, Chlamydia trachomatis, gonorrhea,
and syphilis), are also responsible for a significant disease burden.3
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It is remarkable that most of the infectious diseases that are common in the
developing world are treatable, and access to drugs has improved significantly
over the past decade with the arrival of drug-access campaigns, mass treatment
programs, and public resources.1 However, the lack for accurate and rapid diagnos-
tics remains a major obstacle for disease control. If appropriate diagnostic tests
were available, the burden of infectious diseases in the developing world could be
considerably reduced.1
The next subgroup within Group 1 of diseases are maternal and neonatal
conditions. They significantly contribute to the DALYs of developing countries
(14.5 %).4 It is noteworthy that most of the deaths for children under 5 occur
within the first month of life. Prematurity, intrapartum-related complications
(including birth asphyxia), neonatal sepsis and infections, and congenital abnor-
malities are among the most important causes of neonatal death.4
Nutritional deficiencies represent an important part of the DALYs of low- and
middle-income countries (5.2 % and 2.6 % respectively); with Sub-Saharan Africa
being the most affected area.3,4 Malnutrition is the single most important con-
tributing cause to the disease burden.3,6 Malnourished children are more prone to
suffer and/or die from other diseases. Anemia, vitamin A, and iodine deficiency are
the most common or severe micronutrient deficiencies worldwide.7 Usually treat-
ments are simple and available, however better diagnostics are needed to improve
epidemiological surveillance and help to attract international aid.7,8 In Table 2.3
the leading causes of DALYs for children under 5 are shown, as it can be observed,
nutritional deficiencies are responsible for 8,802 DALYs per 100,000 population in
developing countries, while in developed countries they account for 500 DALYs for
the same amount of population (more than a 17 factor difference).4
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Non-communicable diseases represent an important 30 % of the disease bur-
den within low-income countries; however, unlike communicable diseases, non-
communicable diseases are usually underestimated.3,4 Cardiovascular diseases, can-
cer, mental and behavioral disorders, and musculoskeletal diseases are the condi-
tions that contribute the most to the disease burden as can be observed in Fig-
ure 2.2.4 As life expectancy and quality of life increase in developing regions, the
burden of disease will gradually shift to non-communicable diseases, resembling
more and more the disease burden of high-income countries.3 This shift is intensi-
fied due to the increase of diets rich in sugars and saturated fats, contributing to the
increase of obesity and diabetes in low- and middle-income countries.3 Although
diagnostics for non-communicable diseases are already available in developed coun-
tries, appropriate diagnostics adapted to the specific conditions encountered in
low-resource settings are needed to face the increase of these conditions.3
Figure 2.2: DALYs lost due to different non-communicable diseases as a proportion
of the total caused by infection in low-income countries. Data from 2012.4
A population subgroup very vulnerable which deserves attention are children
under the age of 5. In 2012, 6.6 million children died before reaching their fifth
birthday; almost all (99 %) of these deaths occurred in low- and middle-income
countries.9 Diseases that affect children are the ones that contribute more to the
increase of DALYs since they have a higher potential to result in the loss of many
years of potentially healthy and productive life.2 Table 2.3 summarizes the ten
leading causes of DALYs for children under the age of 5 in low-, middle-, and
high-income countries and the percentage of each cause is provided as well as the
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DALYs per 100,000 population.4 It is observed that neonatal conditions are the
first contributing factor to DALYs for low-, middle-, and high-income settings
and in all the cases they contribute between 30–40 % of the total disease bur-
den; however, when comparing DALYs in a population of 100,000 habitants, they
are more than 10 times higher in low-income countries compared to high-income
ones.4 In developing countries respiratory infections, diarrheal diseases, malaria,
and nutritional deficiencies are among the most important contributing factors to
DALYs.4
Summarizing this first prioritization criteria, Group 1 diseases, the traditional
diseases of the poor, still constitute the most important difference on the disease
burden between low- and high-income countries. More efforts should be directed
towards the diagnosis of communicable, maternal and neonatal conditions, and
nutritional deficiencies. Having said this, non-communicable diseases should not
be forgotten, which are expected to increase as the quality of life improves in de-
veloping regions.
The expected impact of a new test on disease burden is considered the
second criterion for prioritization by Mabey et al.1 Diseases that can be clinically
identified through its symptoms are in less need for POC diagnostics, since they
can be syndromically treated. Diseases which have few, if any, symptoms but can
lead to devastating consequences are diseases for which diagnostic devices can have
a very high impact.1 Gonorrhea and chlamydial infections are often asymptomatic,
and when untreated they can lead to pelvic inflammatory disease, ectopic preg-
nancy or infertility.10 Syphilis is also often asymptomatic during pregnancy but
significantly increases the risks of stillbirth, spontaneous abortion, prematurity,
clinical manifestations of congenital syphilis, infant death, and late sequelae.11
Nutritional deficiencies are also a good example of conditions that can be asymp-
tomatic. Malnourished people and specially children are weaker, grow poorly,
and are more susceptible to infectious diseases.6 These diseases and conditions are
examples of diseases which may only be detected by screening and treating popu-
lations at risk, for which POC diagnostics are very likely to have a high impact.1,10
44
Additionally, it is remarkable that although some diseases that can be de-
tected through its symptoms, it is important to perform periodic identification of
pathogens responsible of the diseases. For example, for syndromic diseases such
as pneumonia and diarrhea, it is recommended to periodically identify changes in
disease spectrum and antimicrobial susceptibility to avoid the rise of antibiotic re-
sistances.1 This prioritization criterion highlights the need of new POC diagnostic
devices for diseases such as chlamydial, gonorrhea and syphilis infections.
Feasibility of global or local disease elimination is the third criterion
that should be considered regarding diseases for POC development prioritization.1
Some infectious diseases are expected to be soon eliminated, either globally or
regionally. Polio, guinea worm, leprosy, trachoma, onchocerciasis, syphilis, South
American trypanomiasis or lymphatic filariasis are some of them.1,12 Although
these diseases are targeted for elimination, there is still a high need for diagnos-
tics devices for surveillance to avoid resistant strains to re-emerge.1 Although the
disease burden of many of these diseases is low, when deciding priorities for POC
device development, the benefits of disease elimination should be taken into ac-
count.1 This prioritization criterion highlights the need of new POC devices for
diseases targeted for elimination.
2.2 Treatment-related prioritization criteria
Availability, expense and toxicity of treatment (criterion 4) is another im-
portant criterion for prioritization. Diseases that require expensive and toxic treat-
ments require a confirmatory diagnosis before the treatment can be initiated since
they never justify a presumptive treatment.1 For these diseases there is urgent need
for specific and sensitive diagnostic devices. Visceral leishmaniosis and African try-
panosomiasis, are examples of these types of diseases in urgent need for appropriate
diagnostics.1,13
In the case of diseases with high morbidity and mortality and widely available
inexpensive treatments, it might seem more cost effective to first treat all pre-
sumptive cases in endemic areas without confirmatory diagnosis. However, this
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practice might lead to the increase of resistant strains and the subsequent need
of new drugs, which at the end might be more costly.1,14 Malaria treatment with
chloroquine is an example of this practice, chloroquine treatment has been re-
commended for all children with fever in malaria-endemic areas.1,15 However new
resistant strains are now common and the alternative treatments are more expen-
sive. Looking at this practice retrospectively, it would probably had been more
cost-effective to only treat confirmed cases and avoid or at least slow down the rise
of new resistant strains.14,16,17
It is remarkable that most of the infectious diseases that are common in the
developing world are treatable, and access to drugs has improved significantly over
the past decade with the arrival of drug-access campaigns, mass treatment pro-
grams and public resources.1 However, the lack for accurate and rapid diagnostics
remains a major obstacle for disease control.1
2.3 Device-related prioritization criteria
Other important criterion for prioritization is related with the diagnostic test itself:
feasibility of developing an appropriate test (criterion 5). Priority should be
given to those tests that are easier and/or cheaper to develop using existing tech-
nology, or that are already in the market but have not been adequately evaluated
and are likely to function successfully.1 Neglected tropical diseases are a good ex-
ample of diseases that should be prioritized according to this criterion.1 Currently,
the methods for diagnosing these diseases are invasive and inadequate mostly due
to the low research priority given to these diseases.3 The WHO considers that
there are powerful, easy and inexpensive interventions to prevent and cure 9 of the
13 neglected tropical diseases (which includes lymphatic filariasis, dengue, Chagas
disease, leishmaniosis, onchocerciasis, schistosomiasis, trypanosomiasis, trachoma,
and guinea worm).18
In order to facilitate a better understanding of the advantages, challenges and
limitations of the wide variety of POC in the in research and commercial, a brief
description of the main types of POC diagnostics is provided. The complexity
and value of a diagnostic device depends on the device principle and the disease
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biomarker. Biomarkers are present in biological fluids and are defined as “char-
acteristic that is objectively measured and evaluated as an indicator of normal
biological processes, pathogenic processes, or pharmacologic responses to a thera-
peutic intervention”19,20 and can be classified as: metabolites and small molecules,
proteins, nucleic acids, and cells.21 According to the principle of the device, POC
tests are based on electrochemical/chemical, antibody/antigen, nucleic acids, and
cell reactions. Next a brief description of the main diagnostic types will be provided
in order to understand their advantages and limitations for POC purposes.
POC devices that use electrochemical methods are probably the simplest. They
allow measuring a wide range of blood, urine or other bodily fluids parameters
including electrolytes, gases, metabolites, pH, lipids, vitamins, therapeutic drugs,
drugs of abuse, hormones, inflammatory markers and cytokines, or coagulation
proteins.21,22 The main disadvantage of electrochemical assays when used for POC
purposes is the high cost of electrodes, which need to be integrated onto disposable
cartridges, considerably increasing the cost per test.21,23 When qualitative or semi-
quantitative detection is enough, paper dipsticks based on chemical reactions are
an attractive option for POC since they are very inexpensive and simple to use and
interpret.24–26 Urinary sticks to detect metabolic products in urine are probably the
best known chemical dipsticks. They usually contain impregnated reagents such
that when a bodily fluid sample with the analyte of interest is applied, it reacts
with the reagents producing a color change that allow estimating the concentration
of analyte in the sample. In many cases the color change can be read by the naked
eye or a small reading device can be used to reduce the potential operator error.26,27
Some diseases with high prevalence in developing countries, such as malnutrition
and micronutrient deficiencies can be diagnosed using electrochemical detection.28
Unfortunately, very often other detection methods are required.
Immunoassays, the most common protein assays for POC diagnostics, are based
on the interaction between antigens and antibodies to detect target proteins from
pathogens or the host immune reaction. Immunoassays have been successfully
used to detect a wide variety of pathogen types (viruses, bacteria, and parasites),
and non-communicable diseases.21 Enzyme-linked immunosorbent assay (ELISA),
is the most common immunoassay.21 However, conventional ELISAs are inappro-
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priate for POC use due to high costs of the equipment and the requirement of
trained personnel. There has been intensive research to miniaturize and reduce
the costs of traditional equipment by using microfluidics.3,21 The main challenges
that are being addressed are focused on signal detection, fluid control, and fluid
actuation and delivery.3,21
Undoubtedly, the best established immunoassay format for POC is the lateral
flow immunoassay.29 Lateral flow assays have a complex biological design but the
resulting tests are user-friendly, rapid and relatively inexpensive, making them
ideal for use at POC. Lateral flow assays usually provide binary results (yes/no),
although they can also be semi-quantitative and a few of them are even quantita-
tive. The most common lateral flow assay is for pregnancy detection, which were
developed in the 1980s.29,30 The main limitations of LFA concern two major areas:
reproducibility and sensitivity.31 Unfortunately, there are considerable variations
between strip-to-strip and the sensitivity of lateral flow immunoassays is often in-
sufficient to detect many diseases.31 Although much research is being conducted
to overcome the limitations of lateral flow immunoassays, the growing demand for
sensitivity in many disease applications is driving attention to nucleic acid-based
tests.
Nucleic acid-based assays are very promising due to its high sensitivity and
selectivity.32 However, they are more complex and historically costly and as a re-
sult mostly used in hospitals and centralized laboratories.21 Currently there is a
great interest in miniaturizing classic nucleic acid equipment, reducing its costs,
and integrating the main functionalities (sample preparation, nucleic acid ampli-
fication, and detection) into a POC device.21,32,33 To date, few POC nucleic acid
tests are marketed. A nucleic acid amplification method is usually required to
obtain enough nucleic acids for identification and quantification since the amount
of nucleic acids from a raw or purified sample is usually too low for immediate
detection.21,32 Typically, an enzymatic reaction is carried out to copy a specific
target sequence in vitro.32 Polymerase chain reaction (PCR), invented in 1986,34
is the most common amplification method. PCR is the preferred nucleic acid
amplification assay due to its simplicity, easy methodology, extensively validated
standard operating procedure and availability of reagents and equipment. Another
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advantage of nucleic acid test is its versatility. Generally, nucleic acid tests de-
veloped can be used for different biomarkers of disease with few modifications in
assay, only modifying the primers and probes.35 This easy translation of nucleic
acid assays contrast with immunoassays, which often require more intensive work
testing antibody/antigen when translating a successful lateral flow immunoassay
to target another disease biomarker. Generally, once a POC nucleic acid device is
developed, the cost of adapting that device to target other disease biomarkers is
usually significantly lower than adapting an immunoassay or cell-based device to
the detection of other diseases.
Lastly, devices that can detect cells are also of great interest. Counting and
identifying target cells in blood or other samples is promising for POC devices since
conventional methods (e.g. flow cytometry) are expensive and bulky.21,36 Full blood
cell counts are useful for the diagnosis and monitoring of diseases such as anemia or
HIV/AIDS (HIV/AIDS is monitored by counting CD4+ lymphocytes).21 Currently
there are few POC cell-based devices commercialized due to the high complexity
and as a result cost, although their presence in the market is increasing.27
All the POC devices types -electrochemical, immunoassay, nucleic acid, cell-
based– are all predicted to have a great impact; however, as previously described,
prioritization should be considered. It is remarkable, that for groups of similar
diseases and even for a single disease in many cases, several classes of assays are
required for an accurate and complete diagnosis.3
Another criterion for POC device development prioritization, which is closely
related to the previous criteria, takes into account the availability of tests in the
market and their sensitivity and specificity (criterion 6). In the appendix,
a detailed table (Table A.1) with the current methods used for the detection of
different diseases is provided. Many diseases still rely on cultures and microscopy
for their diagnosis and lack marketed rapid tests for their diagnosis.1 Prioritization
should be given to the diagnosis of diseases which lack rapid in the market and
to those which sensitivity and/or specificity is low. As an example of diseases for
which the available diagnostic test have low quality are Chlamydia trachomatis
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and tuberculosis; being microscopy and/or cultures the gold standard.20
Another criterion for prioritization takes into account the resources and in-
frastructure required for POC device production (criterion 7). Priority
should be given to those devices that can be locally produced in developing coun-
tries. Medical devices designed and manufactured in the place of use are well
adapted to the local conditions and can be maintained and repaired by locals
and count with local availability of all spare parts.37 Malfunctioning devices due
to an inappropriate design to the local conditions is unfortunately a very frequent
problem in developing countries.37 First, almost all medical devices are designed in
developed countries to be used in high-resource settings. Industry in high-resource
settings has limited interest in developing new diagnostics for the developing world
since they promise a low return of investment.37,38 Additionally, the high number of
medical devices donations, which very often do not match the recipients need, con-
tributes to this problem. Some low-income countries receive nearly 80 % of their
health-care equipment in the form of donations; however, only 10–30 % of donated
equipment becomes functional.37,39 Other factor that contributes to increase the
number of device malfunction is the lack of information and training regarding
selection methods of appropriate medical devices in developing countries.37
Simple devices, such as paper dipsticks based on chemical/biochemical reac-
tions, have a greater potential for production in resource-limited settings than
more complex devices. More complex devices, such as lateral flow immunoassays
and nucleic acid assays, require expensive and delicate reagents. In order to pro-
duce low-cost assays, well equipped infrastructure with capability for industrial
scale production is required to reduce the production costs.
2.4 Bioethics-related prioritization criteria
Last but not least, another criterion for prioritization of POCT development, often
forgotten, is the fulfillment of the bioethical principles (criterion 8), which
should be considered in a holistic approach for POC device development.
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As explained along this chapter, there are many challenges providing health
care for diverse people in multicultural societies. Some of the challenges include
allocating health resources, establishing research priorities for technical innovation,
timing for medical treatment, etc. Bioethics were developed to provide broad
guidelines that could be used to aid in decision making in controversial areas of
biology, medicine, and life-sciences that can be accepted by people of different
cultures, religions, and values.40 Four principles are usually considered: autonomy,
non-maleficence, beneficence, and justice.41 These principles are not considered
absolutes due to the diversity of situations, but serve as powerful tools to guide
health-related actions. All the principles should be supported; however, when
there are conflicts between two or more of them, a balance of the principles should
be established by determining which carries more weight in the particular case.40
The principle of autonomy means that the user or patient has autonomy of
thought, intention, and action regarding health care procedures.40 The opinions,
convictions, personal values and beliefs, rights of all users should be respected and
full information should be provided regarding all risks, benefits of the procedure
and likelihood of success in order to make a fully informed decision; special at-
tention should be given to vulnerable populations such as the elderly, sick, and
children.40 This principle is not very relevant for resource allocation for health
technologies research, but it is important for clinical experiments once the medical
devices are developed.
The principle of non-maleficence requires of the provider not to create harm
intentionally to the user, patient, and/or society. Providing a proper standard of
care that avoids or minimizes the risk of harm is held by the commonly held moral
convictions and the laws of society.40
The principle of beneficence requires that the health intervention, health tech-
nology, or health action provide a benefit the user and/or patient.40 It is remark-
able, that both the provider and user in an autonomous way should consider the
action beneficial; when only the provider opinion is considered, then the action is
considered paternalist and disregards autonomy.40 This is an important difference
between beneficence and non-maleficence. While beneficence is more subjective
and depends on what provider and the user consider good, non-maleficence is
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more absolute and depends merely on the provider.40 The goal of providing bene-
fit can be applied to individual users or patients and the society as a whole. For
example, appropriate and rapid diagnosis for a patient would be an example of
individual benefit while prevention of disease through vaccines, epidemiological
surveillance, or international health research would benefit the society as a whole.
New diagnostic medical devices should provide a benefit, such as improved sensi-
tivity and specificity, be more rapid, lower cost, etc. with strict quality control.
Additionally, appropriate training to health providers should be available to ensure
that the patient is benefitted and not harmed through the use of the assay.
The principle of justice is usually defined as a form of fairness among all groups
in society: benefits/burdens should be fairly distributed. This principle is usually
forgotten in bioethics and it is only applied when problems cannot be solved con-
sidering only the other principles.40 However, the principle of justice is the most
relevant bioethical principle applied during this thesis and it is the only one that
gives a vision of the society as a whole. The focus of this thesis –development
of POC diagnostic devices appropriate for low-income settings– is the result of a
fair and responsible conception of diagnostic devices in the society and the social
relations between individuals, groups and public and private entities. People in
developing countries have less resources and less access to appropriate diagnos-
tic medical devices, and focusing on those who have the least follows the justice
principle.
A remarkable example of unfair funds distribution is the 10/90 gap.42 The
10/90 gap is a term adopted by the Global Forum for Health Research to draw
attention to the finding by the Commission on Health Research for Development
in 1990, that less than 10 % of worldwide resources for health research were put
towards health in Developing Countries, where over 90 % of all preventable deaths
worldwide occurred.42 Nowadays, although progress has been made, we are still
far from correcting this imbalance. The prioritization criteria for POC device de-
velopment presented during this chapter hopes to aid for a fairer and more just
allocation of the scarce resources and research funds.
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During the next chapters, the prioritization criteria will be applied to the de-
velopment of medical devices appropriate for low-resource settings.
As briefly described in the Motivation and Aims Chapter, during Chapter 3 a
simple diagnostic chemical dipstick assay was developed. This assay responds to
several prioritization criteria. First, chemical dipsticks are very simple diagnostic
assays and they do not require new technologies for their development thereby re-
sponding to the feasibility of developing an appropriate test prioritization criterion
(criterion 5). Secondly, inexpensive and limited infrastructure is required for the
design and production of these simple diagnostic devices allowing to be fully pro-
duced in resource limited settings thus obeying the prioritization criterion 7, which
takes into account the resources and infrastructure required for POC device pro-
duction. The assay developed was applied to the diagnosis of a nutritional iodine
deficiency. Thereby, the third prioritization criteria fulfilled by this technology is
criterion 1, which tackles the reduction of the global disease burden. As previously
described, nutritional deficiencies are the single most important contributing cause
to the disease burden worldwide.3,6 Since nutritional deficiencies in many cases do
not have specific symptoms, but rather they contribute to debilitate individuals
and make them more prone to suffer from other diseases, low-cost and appropriate
diagnostic devices are expected to have a high impact on disease burden (criterion
2). Additionally, this diagnostic assay also responds to the prioritization criterion
6, to the best of our knowledge, there are no diagnostic dipsticks for iodine sta-
tus determination in the market nowadays. Furthermore, considering that most
people that suffer from iodine deficiencies live in developing countries, developing
an appropriate test for those who have fewer economical resources considers and
applies the bioethical principles of autonomy, non-maleficence, beneficence and
specially the justice principle (prioritization criteria 8).
However, not all diseases can be diagnosed using chemical dipstick assays. Un-
fortunately for the identification of other diseases and conditions, more complex
antigen/antibody and/or nucleic acid detection methods are required. Chapter 4
focuses on the development of a more complex nucleic-acid based device to over-
come the limitations of chemical dipsticks and immunoassays and allowing diag-
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nosis of diseases that cannot be detected with simpler assay formats. This assay
responds to several prioritization criteria.
Although there are some nucleic acid-based POC devices in the market, it
is likely that for the development of a new device, some kind of technological
invention is needed to improve the current state of the technology. Once the tech-
nology is developed, it can be easily applied to several diseases and conditions.
Flexibility is an attractive characteristic of nucleic acids -opposed to lateral flow
immunoassays– and contributes to increase the feasibility of developing an appro-
priate nucleic acid-based test (criterion 5). The diagnostic device that has been
developed during this thesis was applied to the detection of infectious diseases;
specifically, diarrheagenic Escherichia coli O157:H7, Chlamydia trachomatis and
Ebola Zaire virus. These infectious diseases are more prevalent in developing coun-
tries. A POC nucleic acid device to target these pathogens would contribute to
decrease the current disease burden (criterion 1). The expected impact of a new
test (criterion 2) is dependent on the specific pathogen. Thus, a new test for often
asymptomatic chlamydial infections is expected to have a great impact. As previ-
ously mentioned, even for syndromic diseases, such as diarrheal or febrile diseases,
identifying the causative pathogen may be of high importance. Importantly, it
would help to distinguish viral versus bacterial infections and thus enabling ap-
propriate treatment, reducing antibiotic resistances and avoiding the need for new
treatments for antibiotic-resistant strains. This is an important point for prioritiza-
tion criteria 4, which considers the availability, expense and toxicity of treatment.
In the specific case of Ebola Zaire disease, although there is no effective and con-
firmed treatment yet, the measures that need to be adopted in case of infection
–isolation, personal protective equipment, and materials– are very costly and a
confirmatory diagnosis would be highly desirable before following them. Nowa-
days few nucleic acid-based POCTs are available in the market; their development
should be prioritized according to criterion 6 which considers the availability of
tests in the market and their limitations. Additionally, in a globalized world infec-
tious disease are easily spread and their diagnosis not only benefit the communities
where those infections are endemic, but they also have global benefits (criterion
8). Furthermore, infectious diseases, similarly to nutritional deficiencies, are more
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prevalent in developing countries and devices targeted to the people who have
less economic resources attends to the justice principle (criterion 8) and should be
prioritized.
Bibliography
1. Mabey, D., Peeling, R. W., Ustianowski, A. & Perkins, M. D. Diagnostics for
the developing world. Nature reviews. Microbiology 2, 231–40. issn: 1740-
1526 (2004).
2. Murray, C. J. Quantifying the burden of disease: the technical basis for
disability-adjusted life years. Bulletin of the World Health Organization 72,
429–45. issn: 0042-9686 (1994).
3. Chin, C. D., Linder, V. & Sia, S. K. Lab-on-a-chip devices for global health:
past studies and future opportunities. Lab on a chip 7, 41–57. issn: 1473-0197
(2007).
4. World Health Organization. Disease burden estimates for 2000-2012 2014.
<http : / / www . who . int / healthinfo / global burden disease / estimates / en /
index2.html> (2016).
5. UNICEF & World Health Organization. Diarrhoea: why children are still
dying and what can be done tech. rep. (2009).
6. World Bank. Global Burden of Disease and Risk Factors (eds Lopez, A. D.,
Mathers, C. D., Ezzati, M., Jamison, D. T. & Murray, C. J.) isbn: 0821362623
(Washington, 2006).
7. Flour Fortification Initiative et al. Investing in the future: A united call to
action on vitamin and mineral deficiencies tech. rep. (Ontario, 2009).
8. Food and Agriculture Organization & CAB International. Combating mi-
cronutrient deficiencies: food-based approaches (eds Thompson, B. & Amoroso,
L.) isbn: 9781845937140. doi:10 . 1079 / 9781845937140 . 0000 (Wallingford,
2010).
9. World Health Organization. The top 10 causes of death <http://www.who.
int/mediacentre/factsheets/fs310/en/index2.html> (2016).
55
10. Brunham, R. C., Gottlieb, S. L. & Paavonen, J. Pelvic inflammatory disease.
New England Journal of Medicine 372, 2039–2048. issn: 13573039 (2015).
11. Lago, E. G. Current Perspectives on Prevention of Mother-to-Child Transmis-
sion of Syphilis. Cureus 8. issn: 2168-8184. doi:10.7759/cureus.525 (2016).
12. Remme, J. H. F. et al. Tropical Diseases Targeted for Elimination: Chagas
Disease, Lymphatic Filariasis, Onchocerciasis, and Leprosy isbn: 0821361791
(2006).
13. Goupil, L. S. & McKerrow, J. H. Introduction: Drug Discovery and Devel-
opment for Neglected Diseases. Chemical Reviews 114, 11131–11137. issn:
0009-2665 (2014).
14. Kapasi, A. J., Dittrich, S., Gonzalez, I. J. & Rodwell, T. C. Host biomarkers
for distinguishing bacterial from non-bacterial causes of acute febrile illness:
A comprehensive review. PLoS ONE 11, 1–29. issn: 19326203 (2016).
15. World Health Organization Child and Adolescent Health and Development
Division. Integrated Management of Childhood Illness Information Pack tech.
rep. (Geneva, 1998).
16. Ventola, C. L. The antibiotic resistance crisis: part 1: causes and threats. P
& T : a peer-reviewed journal for formulary management 40, 277–83. issn:
1052-1372 (2015).
17. World Health Organization. Antimicrobial resistance 2016. <http://www.
who.int/mediacentre/factsheets/fs194/en/> (2016).
18. World Health Organization. Global plan to combat neglected tropical diseases
2008 - 2015 tech. rep. (Geneva, 2007).
19. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints:
preferred definitions and conceptual framework. Clinical pharmacology and
therapeutics 69, 89–95. issn: 0009-9236 (2001).
20. Mohd Hanafiah, K., Garcia, M. & Anderson, D. Point-of-care testing and
the control of infectious diseases. Biomarkers in medicine 7, 333–47. issn:
1752-0371 (2013).
56
21. Point-of-Care Diagnostics on a Chip (eds Issadore, D. & Westervelt, R. M.)
isbn: 978-3-642-29267-5. doi:10.1007/978-3-642-29268-2 (Berlin, Heidelberg,
2013).
22. Schleicher, E. The clinical chemistry laboratory: Current status, problems
and diagnostic prospects. Analytical and Bioanalytical Chemistry 384, 124–
131. issn: 16182642 (2006).
23. Myers, F. B. & Lee, L. P. Innovations in optical microfluidic technologies
for point-of-care diagnostics. Lab on a chip 8, 2015–2031. issn: 1473-0197
(2008).
24. Comer, J. P. Semiquantitative Specific Test Paper for Glucose in Urine. An-
alytical Chemistry 28, 1748–1750. issn: 0003-2700 (1956).
25. Free, A. H., Adams, E. C., Kercher, M. L., Free, H. M. & Cook, M. H. Simple
specific test for urine glucose. Clinical chemistry 3, 163–8. issn: 0009-9147
(1957).
26. Then, W. L. & Garnier, G. Paper diagnostics in biomedicine. Reviews in
Analytical Chemistry 32, 269–294. issn: 2191-0189 (2013).
27. St John, A. & Price, C. P. Existing and Emerging Technologies for Point-of-
Care Testing. The Clinical biochemist. Reviews 35, 155–67. issn: 0159-8090
(2014).
28. Li, S., Kiehne, J., Sinoway, L. I., Cameron, C. E. & Huang, T. J. Microfluidic
opportunities in the field of nutrition. Lab on a Chip 13, 3993. issn: 1473-
0197 (2013).
29. Yetisen, A. K., Akram, M. S. & Lowe, C. R. Paper-based microfluidic point-
of-care diagnostic devices. Lab on a chip 13, 2210–51. issn: 1473-0189 (2013).
30. Hawkes, R, Niday, E & Gordon, J. A dot-immunobinding assay for mono-
clonal and other antibodies. Analytical biochemistry 119, 142–7. issn: 0003-
2697 (1982).
57
31. Farrell, B. O. Lateral Flow Immunoassays Systems: evolution from the current
state of the art to the next generation of highly sensitive, quantitative rapid
assays 89–107. isbn: 9780080970370. doi:10.1016/B978-0-08-097037-0.00078-
6 (Elsevier Ltd, 2013).
32. Lee, T. M. H. & Hsing, I. M. DNA-based bioanalytical microsystems for hand-
held device applications. Analytica Chimica Acta 556, 26–37. issn: 00032670
(2006).
33. Chen, L., Manz, A. & Day, P. J. R. Total nucleic acid analysis integrated on
microfluidic devices. Lab on a Chip 7, 1413. issn: 1473-0197 (2007).
34. Mullis, K. et al. Specific enzymatic amplification of DNA in vitro: the poly-
merase chain reaction. 1986. Biotechnology (Reading, Mass.) 24, 17–27. issn:
0740-7378 (1992).
35. Park, J. W. Development and Validation of Novel Molecular Techniques to
Elucidate Mechanisms of Endocrine Disruption (Michigan State University.
Department of Zoology-Environmental Toxicology, 2008).
36. Gubala, V., Harris, L. F., Ricco, A. J., Tan, M. X. & Williams, D. E. Point of
care diagnostics: status and future. Analytical chemistry 84, 487–515. issn:
1520-6882 (2012).
37. World Health Organization. Medical devices: Managing the mismatch isbn:
978 92 4 156404 5 (Geneva, 2010).
38. Hay Burgess, D. C., Wasserman, J. & Dahl, C. a. Global health diagnostics.
Nature 444 Suppl, 1–2. issn: 1476-4687 (2006).
39. Dyro, J. F. in Clinical Engineering Handbook (ed Dyro, J. F.) 155–158 (Aca-
demic Press, Burlington, 2004). isbn: 978-0-12-226570-9.
40. Alonso, A. H. & Hortal, A. E´tica general de las profesiones isbn: 9788433017185
(Descle´e de Brouwer, 2002).
41. Beauchamp, T. L. & Childress, J. F. Principles of Biomedical Ethics isbn:
9780195335705 (Oxford University Press, 2009).
42. Global Forum for Health Research. The 10/90 report on health research 2000
(ed Davey, S.) isbn: 2-940286-01-9 (Geneva, 2000).
58
Chapter 3
Paper Chemical Dipsticks for
Disease Diagnosis Produced with
Domestic Inkjet Printers
3.1 Introduction
As previously mentioned, this chapter is focused on the development of chemical
dipstick assays, hereinafter referred to as ‘dipsticks’, that can be simply manufac-
tured in developing countries. We believe that enabling developing countries to
design and manufacture their own diagnostic devices would ensure well adapted
medical devices to local environments and needs that can be locally maintained,
repaired, and further improved. Thus, the high number of malfunctioning and
broken devices encountered in developing countries due to the lack of training on
correct use and maintenance or absence of in-country spare parts and supplies
could be significantly reduced.1 Specifically, we propose the use of domestic desk-
top inkjet printers to easily produce dipstick diagnostic assays.
Dipsticks are probably the simplest diagnostic devices and have been in the
market for more than 50 years.2–4 They are paper strips impregnated with chemi-
cal reagents that can determine the presence of an analyte in a biological fluid
qualitatively or semi-quantitatively through a colorimetric reaction. Most chemi-
cal reactions with color change can be achieved on paper in a one-step procedure.
Probably the best known dipstick tests are pH strips, such as litmus strips, which
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allow detecting alkaline and acid conditions.5 Test strips to detect metabolic prod-
ucts in urine and blood analytes (such as protein, glucose, salt, etc.) are also very
popular.5,6
Paper is an ideal substrate for low-cost diagnostics as it is inexpensive, widely
available, disposable, biodegradable, flammable, and easy to functionalize due to
its physico-chemical properties.4,5,7 In addition to dipsticks, other point-of-care
(POC) diagnostic tests also use paper as substrate: lateral flow immunoassays
and microfluidic paper-based analytical devices (mPADS).8,9 Both of them are rela-
tively low-cost and easy to use; however, their manufacturing process is generally
too complex and/or costly to be fully produced in developing countries.5,10,11
For depositing liquids on paper, inkjet printers are an attractive solution due to
their capability to deposit drops with high accuracy in a low-cost, simple, fast, and
reproducible way. Inks can be made of a variety of reagents beyond classical dyes,
such as chemical or biological reagents, allowing inkjet technology to evolve from
office printing to other industrial process and research applications including di-
agnostics.12–15 Drop-on-demand (DOD) piezoelectric and thermal printers are the
most widely used technologies for industrial and domestic applications.16 In piezo-
electric printing, applying a voltage to a piezoelectric element in contact with the
printer nozzle results in a volume displacement and the ejection of an ink droplet.
In thermal inkjet technology, the volume displacement is achieved by the creation
of a gas bubble on a heating element inside the nozzle.16 Piezoelectric technology
is usually preferred in applications that involve chemical and biological reagents to
avoid damage when exposed to high temperatures.16 Within piezoelectric printers
there are a wide variety of printers with different degrees of sophistication. On the
one hand, sophisticated printers are generally used for research applications and
allow full control of printing parameters (e.g. choice of nozzle diameter, printing
stages, visual confirmation of ink droplet formation) and software (e.g. control of
piezo-pulse voltage and duration).16 On the other hand, consumer printers provide
limited user control via the original printer driver and software, but critically are
lower cost and user-friendly.16
By using domestic printers to produce diagnostic assays we hope to offer peo-
ple in low-income countries with tools for local diagnostic assay production and
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technology transfer, and provide means and ideas for innovation. Thus, as previ-
ously anticipated, this assay responds to the prioritization criteria 5 and 7, which
emphasize the feasibility of developing an appropriate test and the resources and
infrastructure required for POC device production respectively.
As proof of concept, our platform for manufacturing diagnostic test strips was
tested for the detection of iodine status. Health conditions derived from a defi-
cient or excessive dietary iodine intake are called iodine deficiency disorders (IDD)
and are considered a severe global health problem around the world.17,18 IDD
consequences are varied; goiter, hypothyroxinemia, stillbirth, neurologic disorders,
mental retardation or cretinism are some of them.19 Worldwide, iodine deficiency
is the most important cause of preventable mental retardation.17,20 The WHO esti-
mates that ‘people living in areas affected by severe IDD may have an intelligence
quotient (IQ) of up to about 13.5 points below that of those from comparable com-
munities in areas where there is no iodine deficiency’.17 The economic productivity
of countries with high number of people suffering IDD is severely affected due to
the effect of IDD on health, well-being, intelligence and learning capacity of its
habitants.17,20
Preventing of IDD is straightforward.17 Supplementing iodine intake into the
diet of people living in areas of endemic iodine deficiency can successfully prevent
IDD.17,21 Iodination of salt is an inexpensive and commonly used method to in-
crease iodine intake in a community.17,21 Despite the effectiveness and low cost
of this intervention, millions remain at risk for IDD.21 Periodic monitoring and
testing for iodine deficiency is key to the success of any supplementation program,
for which medical devices play an essential role.
Iodine deficiency was selected as proof of concept since diagnostic assays for
this condition should be highly prioritized according to criteria 1, 2, 6, and 8. Di-
agnostic assays for this condition are expected to highly contribute to reduce the
global disease burden (criteria 1 and 2) since nutritional deficiencies and illness
are interconnected and are part of a vicious cycle which also includes poverty.22,23
In Copenhagen in 2008, eight internationally recognized economists selected mi-
cronutrient initiatives as the worlds best investment for development.24 The low
cost of food fortification and supplements together with the high rates of return
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make these interventions extremely profitable. The diagnosis of nutritional defi-
ciencies, and specifically iodine deficiency, is the first step to combat them. To
the best of our knowledge, no diagnostic dipsticks for iodine status determination
are currently available in the market and their development follows prioritization
criterion 6. People living in developing countries are the most affected by this con-
dition and focusing on them responds to bioethical principles (criterion 8)– most
notably the principle of justice.
Iodine is a micronutrient required for normal thyroid function and production
of thyroid hormones.25 Thyroid hormones play a key role in the regulation of pro-
tein synthesis, enzymatic activity, hormonal activity and several other biochemical
reactions.25 There are different indicators to assess iodine deficiency including es-
timation of thyroid size, measurement of thyroid stimulating hormone (TSH) or
thyroglobulin levels, and determination of urinary or salivary iodine.17 IDD control
programs use urinary iodine as principal indicator17–19,26 due to the long response
time after supplementation in the case of thyroid size and the high cost of analy-
sis for TSH and thyroglobulin.17 Urinary iodine is a highly accepted biomarker
as short term indicator of recent iodine dietary intake and when used in a large
representative population it can provide useful information of iodine status.17,27
Additionally, urinary samples are easy to collect, store, and analyze, and it is es-
timated that more than 90 % of the iodine ingested in the diet is released in the
urine.17,25
Although there are a wide variety of methods to determine iodine and iodide,
to date there are no available techniques that fully fit the needs of developing
countries.28 Currently, iodine measurement in biological samples is carried out al-
most exclusively by inductively coupled plasma mass spectrometry (ICP-MS) or
methods based on the Sandell-Kolfhoff reaction.18,26,28 ICP-MS allows for high sen-
sitivity and reliability; however, its high cost make it unrealistic for widespread
use.26 Methods based on Sandell-Kolfhoff (S-K) reaction rely on iodides role as a
catalyst in the reduction of ceric ammonium sulfate (yellow color) to the cerous
form (colorless).17 The main drawback of S-K methods are the toxic waste prod-
ucts generated during urine digestion that is required prior to the colorimetric
reaction.26
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In 1998, Rendl et al. described a sensitive colorimetric method based on io-
dide function as catalysts in the oxidation of 3,3’,5,5’-tetramethybenzidine (TMB)
by peracetic acid/H2O2 which avoids toxic waste production.
29 We selected this
method to perform a proof of concept of the platform here presented. Additionally,
initial experiments were performed with the well-known iodine-starch reaction.
The ‘holistic approach’ for POC medical device development, explained in
Chapter 1, is here applied to the development of dipstick assays that are easily
and fully manufacturable in low-resource settings using a domestic inkjet printer.
Major attention was given to the context, the users, and the end goal of production
and implementation of the device. We describe simple chemical ink preparation
formulations, easy and rapid methods for ink characterization allowing printing
inexpensive diagnostics with domestic inkjet printers, and we provide guidelines
for new ink development. Our platform is very versatile and can be used to detect
a wide variety of biomarkers of diseases; its application to the detection of iodine
deficiency is provided as a proof of concept.
3.2 Materials and Methods
3.2.1 System description and operation procedure
Diagnostic dipsticks were produced with a desktop piezo driven printer Epson Sty-
lus SX420W. Compatible empty refillable cartridges (series T128) were purchased
from Prink Ltd. and freshly prepared inks were introduced with a syringe into
the cartridges. Once filled, cartridges were introduced into the printer. Previous
to printing the diagnostic test, the printer injectors were primed using the ‘clean
head’ function in the printer. Uncoated pure-cellulose filter paper was used as
substrate.
The concentration of each ink could be controlled by printing colors that com-
bine the corresponding basic printing color (black, blue cyan, magenta, and yellow)
in the desired proportion. For printing only one reagent, only the corresponding
basic color was used. For the experiments here presented, a 6 × 16 cm2 area
was printed for 5 five times over the same area in order to increase the reagent
concentration. Then the printed paper was cut in 1.5 × 1.5 cm2.
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Table 3.1: Reagents and equipment for the production of paper dipsticks.
Name Reference Vendor
Reagents
Soluble starch 33615 Sigma-Aldrich
Sodium nitrite 237213 Sigma-Aldrich
Triton X-100 T9284 Sigma-Aldrich
Tween-80 P1754 Sigma-Aldrich
Benzotriazole B11400 Sigma-Aldrich
Ethanol 99.8 % 51976 Sigma-Aldrich
Hydrogen peroxide 30 %(w/v) 216763 Sigma-Aldrich
Sulfuric acid 98 %(v/v) 320501 Sigma-Aldrich
Peracetic acid 433241 Sigma-Aldrich
3, 3′, 5, 5′-tetramethylbenzidine 860336 Sigma-Aldrich
potassium iodide 60399 Sigma-Aldrich
Paper Uncoated cellulose paper
Refillable cartridges T128 Prink Ltd.
Printhead cleaner solution Magic liquid Prink Ltd.
Equipment
Desktop printer SX420W Seiko Epson
Drop Shape Analysis System DSA100 KRU¨SS GmbH
Rheometer AR550 TA Instruments
When replacing ink cartridges and for short term printer storage, the printer
nozzles were cleaned using a printhead cleaner solution (Magic Liquid from Prink
Ltd.). Chemical ink cartridges were substituted by cartridges filled with printhead
cleaner mix with de-ionized water in 1:1 proportion. Then the ‘clean head’ function
in the printer was selected in order to clean the printer nozzles. For long term
storage of the printer and unclogging nozzles, the printhead cleaner was directly
added to the sponges under the printhead assembly using a syringe. First, the
printhead assembly was moved in order to have access to the sponges and once the
sponges were saturated, the printhead assembly was moved back over the sponges.
The printer was left in this condition until the nozzles were unclogged or until it
was used again.
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3.2.2 Reagents for ink fabrication
Original inks for the printer Epson Stylus SX420W were purchased from Seiko
Epson Corp. and were used to characterize their physico-chemical properties.
Reagents used to prepare chemical inks were purchased from Sigma Aldrich Corp.
and included Triton X-100, Tween-80, benzotriazole, ethanol 99.8 %, hydrogen
peroxide 30 %(w/v), sulfuric acid 98 %(v/v), sodium nitrite, soluble starch, per-
acetic acid solution 36–40 %(w/v) in acetic acid, 3,3’,5,5’-tetramethylbenzidine,
and potassium iodide. The composition of the inks is described in Section 3.3.
3.2.3 Methods for determination the physico-chemical pro-
perties of an ink
Surface tension and viscosity are the most crucial ink properties since they deter-
mine drop formation and jetting performance.30 The methods used to determine
both parameters are described. Since the nature of the ink can affect the chemical
integrity (corrosion) of the inkjet printer, a method to determine copper corrosion
inside the printer injectors by acidic chemical inks is presented in this section as
well.
Surface tension
Surface tension was calculated using a method based in Tate’s law (Equation 3.1).
For the same capillary radius, the ratio of mass and surface tension is constant for
all liquids.
m · g = 2 · pi · r · γ (3.1)
m1
γ1
=
m2
γ2
(3.2)
where m is the drop mass, g is the gravity, r is the capillary radius, and γ is
the surface tension.
The surface tension of a fluid was determined using water as reference. The
mass of 25 drops of water and the fluid were measured, the surface tension of water
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is known (72 mN/m at 25 ◦C)31 and the surface tension of the fluid was calculated
from Equation 3.2. Additionally, confirmatory surface tension measurements were
taken with Drop Shape Analysis System DSA100.
Dynamic viscosity
Dynamic viscosity was determined using AR550 rheometer from TA Instruments.
A shear stress between 0 and 50 Pa was applied to the samples for 5 min. A 60 mm
diameter plate and a 250 µm gap were used. Results were analyzed using TA Data
Analysis.
Corrosion quantification
Corrosion was determined by weighting 1 mm thick copper plates before and after
incubation in an acidic solution with or without the addition of a corrosion inhibitor
for 12 days. The mass loss due to corrosion under accelerated conditions was
calculated as the mass difference between the initial and final copper plates mass.
Benzotriazole was used as corrosion inhibitor.
3.3 Results
3.3.1 Materials selection and chemical inks preparation
and description
Inkjet printers are widely available worldwide, easy to use and inexpensive. For
the experiments presented here a $60 Drop-On-Demand (DOD) piezoelectric based
inkjet printer was used. As previously described, pure cellulose filter paper was
used as substrate. All the inks here described were successfully printed on filter
paper, reagents were homogeneously deposited on paper, properly absorbed and
color differences from colorimetric reactions performed on filter paper were well
distinguished. For depositing inks on paper, hand dispensing and direct immersion
were tested as well. These techniques led to uneven distribution of reagents, and
when the colorimetric reaction took place, the heterogeneous color formation made
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semi-quantification impossible. The superior performance of printing versus hand
dispensing and direct immersion, led us to focus on this technique.
In order to print chemical/biological reagents, they should be compatible with
the printer materials and should be similar to commercial inks in terms of its
physico-chemical properties.30 As described in the Materials and Methods section,
the most important ink physico-chemical properties are the surface tension and
viscosity since they determine drop shape and jetting operation.30 Water or aque-
ous buffers are the most common solvents for the different inkjet-printed chemical
and biochemical analytical assays that target ions, proteins, antigens or metabo-
lites. Water has a surface tension and viscosity of 72 mN/m and 1 mPa·s at 25 ◦C
respectively. In addition to water or aqueous solutions, general ink compositions
for piezo electric printers include a surfactant to adjust the surface tension and
sometimes require a viscosity modifier.14,30 Triton X-100 is generally used as a non-
ionic surfactant to adjust surface tension, and glycerols and glycols are commonly
used as viscosity modifiers.14
The physico-chemical properties of the commercial pigmented ink for our se-
lected printer were determined as explained in Section 3.2.3. The surface tension is
25.75 mN/m. Ink viscosity is 2.7 mPa·s and was calculated form Figure 3.1, which
shows the rheological properties of the ink. Figure 3.1 A shows proportionality
between shear stress and shear rate indicating Newtonian fluid behavior.
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Figure 3.1: Ink rheometric curves of the commercial pigmented ink for our selected
printer at 25 ◦C. A) Shear stress versus shear rate. B) Viscosity versus shear rate.
As proof of concept, it is described the development of chemical inks for two
colorimetric reactions for iodide detection: the iodine-starch reaction and the TMB
reaction.29
3.3.2 Starch-iodine reaction
The specific reaction between amylose in starch and iodine leads to the formation
of a deep blue complex that can be used as a semiquantitative test for iodine. In
presence of iodide, water insoluble iodine leads to triiodide anion (Reaction 3.3)
which is highly soluble and complexes with amylose causing the deep blue color
(Reaction 3.4). Iodine can be produced reacting sodium nitrite with potassium
iodide and sulfuric acid (Reaction 3.5).32
I2 + I
− → I−3 (3.3)
I−3 + starch→ blue colored complex (3.4)
2NaNO2 + 2KI + 2H2SO4 → I2 + 2NO +K2SO4 +Na2SO4 + 2H2O (3.5)
As start point to develop sodium nitrite, sulfuric acid, and starch inks, the
concentrations recommended by Burriel et al. were used.33 To 0.5 ml of sample,
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1 or 2 drops of sulfuric acid 1 M were added until the sample turned acidic, then
210 g/L of soluble starch and one solid crystal of sodium nitrite were added. In
order to assure that iodide is the limiting reagent and since all inks should be in
liquid state, a very concentrated sodium nitrite solution was prepared: 0.7 g/ml.
In the case of the soluble starch solution, a filtration step was carried out to
separate amylopectin, which does not participate in the colorimetric reaction and is
insoluble in water compromising the stability of the ink. Only an amylose solution
was used for ink preparation. 1 M sulfuric acid solution was also prepared. Using
these reagents, Reaction 3.5 was tested on paper. Color changes were successfully
observed on paper; however as previously mentioned, due to imprecise manual
reagent deposition on paper, discrimination of various iodide concentrations was
not possible. Afterward, we proceeded to fabricate inks from these reagents.
The three solutions -sodium nitrite, sulfuric acid, and amylose– are aqueous.
Sodium nitrite and sulfuric acid solutions present very similar surface tension and
viscosity compared to water. However, amylose solution presents a very high vis-
cosity due to its high concentration (see Figure 3.2, pink data set). Filtered amy-
lose solution was diluted using water in order to decrease the viscosity to make it
more closely match the viscosity of water. Shear stress versus shear rate was mea-
sured for each dilution and in Figure 3.2 the corresponding rheological curves can
be observed. Commercial ink rheological curves are included for comparison. As
can be observed, amylose solution has a pseudoplastic behavior. As expected, the
more water added to the amylose solution, the lower the viscosity. For 10 %(v/v)
amylose solution, the viscosity is approximately 9 mPa·s. We verified that al-
though the viscosity of 10 %(v/v) amylose solution and pigmented inks differ in
6.3 mPa·s, adjustment of the viscosity was not required for good inkjet printing.
Thus, 10 %(v/v) amylose solution, which corresponds to 21 g/l of filtered soluble
starch, was selected.
Next, different experiments were conducted with each of the solutions to de-
termine the appropriate composition of additives required for proper inkjet prin-
ting. The surface tension of the chemical solutions is around 72 mN/m, approxi-
mately three times higher than the surface tension of standard pigmented ink
(25.75 mN/m). Triton X-100 and Tween-80 were used as surfactant to reduce the
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Figure 3.2: Rheometric curves of the different concentrations (expressed in %(v/v))
of amylose solution at 25 ◦C. A) Shear stress versus shear rate. B) Viscosity versus
shear rate. Commercial ink rheological curves are shown for comparison purposes.
surface tension of the chemical solution; the results at different surfactant con-
centrations are shown in Table 3.2. 1 %(v/v) Triton X-100 resulted to be the
most efficient achieving values between 27–30 mN/m for the different inks and
allowing for good jetting performance. Higher concentrations of Triton X-100 did
not decrease the surface tension substantially. Regarding viscosity, as previously
mentioned, viscosity values similar to water did not need to be adjusted for good
inkjet printing.
Table 3.2: Starch, sodium nitrate, and sulfuric acid ink surface tension varying the
concentration of two surfactants, Tween-80 and Triton X-100.
Surfactant Surfactant surface tension (mN/m)
conc. Starch ink Sodium nitrite ink Sulfuric acid ink
% (v/v) Tween Triton Tween Triton Tween Triton
0,1 66,53 37,34 53,24 34,72 43,44 33,25
0,5 54,85 30,86 38,93 28,86 38,13 28,45
1 51,08 29,65 37,79 27,35 36,67 27,34
2 48,28 29,49 36,92 27,29 34,52 27,12
When formulating the inkjet printing ink, the compatibility of the ink with
the printer components need to be taken into account.30 Thus, in the case of the
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sulfuric acid ink, corrosion studies were conducted as acids mays corrode copper
in the printer injectors and as a result damage the printer. 1 M solution of sulfuric
acid and 4 different concentrations of the corrosion inhibitor benzotriazole were
used. 1 M benzotriazole concentration was the minimum concentration of inhibitor
required in order to form a passivating benzotriazole self-assembly monolayer that
protects the copper from corrosion (Figure 3.3). For 1 M benzotriazole, the mass
loss of the copper plate was less than 0.1 % as can be seen in Table 3.3, which was
considered negligible.
Figure 3.3: Copper plates incubated for 12 days in a 1 M solution of sulfuric
acid with different concentrations of benzotriazole. Benzotriazole concentrations
indicated above each copper sample.
Table 3.3: Corrosion inhibition study by 1 M sulfuric acid on copper in presence
of different concentrations of benzotriazole.
Benzotriazole concentration [M] Weight loss [%(w/w)]
0 0.33
0.05 0.17
1 0.09
2 0.08
Table 3.4 summarizes the composition of the sodium nitrite, sulfuric acid and
starch inks (Lanes 1-3). Once the three chemical inks that participate in the
reactions 3.3–3.5 were developed, analytical test strips were produced. Amylose,
sodium nitrite, and sulfuric acid inks were printed following that order over the
same paper area. Each chemical ink was introduced in a different printer cartridge
and by selecting the equivalent colored cartridge it was possible to select which ink
was printed at each time. The dipstick was tested through immersion in solutions
with different iodide concentration. Results were evaluated after 30 s (Figure 3.4).
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Table 3.4: Composition of various chemical inks.
Ink Main component Additives γ (mN/m) µ (mPa·s)
Starch 21 g/L filtered
soluble starch
1 % Triton X-100 29.7 1.53
Sodium nitrite 0.7 g/ml NaNO2
in H2O
1 % Triton X-100 27.3 3
Sulfuric acid 1 M H2SO4 in
H2O
1 % Triton X-100,
1 M benzotriazole
27.3 0.99
3,3’,5,5-TMB 2.5 mM 3,3’,5,5-
TMB in ethanol
– 22.1 1.21
References: γ is the surface tension; and µ is the viscosity.
Figure 3.4: Color observed in printed paper with amylose, sodium nitrite and
sulfuric acid inks after immersion in potassium iodide solutions of different con-
centrations. Iodide concentrations indicated above each corresponding colored
paper.
Figure 3.4 shows how color differences allow determining semi-quantitatively a
wide range of iodide concentrations demonstrating successful ink preparation and
printing. However, while this worked as proof of concept, the level of detection
was not sufficiently low to detect physiological levels of iodine in the urine. It
should be noted that chemical reagents, chemical inks and printed paper strips
were stored at room temperature without observing activity loss or ink instability
for several months.
3.3.3 Reaction with 3,3’,5,5’-tetramethylbenzidine (TMB)
TMB reaction is more sensitive and allows detecting iodine in the concentration
present in the urine (20–300 µgI/L).29 This method is a colorimetric assay in
which iodide catalyzes the oxidation of 3,3’,5,5’-tetramethylbenzidine (TMB) by
peracetic acid/H2O2 yielding colored products (Figure 3.5). A blue charge-transfer
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complex exists in rapid equilibrium with the TMB-radical cation. Depending on
the color of the products it is possible to estimate the range of iodide concentration.
It should be considered that for this method urine needs to be pretreated.
However, contrary to Sandell-Kolfhoff methods which require digestions with high
toxic waste production, Rend et al. developed simple carbon activated columns
which remove the interfering substances without producing toxic wastes.29 Since
these reactions are presented as proof of concept of the system, solutions with
different concentrations of iodide were used as samples and no urine experiments
were performed.
Figure 3.5: 3,3’,5,5’-tetramethylbenzidine (TMB) reaction. 3,3’,5,5’-
tetramethylbenzidine (TMB) is oxidized in the presence of peracetic acid/H2O2
and iodide generating colored products.29
As a starting point, the concentrations described by Rend. et al were used.29
The reagents required were: 2.5 mM 3,3’,5,5’-TMB in ethanol and 1.2 % peracetic
acid in 30 % H2O2. Reagents implicated in the reaction were prepared and the
change in color was observed on paper.
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Since the concentration of TMB is low, the properties of this solution are
considered to be very similar to ethanol properties. Thus, ethanol studies were
carried out. Ethanol surface tension and viscosity are 22.0 mN/m and 1.04 mPa·s
at 25 ◦C respectively. Both parameters are very close to pigmented ink parameters
and good jetting performance was observed with ethanol and TMB ink without
the need of additives. The composition of TMB ink is shown in Table 3.4 Lane
4. Peracetic acid in H2O2 was not converted to an ink format due to its very
oxidative power. If peracetic acid was printed on TMB printed paper, TMB was
instantly oxidized impeding its later use.
Paper strips printed with TMB were tested by introducing them into solu-
tions with different iodine concentration in the range present in urine. A drop
of peracetic acid in H2O2 was added at the end to start the catalytic reaction.
The results were read 2 min after the addition of peracetic acid and are shown in
Figure 3.6. Different read-out times were tested, and 2 min produced the grea-
test color differences between the iodide concentrations evaluated. Shorter times
produced lighter colors and longer exposures led to color saturation for the higher
iodide concentrations. TMB ink and paper strips were stable for several months
stored at room temperature without observing activity loss.
Figure 3.6: Color observed in paper printed with TMB reagent after immersion
in iodide solutions of different concentration and addition of a drop of peracetic
acid/H2O2. Iodide concentrations indicated below each corresponding colored pa-
per.
In Figure 3.6 it can be observed how the color differences, when comparing with
a printed colored scale, allow for semi-quantitative determination of the iodine
concentration which could identify iodine deficiency and the degree of severity.
The WHO considers the iodine nutritional state as: severe deficiency when urinary
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iodine is below 20 µg/L, moderate deficiency for 20–49 µg/L, mild deficiency in
case of 50–99 µg/L, optimal when urinary iodine is 100–199 µg/L, mild iodine
excess for 200–299 µg/L, and severe excess when urinary iodine is higher than
300 µg/L.17 Although differences between some of the iodine concentrations tested
are subtle, differences between deficient (20 µgI/L, 50 µgI/L), adequate (100 µgI/L,
150 µgI/L, 200 µgI/L) and excessive (300 µgI/L) iodine intake groups can be well
discriminated unambiguously.
3.3.4 Cost analysis
A cost analysis for dipstick production using TMB reaction was performed. Taking
into account the price of the chemical reagents and paper, considering the average
cartridge yield provided by the manufacturer (approximately 165 pages/3.5 ml
cartridge), and a 2.25 cm2 dipstick surface area, it is estimated that more than
5000 dipsticks assay can be manufactured with less than $10 consumables. Additio-
nally, the cost of an inkjet printer and compatible empty inkjet cartridges should
be considered. As previously mentioned, for the experiments here presented a
$60 printer was used and 4 empty cartridges which cost $20. Thus, a 100,000
population could be screened for merely $200.
3.4 Discussion
3.4.1 Advantages of iodine determination using low-cost
dipsticks
We have here presented dipsticks that can be produced locally using inkjet printers.
As proof of concept, this method was applied to the determination of urinary
iodine, and TMB reaction turned to be particularly useful. 3,3’,5,5’-TMB, ethanol,
peracetic acid, and H2O2 were the only chemical reagents required for the semi-
quantification of iodine in the same concentration range as present in the urine.
Our semi-quantitative urinary dipstick assays are well suited for epidemiological
purposes.34 IDD is a nutritional deficiency that is primarily the result of deficiency
of iodine in soil which in turn leads to the lack of iodine in groundwater and foods
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grown locally in those areas.34 Communities living in the same areas have usually
similar levels of bodily iodine. Urinary dipsticks would allow identifying endemic
regions, communities at risk of IDD, and establishing public health programs,
such as inexpensive salt iodization interventions, to address this problem.35 Even
after IDD elimination in a community, control programs should be constantly
maintained17 and locally produced urinary dipsticks would be highly useful. Singe
individual estimates are also possible; taking several measurements during different
days and/or times of the day would help to increase the accuracy.
Chemical handling for ink preparation and paper dipsticks production should
be performed at health clinics; then, the dipsticks could be used at the patient
site. Providing small rural clinics with low-cost and rapid diagnostics to assess
iodine status would motivate them to promote the consumption of iodized salt or
other sources of iodine if the iodine status of the community is low.
3.4.2 Comparison with other currently available methods
Local production and technology transfer is key to increase access to medical de-
vices, especially in low- and middle-income countries (LMICs). It is estimated
that a mere 13 % of medical device manufacturers are located in LMICs.36 How-
ever, few technologies are developed to facilitate local production in developing
countries. Some interesting examples of health technologies in this line are the
MediKit37, which includes modular components to allow medical professionals to
design their own appropriate solutions, and Pharmacy-on-Demand38, which con-
sist in a portable system can be configured to produce at small scale different drugs
locally. Our system allows local production of diagnostic devices because its main
component is an inkjet printer, which are low-cost and available in every country
around the world. Thus, our approach for innovation was to adapt methods and
designs to new functions rather than the typical innovation approach based on
designing new technologies.22
Wide varieties of bio(chemical) sensing devices use inkjet printers during their
manufacturing process.16 Electrochemical and optical-based devices have been re-
ported. Inkjet-printed features include electrodes, hydrophobic barriers, chemical
solutions, antibodies, and enzymes which were printed in substrates such as paper
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(filter, chromatographic, nitrocellulose) and electrodes.16,39–44 In most cases re-
search printers were used, especially when printing costly and/or sensitive reagents
such as antibodies.16,42,44 In few of them, if any, the whole assay was inkjet-printed,
but rather specific parts of the assay were printed.16 Additionally, to the best of our
knowledge, none of them is simple enough to be fully produced in poor-resource
settings. One of the main advantages of our assay is its simplicity which allows
to be fully be manufactured using merely a desktop printer and few inexpensive
resources.
Regarding the techniques for iodine detection in biological samples, to the best
of our knowledge, no available techniques are appropriate to meet the needs of
low-income countries.28 As previously described, ICP-MS and methods based on
Sandell-Kolthoff reaction (S-K) are the most common methods used for iodine
measurement in biological samples.28 The sensitivities of both methods are ade-
quate for the detection of severe iodine deficiency in iodine samples; however, each
of them present an important shortcoming. In the one hand, S-K reaction requires
complete mineralization of the sample, which is usually performed through diges-
tion techniques using perchloric acid for which special precautions are required due
to explosion hazards.28 In the other hand, ICP-MS is a sophisticated and costly
technique unaffordable for widespread use.28 Other techniques worth mentioning
include inductively coupled plasma optical emission spectrometry (ICP-OES), neu-
tron activation analysis (INAA), and atomic absorption spectrometry (AAS). All
these techniques are sensitive for severe iodine determinations but present simi-
lar limitations to S-K based reactions or ICP-MS: they require extensive sample
preparation and/or are costly.28
3.4.3 Guidelines for the development of new inks
When developing new inks, the first step is to identify a one-step colorimetric
chemical reaction that monitors the target analyte. Two situations can be ob-
served depending on reagents that participate in the chemical reaction. The first
situation is when the concentration of a chemical reagent in the solution is low
and does not considerably alter the viscosity and surface tension of the solvents.
In this case, when ethanol is the solvent, the solution can be directly used as ink.
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As previously shown, the surface tension and viscosity are very close to pigmented
inks parameters and good jetting performance was observed with ethanol based
inks without the need of additives. For water-based formulations, the addition of
1 %(v/v) Triton X-100 is enough to sufficiently modify the surface tension while
the viscosity does not require modification for good jetting performance. In the
case of a reagent that is added to the reaction in the solid state, a solvent should
be used to dissolved it in. The second situation is when the properties of the
chemical solutions differ from the ones of water or ethanol solvents, or when using
a different solvent, more ink studies need to be performed. Viscosity and surface
tension should be measured and additives need to be added until both properties
resemble those of pigmented inks. In our experience, the addition of Triton X-100
in the range of 0.5–2 %(v/v) is a good method to achieve adequate surface tension.
For the determination of surface tension, only a scale and pipette or thin capillary
are required. In the case of viscosity, viscosities between 1 and 9 mPa·s did not
required modification of their viscosity for good jetting performance. Moreover, as
previously mentioned, new inks developed need to be compatible with the printer
components.30 In the case of using reagents that might damage the printer, such
as corrosive reagents, experiments to guarantee the printer stability need to be
performed. Similar experiments to the described herein for corrosion need to be
implemented. Depending on the acid of intended use, its concentration, and the
intended time for the ink to be inside the printer cartridge, performing corrosion
experiments as described in the materials and methods section is highly recom-
mended as the ink here presented is just an example.
In addition to iodine deficiency, this versatile method to design and produce
inkjet-printed dipsticks can be applied to detect biomarkers of other diseases. Uri-
nary dipsticks are widely available and use well known reactions to detect analytes
that may signal abnormal conditions.45 For example, high sugar levels in the urine
may indicate diabetes; nitrites and/or leukocytes could be present due to urinary
tract infection; high protein levels might be indicative of kidney disease; large
amounts of ketones are present in the urine due to diabetes, starvation or a diet
low in vegetables or carbohydrates; red blood cells may be a sign of urinary tract,
kidney disease, or tumors.45,46 Chemicals needed to produce common urinary dip-
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sticks could be converted into inks and then inkjet-printed on paper. In the same
way as with urinary dipsticks, analytes present in other biological fluids -blood,
saliva, sweat– could be used to detect other diseases, dietary conditions, or drug
abuse situations.4,47
Furthermore, this platform may be suitable to print immunoassays. Immuno-
assays are based on the interaction between antigens and antibodies to detect
target proteins from pathogens or the host immune reaction and have been suc-
cessfully used to detect a wide variety of pathogen types (viruses, bacteria, and
parasites), and non-communicable diseases.48 Immunoassays have been produced
using inkjet printers;11 however, to best of our knowledge, no immunoassays have
been developed using inexpensive desktop printers.16 We performed preliminary
experiments printing ‘capture’ antibodies on nitrocellulose paper. Printed anti-
bodies were fully functional. They recognized a ‘detection’ antibody conjugated
to Alexa Fluor R© (Thermo Fisher Scientific). These preliminary experiments show
great promise to produce fully printed deployable immunoassays using consumer
printers. More information about these preliminary experiments can be found in
Appendix B.
We are currently working on expanding the amount of inks and increasing
the application to other diseases that are mostly prevalent in emerging nations.
Additionally, an online database with ink formulations and properties could be
developed and shared between users around the world. Next steps include applying
this system in developing countries with printers and resources locally available
and providing mentorship when needed.
To conclude, although there are a wide variety of diagnostic assays for develop-
ing countries, they very rarely can be produced locally. Future research in the area
of diagnostics for developing countries should prioritize the end goal of fabricating
the diagnostic devices by locals, with local resources, and giving more autonomy
to the local population.
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3.5 Concluding Remarks
We herein described simple chemical ink preparation formulations, and easy and
rapid methods for ink characterization allowing printing inexpensive diagnostics
with domestic inkjet printers. A successful proof of concept for iodine determi-
nation in the concentrations present in the urine is provided, demonstrating the
versatility of this fabrication method. With only a low-cost inkjet printer, few
chemical reagents, and easy to follow chemical ink preparation recipes, it is possi-
ble to develop diagnostic strips for biomarkers of a wide variety of diseases. The
fact that no high-tech infrastructure and no highly trained personnel is needed,
makes this technology ideal to be exploited in developing countries. When medi-
cal devices are fabricated by locals with local resources, they are no longer black
boxes that cannot be repaired when they breakdown or malfunction, but rather
they are technologies that can be locally sustained and fixed, and open the door
to innovation.
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Chapter 4
Low-cost, real-time,
continuous-flow PCR and
RT-PCR systems for pathogen
detection
4.1 Introduction
As described in previous chapters, currently the diagnosis of infectious diseases is
usually done by culture (bacterial), immunoassays, or nucleic acid assays. How-
ever, each format has its drawbacks. Cultures are very slow (18–48 h) and are typi-
cally performed in centralized laboratories by trained personnel, making adapta-
tion to POC devices cumbersome. Immunoassays are an improvement over cultures
in that they can be very rapid but unfortunately, they can exhibit poor sensitivity
in many cases. Nucleic acid assays are rapid and sensitive but are historically
costly and nearly always require trained personnel. The sensitivity and rapidity of
nucleic acid-based tests have prompted us, and others, to re-engineer these types of
tests to substantially reduce the associated costs and training required. A nucleic
acid based POC device would be highly desirable and particularly promising for
developing countries. They would allow rapid diagnosis of pathogens and diseases
which otherwise would be impossible in terms of rapidity, sensitivity, and prompt
treatment initiation. As previously described in Chapter 2, the development of this
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nucleic acid device addresses the prioritization criteria 1, 5, 6, and 8 for device de-
velopment. First of all, this device would aid to reduce the burden of infectious
diseases (criterion 1). Criterion 5 (feasibility of developing an appropriate test)
was selected for inclusion because the individual technologies required to build the
system are very close to hitting low-cost, and large-scale production benchmarks.
Currently, there are few nucleic acid-based POCTs available in the market; there-
fore their development should be prioritized according to criterion 6 (availability
of tests in market and their sensitivity and specificity). Additionally, since infec-
tious diseases are more prevalent in developing countries, which have the fewest
economical resources, the bioethical justice principle (criterion 8) is emphasized.
Three cases where prompt diagnosis and treatment of infectious disease would
substantially reduce patient morbidity are Chlamydia trachomatis, Escherichia
coli O157:H7 and Ebola virus (EBOV). C. trachomatis is the most common bac-
terial sexually transmitted disease and the single most important infectious agent
associated with blindness (trachoma).1 Approximately 92 million people are in-
fected with C. trachomatis each year with more than two thirds of them living
in developing countries.2 Long-term infected patients may develop pelvic inflam-
matory disease, infertility, or miscarriage.3,4 Worldwide, approximately 84 million
people suffer C. trachomatis eye infections and 8 million are irreversibly visually
impaired by trachoma.5 Diagnosis of the bacteria and initiating treatment in the
first clinical encounter is key for increasing treatment success rates. C. trachomatis
infection is very often asymptomatic (approximately 80 % of women and 40 % of
men)2 and most prevalent in young people, who generally are less prone to seek
for medical attention, return to second medical appointments, or follow lengthy
treatments, especially when asymptomatic.6 As previously stated, the expected
impact of a new test to diagnose often asymptomatic chlamydial infections is very
high (prioritization criterion 2).
Infection with E. coli O157:H7 can cause hemorrhagic diarrhea and kidney
failure and is associated with consuming contaminated food or drinking-water
(fecal-oral route).7,8 Diarrheal disease is the second leading cause of death due to
infection in children under five years of age worldwide.9,10 Diarrheal diseases are
responsible for more than 15 % of all deaths of children between 1 month and 5
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years of age in low-income countries and more than 30 % of all deaths due to infec-
tious diseases for the same population group.11 The risk of dying due to diarrheal
diseases is 100 times higher for a child living in low-income countries compared to
one of high-income countries.11 Diarrheal diseases can be caused by a variety of
bacterial, viral, and parasitic organisms. Making a prompt and accurate diagnosis
of the responsible pathogen would allow for rapid initiation of the right treatment
and would avoid the overuse of antibiotics and the rise of antibiotic resistance.6,12
Diagnostic devices for diarrheal causative pathogens should be prioritized accord-
ing to criterion 4 (availability, expense and toxicity of treatment). The importance
of receiving the right treatment is even more critical in the case of these entero-
hemorrhagic strains of E. coli as receiving the wrong treatment often makes the
disease worse.7,13
Ebola virus disease (EVD) is an acute, severe, and often fatal illness in hu-
mans which is caused by infection with a virus of the family Filoviridae, genus
Ebolavirus. There are five identified Ebola virus species: Zaire, Bundibugyo, Su-
dan, Reston and Ta¨ı Forest.14,15 The virus is transmitted to people from wild
animals and spreads in the human population through human-to-human trans-
mission.14 Currently, most of the infections occur in equatorial Africa. The average
EVD case fatality rate is around 50 %, although case fatality rates have varied
from 25 % to 90 % in past outbreaks. In the case of 2014 West African outbreak,
the case fatality rate was approximately 50 % and was caused by Ebola Zaire
virus.16 EVD is difficult to diagnose through its early symptoms, such as fever,
since they are very similar to other common infectious diseases such as malaria,
typhoid fever, and meningitis. Prompt and accurate EVD diagnosis is key for
successful outbreaks control since it requires isolating patients from the commu-
nity to prevent continued virus spread. Additionally, early supportive care with
rehydration and symptomatic treatment improves survival.14 Unfortunately, there
is no proven treatment or vaccine available for EVD; however, a range of potential
treatments and vaccines are being evaluated.14 The development of a diagnostic
device that allows differentiating Ebola disease when the early symptoms appear
from other fever related diseases, attends to prioritization criteria 2 and 4.
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As previously stated, nowadays there are few POC nucleic acid tests (NAT)
to diagnose infectious diseases like those described; however, new technological
advances are enabling PCR to be used for POC diagnostic devices. Thus, since
the development of the first PCR, there has been ongoing research in the area
to miniaturize conventional thermocyclers, allowing for faster amplification, lower
fabrication costs, reduction of sample and reagents required, higher portability,
and easier integration.17 These advances are enabling PCR to be used as a POC
diagnostic device.
Most nucleic acid assays are based on selective amplification of target nucleic
acid sequence through specific in vitro enzymatic reactions.18 Polymerase chain
reaction (PCR), invented in 1986, is the preferred method due to its simplicity,
well understood methodology, extensively validated standard operating procedure,
and availability of reagents and equipment.19 PCR is based on thermal cycling and
generally involves three basic steps: denaturation, annealing, and extension. Du-
ring the denaturation step, a double-stranded DNA molecule is separated into two
single-strands by a heat separation conducted at approximately 95 ◦C. The anneal-
ing step takes place at approximately 55–65 ◦C during which two oligonucleotide
primers (approximately 20 nucleotides) which flank the target sequence, bind in
a complementary fashion to the two single strands (annealing). Afterwards, the
temperature is increased to approximately 72 ◦C, at which a DNA polymerase ex-
tends the primers (successive additions of deoxy-nucleotide triphosphates dNTPs).
At the end of each thermal cycle, the amount of target sequence doubles. Multiple
thermal cycles increase the target sequences exponentially.18
Most commonly, PCR is performed in a stationary chamber and the tempera-
ture of the surrounding reaction chamber is cycled between two or three different
temperatures.20 The first PCR chip, developed in 1993, was based on stationary
chamber.21 However, in 1998, a flow-through PCR chip was developed which uti-
lizes fixed temperatures zones and flows the PCR solution between the heated
areas in a cyclic manner.22 With this design, the device does not have to be heated
and cooled and this facilitates faster cycling, and as a consequence, faster PCR.
This design also allows higher flexibility to change the reaction rate, reduces the
possibility of cross-contamination allowing for very specific amplification, and faci-
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litates the integration to other systems.17,20 Within flow-through PCR, three main
design types are usually distinguished: serpentine rectangular channels, circular
arrangement of temperature zones, and single straight capillary.20 A schematic
figure of these designs is presented in Figure 4.1.
Figure 4.1: Design types of continuous-flow PCR. A) Serpentine channel
continuous-flow PCR. B) Spiral channel-based continuous-flow PCR. The sam-
ple is introduced at the inlet and pumped unidirectionally towards the outlet. C)
Straight channel oscillatory-flow PCR. The sample is introduced in the inlet and
pumped back and forth in a straight channel. Temperature zones are provided by
three heaters.23
In order to achieve rapid heat transfer with any of the PCR designs, the chip
substrate material plays a key role. Additionally, the selection of substrate ma-
terial to create the chip device is also crucial to determine the chip cost, ease of
fabrication, disposability, biocompatibility, optical transparence, etc.20 Much re-
search on chip materials has been conducted over the years. Although no single
material is ideal, currently polymeric materials are considered the preferred and
most promising option.17,20
The success of the amplification can be either detected at the end of the PCR
(end-point PCR) or while the amplification takes place (real-time PCR). Real-
time PCR allows for fine quantification of the initial DNA template or pathogen
load, is faster, more sensitive, and avoids post-sample processing;20,24,25 however, as
expected, it is a more expensive technique than end-point detection. The sensing
protocol basically involves the use of reporters or labels that emit a signal when
the binding event takes place. The reporters can be of various natures, such as
optical, electrochemical, and microgravimetric (mass-sensitive).18 Among them,
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optical methods, and particularly fluorescence-based techniques are the most popu-
lar due to the high sensitivity, high selectivity, and commercial availability (and
therefore reduced costs) of fluorophores.18
While both individual technologies of real-time PCR and continuous-flow PCR
have been in use for some time, to the best of our knowledge, there are no
continuous-flow quantitative PCR systems available in the market. A possible rea-
son for the absence in the market of these types of devices is that newly proposed
devices in the literature are not typically designed with the ultimate production
and distribution goal of the device in mind. A standard approach to developing
new diagnostic devices is to optimize all features for detection of the disease state
without much thought being given to materials used or available industrial-scale
manufacturing methods. A severe shortcoming of this approach is that while the
device ‘works’, introduction to the market is often significantly delayed or is pre-
vented altogether because the device cannot be translated to the industrial scale.
Thus, many promising diagnostics are stuck in the ‘R&D’ phase indefinitely.
As previously described in Chapter 2, a ‘holistic approach’ to POC device
design is one in which considerable attention is given to the end goal of introduction
to the market by selection of materials and designs that can be used in industrial-
scale manufacturing processes. The biology and laboratory work is optimized
within the context and constraints of those initial design and material choices.
Thus, translation to the market at the end of development is greatly facilitated.
In this context, we present here such a holistic approach to the development
of a portable and low-cost POC real-time fluorescence-based continuous-flow PCR
system. The system is based on a disposable serpentine channel chip designed
for economic manufacture by roll-to-roll methods which would allow for scale-
up to industrial-level production. We describe the system design and the chip
prototype and production. We specifically discarded designs that had low potential
for translation to the industrial scale. The system could be applied to the diagnosis
of any DNA pathogen and it was here tested with three infectious pathogens, C.
trachomatis L2, E. coli O157:H7 and Ebola Zaire virus.
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4.2 Materials and Methods
4.2.1 Chip design, manufacture, and bonding
Table 4.1: Reagents, equipment, and software for chip design, manufacturing, and
bonding.
Name Reference Vendor
Reagents
Chip blank Zeonex COP690R, 2 mm Zeon Chemicals L.P.
Chip blank Zeonex 690R, 0.25 mm Plitek LLC
Chip cover slip ZF14–188, 0.185 mm Zeon Chemicals L.P.
Decahydronaphthalene D251 Sigma-Aldrich
Ethanol 187380 Sigma-Aldrich
Equipment
Hydraulic hot press In-house Fraunhofer CMI
Milling machine UPM 0005 Fraunhofer IPT
Oven IsoTemp Oven 851F Thermo Fisher Scientifc
Profilometer Conturograph CV200 Mahr GmbH
Laser cutting machine Zing 16 Epilog Laser
Ultrasonic cleaner 1510–DTH Branson Ultrasonics
Plasma Treatment System PS 0500 Plasma Tech. Systems
Drop Shape Analyzer DSA 100 KRU¨SS GmbH
Software
Pro/ENGINEER Wildfire 3.0 Parametric Tech. Corp.
Several chips with different characteristics were designed and fabricated during
this thesis. All chips were designed in-house using the CAD program Pro/ ENGI-
NEER Wildfire 3.0. Chips were fabricated in-house using either an ultra-precision
milling machine or by hot embossing as described.
Chip manufacture
Chip milling Blank chips were machined according to the desired design using
an ultra-precision milling machine. Once the chips were completed, the chip lu-
bricant was cleaned off using soap and the burrs were removed. Chips were then
rinsed with water and stored.
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Chip embossing Embossing is the process by which a metal mold containing
the negative image of the device’s desired features is pressed into the final device
material. Negative molds were produced in-house using an ultra-precision milling
machine according to the requested design. A Fraunhofer CMI custom-made hy-
draulic hot press was used to press the chip blank with the mold. The mold and
chip blank were placed between aluminum platens and stainless steel sheets and
shims. They were stacked inside the hot press as shown in Figure 4.2 and pressed
under vacuum at high temperature and pressure conditions. The specific tempe-
rature and pressure conditions were improved over the course of this work and are
described in the Improvement section (Section 4.4.1). In Figure 4.3 pictures of
the hydraulic hot press and a chip mold are shown.
Figure 4.2: Disposition of platens and shims for hot embossing technique. 1, 2)
Aluminum platens. 3) Stainless steel sheet. 4) Stainless steel shim. 5) Chip
substrate material. 6) Embossing mold.
Once the hot embossing process was completed, inlet and outlet holes were
carefully drilled using a screwdriver since they were not fully drilled from the
embossing process. Afterwards, chips were cleaned off using soap and then rinsed
with water. Chips were dried inside the oven and stored.
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Figure 4.3: Pictures of CMI hot-press and hot embossing PCR mold. A) Picture
of CMI custom-made hydraulic hot press. B) Picture of the PCR chip mold used
for hot embossing. C) Close view of some features of the PCR chip mold.
Chip bonding
In order to seal the channels, chips were bonded with a cover slip from the same ma-
terial. Two types of bonding procedures were performed: solvent-assisted bonding
and plasma bonding.
Solvent-assisted bonding The surface of the chips and the cover slips were
activated for the bonding process. The surface activation steps were performed in-
side the fume hood using two closed stainless steel containers to avoid evaporation
of the chemicals and prevent variations in the chemical composition. The first con-
tainer was filled with a mixture of decahydronaphthalene:ethanol (35:65 %(v/v))
and the second container with ethanol. Using tweezers, the microstructured chip
was placed in the decahydronaphthalene:ethanol mixture container and gently agi-
tated for a specific time period between 30–60 s. Then, the chip was introduced in
the ethanol container and agitated constantly for 2 min. Afterwards the chip was
dried using compressed air. The same procedure was repeated with the cover slip
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with the side to be bonded to the chip facing up. The time inside the decahydro-
naphthalene:ethanol mixture container was optimized over the course of this work
and is discussed in detail in Section 4.4.1. Briefly, longer times result in stronger
bonding while shorter times result in weaker bonding. After the surface of both
chip and cover slip was activated, they were pressed together using the Fraunhofer
CMI hydraulic hot press. The chip and cover slip were placed inside the hot press
between aluminum platens, and stainless steel shims and sheets stacked as shown
in Figure 4.4. Chips were hot pressed at 130 ◦C and 3.93 MPa for 2 min.
Figure 4.4: Arrangement of platens and shims for thermal bonding. 1, 2) Alu-
minum platens. 3) Stainless steel sheets. 4) Stainless steel shim. 5) Chip. 6) Chip
cover slip.
Plasma bonding A low-pressure Plasma Surface Treatment System Model PS
0500 was used. Chips and cover slips were placed inside the vacuum chamber
with the sides to be bonded together facing up. The plasma treatment system
was programmed with the desired parameters. Plasma parameters were varied
and improved during this thesis and are discussed in detail in the Improvements
section. After surface activation, the cover slip was placed on top of the chip, with
their activated sides against each other, and were pressed using the Fraunhofer
CMI custom-made hydraulic hot press at 130 ◦C and 3.93 MPa for 2 min.
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Annealing step An annealing step after either solvent or plasma-assisted ther-
mal bonding was always performed. Chips were placed inside an oven and the
annealing step consisted of a temperature increase of 0.5 ◦C/min until 125 ◦C was
reached, then the temperature was held at 125 ◦C for 15 h, and afterwards a tem-
perature decrease of 0.5 ◦C/min took place until room temperature was reached.
4.2.2 Design and description of the chip surrounding ins-
trumentation
Table 4.2: Reagents, equipment, and software for chip surrounding instrumenta-
tion.
Name Reference Vendor
Reagents
FAM C1359 Thermo Fisher Scientific
Equipment
Microfluidic connector 3000024 Dolomite Microfluidics
Syringe pump RS232 KDScientific Inc.
Cartridge Heaters FIREROD Watlow
Temperature controller CN77523 OMEGA Engineering
Thermocouples
Dichroic mirror 25x35mm Edmund Optics
Emission filter 65-699 Edmund Optics
Excitation LED light (470 nm) M470L2 ThorLabs
Excitation LED light (490 nm) M490L3 ThorLabs
Camera UI-1480-C IDS GmbH
Camera UI-3240CP-M 1st Vision
10x microscope objective 46–144 Edmund Optics
FITC fluorescence filter set MDF-FITC ThorLabs
Femtowatt photodetector Newport Corp.
30/70–beamsplitter, 25 mm2 MDF-FITC ThorLabs
Filter cube for detection 56-264 Edmund Optics
Filter cube for excitation 56-264 Edmund Optics
Optical meter 1835-C Newport Corp.
Software
ImageJ NIH
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The system was designed around a microfluidic chip with fluidic, thermal, and
optical interfaces. A schematic drawing of the system is presented in Figure 4.5.
The nucleic acid sample and other PCR reagents were introduced to the chip using
a syringe pump. A microfluidic connector was used between inlet and outlet tubes
and the microfluidic chip to facilitate easy loading of the chip. Heaters below the
chip control the chip temperature in the different zones. Each heater consisted
of an aluminum heat block, a Watlow FireRod cartridge heater, a thermocouple,
and a programmable temperature controller. Heaters were thermally isolated from
each other and the rest of the setup by a ceramic baseplate which has low thermal
conductivity.
Figure 4.5: Schematic drawing of the instrumentation surrounding the PCR chip.
1) Chip input port connected to a syringe pump. 2) Chip. 3) Heaters. 4) Micro-
scope objective. 5) Camera. 6) Chip output port.
Fluorescein amidite (FAM) probes were used as fluorescent reporters of the
amplicons generated during the PCR. Fluorescence was excited by a 490 nm LED
source through the standard microscope fluorescein isothiocyanate (FITC) fluo-
rescence filter set with excitation centered at 475 nm and emission centered at
530 nm. The excitation light was focused onto the sample using a 10x microscope
objective. Fluorescence generated by the sample was collected through the same
microscope objective into the tube lens assembly. The image of the sample fluo-
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rescence was formed 200 mm from the back surface of the lens. Collected light was
directed to the optical detector/measuring system which was modified during this
thesis and more details are provided in the Improvements section (Section 4.4.2).
A charge-coupled device (CCD) camera was placed into the sample image plane.
During the experiment, the real-time CCD image of the sample was generated
with a broadband illumination source placed underneath the sample. The image
was used to pre-align the target channel. Further information about the optical
system improvements can be found in Section 4.4.2.
4.2.3 PCR reagents and protocol
PCR Reagents
Table 4.3: Reagents, equipment, and software for the preparation of the PCR
reagents
Name Reference Vendor
Reagents
Genomic DNA E. coli O157:H7 0801622DNA-10UG ZeptoMetrix
PCR kit for E. coli Path-e.coli-0157-std PrimerDesign
E. coli IDT primer/probe set 1
Forward primer ATGT CAGA GGGA
TAGA TCCA
IDT
Reverse primer TATA GCTA CTGT
CACC AGAC AAT
IDT
Probe CGCT TTGC TGAT
TTTT CACA TGTT
ACC
IDT
E. coli IDT primer/probe set 2
Forward primer TGTC CGTA ACAT
CCTG TGTA TC
IDT
Reverse primer CAAA GAGA GCTG
CAAC CTTA AC
IDT
Probe TCAA GTAG TCGC
ATGA GATC TGAC
CAGA
IDT
USB VeriQuest R© Fast Probe
qPCR Master Mix
75680 Affymetrix
C. trachomatis bacteria Kindly provided by Dr.
Michael N. Starnbach
Continued on next page
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Table 4.3 – continued from previous page
Name Reference Vendor
Genomic DNA purification kit 51104 Qiagen
C. trachomatis primer/probe set
Forward primer GGAG GCTG CAGT
CGAG AATC T
IDT
Reverse primer TTAC AACC CTAG
AGCC TTCA TCACA
IDT
Probe TCGT CAGA CTTC
CGTC CATT GCGA
IDT
pcDNA3.1(+) plasmid with tar-
get EBOV sequence
Genscript
Competent cells C2988J New England Biolabs
Plasmid DNA purification kit 27104 Qiagen
Restriction enz. SmaI R0141S New England Biolabs
Restriction enz. NdeI R0111S New England Biolabs
Restriction enz. XhoI R0146S New England Biolabs
Restriction enz. buffer CutSmart R© Buffer New England Biolabs
Gel extraction kit 28704 Qiagen
In vitro transcription kit AM1333 Thermo Fisher Scientific
Purification kit for in vitro trans-
cribed RNA
AM1908 Thermo Fisher Scientific
EBOV IDT primer/probe set
Forward primer GTCC GTCG TTCC
AGTC ATTT
IDT
Reverse primer CCCT CTTG GATG
CTGA GTTA TG
IDT
Probe TAAG TGAC TCTG
CTTG CGGT ACAG C
IDT
DNA Decontamination AM9890 Thermo Fisher Scientific
RNase Decontamination 10328011 Thermo Fisher Scientific
BSA BlockerTM 37525 Thermo Fisher Scientific
PEG 8000 V3011 Promega Corp.
96 well PCR plate N8010560 Thermo Fisher Scientific
Adhesive Film for PCR plate 4311971 Thermo Fisher Scientific
DNA Ladder N04745 New England Biolabs
SYBR R© Green Nucleic Acid
Stain
50513 Lonza
6 % TBE Gels 10 Well EC6265BOX Thermo Fisher Scientific
6 % TBE Gels 15 Well EC62655BOX Thermo Fisher Scientific
TBE Sample Buffer LC6678 Thermo Fisher Scientific
Continued on next page
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Table 4.3 – continued from previous page
Name Reference Vendor
Equipment
qPCR thermal cycler AB 7500 Thermo Fisher Scientific
Spectrophotometer NanoDrop Lite Thermo Fisher Scientific
Rotary shaker Maxi Rotator Lab Line Instruments
Electrophoresis chamber XCell SureLockTM Thermo Fisher Scientific
Power source 93000-744 VWR International
Blue Light Transilluminator Safe ImagerTM2.0 Thermo Fisher Scientific
Software
GraphPad Prism Version 6.07 GraphPad Software
The performance of the PCR and RT-PCR systems were evaluated with C.
trachomatis, E. coli, and Ebola virus (EBOV). Next is described the materials and
methods followed for the preparation of the DNA and RNA pathogenic templates
and for on-chip and off-chip PCR and RT-PCR.
C. trachomatis genomic DNA and primer/probe sets. C. trachomatis
genomic DNA was isolated and purified from C. trachomatis bacteria using Qiagen
kit 51104 following a protocol for isolation of genomic DNA. The purified DNA
concentration was measured with NanoDrop Lite Spectrophotometer and diluted
to the desired concentration. The number of DNA copies of the target sequence
per volume of stock solution (Cs) was calculated using Equation 4.1 and based on
the measured concentration (m), and the length of C. trachomatis strain L2 (Ls)
(1038842 bp, NCBI GenBank database).26 A molar mass per base pair (Mbp) of
660 (g/mol)/bp was used. The primers/probes were designed to amplify a 85 bp
long segment of the 16S RNA gene and were custom-made by Integrated DNA
Technologies (IDT); their sequences are shown in Table 4.2.
Cs =
NAv ·m
Ls ·Mbp (4.1)
where Cs is the copies of target sequence per volume of stock solution, NAv is
Avogadro’s number, m is the spectrophotometrically measured concentration, Ls
is the target sequence lenght, and Mbp is the molar mass per base pair.
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E. coli genomic DNA and primer/probe sets. Genomic DNA E. coli
O157:H7 strain EDL933 was used as target. The DNA concentration in the stock
solution was measured using NanoDrop Lite Spectrophotometer and diluted to
the desired concentration as indicated. The number of DNA copies of the tar-
get sequence per volume of stock solution was calculated using Equation 4.1
and based on the measured concentration, and the length of E. coli O157:H7
EDL933 (5528445 bp, NCBI GenBank database).26 A molar mass per base pair
of 660 (g/mol)/bp was used. Three primer/probe sets for E. coli 0157:H7 were
tested. The first set of primer/probe was designed and purchased from Primer
Design. The primers/probe sequences were not provided. The amplicon generated
during PCR was 76 bp long and the predicted Tm was 71.5
◦C. The two other
primer/probe sets were purchased from Integrated DNA Technologies (IDT). Both
sets were targeted against the virulence gene STX1A. The primer/probe sequences
for both IDT sets are specified in Table 4.2; the amplicon size for set 1 and 2 are
69 bp and 99 bp respectively. Bovine serum albumin (BSA) (Thermo Fisher Sci-
entific Inc., Waltham, MA) at a final concentration of 0.05 %(w/v) was added to
VeriQuest R© Fast Probe qPCR Master Mix at a final concentration of 1x for both
C. trachomatis and E. coli O157:H7 amplification.
EBOV RNA and primer/probe sets. A pcDNA3.1(+) plasmid vector con-
taining a target region of EBOV L gene was designed in-house from Makona vari-
ant EBOV sequences (2014 EBOV outbreak) and was purchased from Genscript R©.
The L gene was selected as the target since it codes for the well-conserved RNA-
dependent RNA polymerase.23,24 Competent bacteria 5-alpha E. coli cells were
transformed with the plasmid of interest for plasmid banking and replication pur-
poses. Bacteria containing the target plasmid were selected by exposure to ampi-
cillin antibiotic. The plasmid containing the L gene fragment was isolated and
purified using Qiagen kit 27104. The plasmid was then linearized using the re-
striction enzyme SmaI and subsequently double digested using the restriction en-
zymes NdeI and XhoI. The cloned L gene fragment was digested and gel purified
to provide clean template for RNA in vitro transcription using the MEGAscript
in vitro transcription kit AM1333 and MEGAclear kit AM1908 respectively. The
primers/probe were designed to amplify a 120 bp long segment of the L RNA
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gene and were custom-made by Integrated DNA Technologies; their sequences are
presented in Table 4.2.
Two one-step RT-qPCR master mixes were tested. First, the commercial
Affymetrix VeriQuest R© Probe One-Step qRT-PCR 75700 was used. It is composed
of an RT-enzyme and a standard DNA-polymerase and is referenced as ‘commer-
cial’ master mix. Secondly, a custom made one-step master mix which combines
the RT-enzyme from Affymetrix VeriQuest R© Probe One-Step qRT-PCR 75700 and
the fast DNA-polymerase included in Affymetrix VeriQuest R© Fast qPCR Probe
75680 was kindly provided by Affymetrix Inc. and is referenced as ‘custom’ master
mix. Independently of the master mix used, bovine serum albumin (BSA) at a
final concentration of 0.05 %(w/v) was added.
Off Chip-PCR protocol
The working area and pipettes were cleaned with DNA and/or RNAse deconta-
mination solutions to avoid DNA and/or RNAse contamination. DNA/RNAse
free reaction tubes were used to prepare the PCR solutions. Each PCR reagent
was incorporated to the PCR mix according to the desired PCR mix composition.
The final volume of each PCR sample was 20 µl. An optical 96 well PCR plate
was used and it was sealed with an optical adhesive film. The PCR plate was
shortly centrifuged. An Applied Biosystems 7500 PCR system was used for off-
chip real-time qPCR. The thermal profile protocol was programmed as required
and fluorescence measurements were acquired during the thermal cycling phase
automatically.
In the case of C. trachomatis and E. coli off chip PCR, the thermal protocol
consisted in an initial hold of 2 min at 50 ◦C and a 95 ◦C hold for 5 min followed
by 40 cycles of 95 ◦C for 3 s and 60 ◦C for 30 s. For EBOV off chip RT-qPCR
different off-chip thermal profile protocols were followed and they are summarized
in Table 4.4. For both master mixes, the ‘slow’ protocol corresponds to the protocol
recommended by the manufacturer.
The ratio of fluorescence emission intensity of the reporter dye to the fluores-
cence emission intensity of the passive reference dye (∆Rn) was provided by the
PCR machine. FAM probes were used as reporter dyes. ∆Rn was plotted against
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Table 4.4: Thermal profile protocol for off chip RT-qPCR.
Name RT Polymerase Activation Thermal Cycling
Commercial 1 step RT-PCR mix
Slow 15 min, 50 ◦C 10 min, 95 ◦C 15 s, 95 ◦C 30 s, 60 ◦C
Mid 5 min, 50 ◦C 10 min, 95 ◦C 15 s, 95 ◦C 30 s, 60 ◦C
Rapid 5 min, 50 ◦C 5 min, 95 ◦C 3 s, 95 ◦C 30 s, 60 ◦C
Custom 1 step RT-PCR mix
Slow 15 min, 50 ◦C 5 min, 95 ◦C 3 s, 95 ◦C 30 s, 60 ◦C
Rapid 5 min, 50 ◦C 5 min, 95 ◦C 3 s, 95 ◦C 30 s, 60 ◦C
the PCR cycle. The CT values of each PCR curve were provided by the PCR pro-
gram. The CT value is the fractional cycle number where the fluorescence passes
the fixed threshold of the negative control. The threshold was internally deter-
mined by the system. CT values were plotted versus the concentration of template
nucleic acid sample on a logarithmic scale. The slope (s) of the linear regression
was used to determine the PCR efficiency (ηPCR) according to Eq. 4.2.
ηPCR = 100 % ·
(
10−
1
s − 1
)
(4.2)
On-chip PCR protocol
Previous to performing on-chip PCR, chips were sterilized. Only chips used for the
first time did not require a sterilization step. For sterilization, a 10 %(v/v) bleach
solution was flushed through the chip channel for 10 min. Sterile DNA free water
was then flushed to remove bleach residue from the chip. The chip was then vacuum
dried. In some cases, the inner walls of the PCR chip were statically passivated
with 1 %(w/v) BSA prior to performing PCR. BSA was flushed through the system
and chip channel for approximately 30 min. The effect of static passivation in
on-chip PCR performance was studied and further details are described in the
Improvement section.
Once the chip was sterile and ready to be used, the PCR mix solution was
prepared and the heaters under the chip were turned on. Heaters were switched
on approximately 30 min before starting the PCR experiment to assure stable
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heating at the desired temperature. The working area and pipettes were cleaned
with DNA and/or RNA decontamination solutions to avoid DNA and/or RNA
contamination. DNA/RNA free reaction tubes were used to prepare the PCR
solutions. Each PCR reagent was incorporated to the PCR mix according to
the desired PCR mix composition. The final volume of each PCR sample varied
between 70–250 µl; although most PCRs had a 70 µl total volume. Master mix
reagents were pre-mixed prior to start the PCR run. The PCR mix was aspirated
through a sterile empty microfluidic tube which was connected to a 1 ml syringe
filled with approximately 200 µl of DNA/RNA free water. The water inside the
syringe allowed for a more constant flow rate of the PCR mix as fluids are less
compressible than air. Air inside the microfluidic tube separated the PCR mix
from the water that was used for pushing the PCR sample. The tube containing
the PCR mix was connected to one of the input ports of the chip through a
Dolomite microfluidic connector. The syringe was placed on the syringe pump
and the liquid was pumped into the chip. There is also an option of introducing
DNA sample and master mix reagents through different input ports and achieving
mixing inside the chip. This option was not used for the experiments described in
this thesis but was incorporated in the design for future iterations of the assay.
The flow velocity inside the chip was routinely calculated through the course
of the PCR by measuring the time that an air bubble or a fluid front traveled
through a known distance. The flow rate set in the syringe pump was adjusted
as needed such that the flow velocity was as close as possible to the target. The
flow velocity was used to determine the residence time inside the chip (the time it
takes for a single fluid voxel to travel through the chip). The amplicons generated
during the PCR were detected by real-time fluorescence measurement and/or gel
electrophoresis depending on the stage of improvements of the optical system.
Thus, the method of collection of fluorescence measurements varied depending on
the optical system version. Collected fluorescence measurements in most cases
were normalized with the average fluorescence values from PCR cycles 4 to 16.
However, in some cases, fluorescence measurements were directly plotted against
the PCR cycle. A sigmoidal dose-response (variable slope) curve fit was applied
to the data using GraphPad Prism version 6.07 for Windows. Error bars are
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presented when there are enough data collected from each data point. Error bars
represent the standard deviation. The cycle threshold (CT ) value was interpolated
from the curve fit at the intersection with a threshold line, which was set at the
average baseline signal of channels 4 to 16 plus two times its standard deviation. In
order to determine the PCR efficiency, the cycle thresholds were plotted against
the logarithm of the initial template concentration and the slope of the linear
regression was used in Eq. 4.2.
Amplicon detection by gel electrophoresis. Amplicons generated by ei-
ther off-chip or on-chip PCR/RT-PCR were examined by gel electrophoresis. A
XCell SureLockTMelectrophoresis chamber was used with 6 % polyacrylamide Tris/
Borate/EDTA buffer (TBE) gels. TBE 1x was used as running buffer. Samples
were prepared by adding TBE sample buffer to the PCR samples in a 1:5 %(v/v)
proportion. A low molecular weight DNA ladder, with a 25–766 bp range, was
used. Samples mixed with TBE sample buffer were loaded to the gel and run at
a constant voltage of 125 V for 40 min. The gel was gently agitated in 50 ml of
1x SYBR R© Green staining buffer for 25 min for visualization. A blue light tran-
silluminator was used to visualize the nucleic acid bands. Gel pictures were taken
with a digital camera.
4.3 System Description and State-of-the-Art of
the Technology
This section aims to provide a vision of the state-of-the-art of the technology con-
cerning microfluidic lab-on-a-chip devices, and it is specially focused on continuous-
flow and real-time PCR in order to aid the understanding of the design of our
system. Continuous-flow microfluidic PCR systems can be divided in two major
components: a microfluidic chip and the instrumentation that surrounds it. Addi-
tionally, the reagents required for the amplification also play a key role. Thus, this
section is subdivided into three main areas: chip, surrounding instrumentation,
and reagents.
104
4.3.1 Chip
Chip designs state-of-the-art
As previously described, within continuous-flow PCR three main design types
are usually distinguished: serpentine rectangular channel, circular arrangement
of temperature zones, and single straight capillary.20 A schematic figure of these
designs was presented in Figure 4.1. The serpentine rectangular channel is the
most common design used in flow-through PCR due to its simplicity.22,27–30 Some
of the designs included outlets at different channels to allow performing thermal
cycling a variable amount of cycles.27 For the circular design, it is acknowledged
that PCR channels can consist of either capillary tubes31,32 or an on-chip annu-
lar channel.20,33,34 The single straight capillary design is very flexible and allows
performing variable amounts of cycles.20,35–37
Depending on the DNA-polymerase used, PCR is performed in two or three
steps and consequently chips incorporate two29,30,38 or three37,39 heating areas. On
the one hand, three-step PCR performs a denaturation step at 95 ◦C, then anneal-
ing of the primers takes place at approximately 60 ◦C, and elongation of the DNA
strands occur at 72 ◦C. Two-step cycling polymerases combine the primer anneal-
ing and the elongation step at approximately 60 ◦C. In the case of continuous-flow
RT-PCR chips, an extra heating station can be incorporated to the previous PCR
designs to allow reverse transcription to take place.27 Depending on the chip and
system design, RT-PCR is performed in one40,41 or two27,39 (RT and PCR) separate
steps. Additionally, some authors have reported RT-PCR designs which combine
stationary RT step with a continuous-flow PCR step.42
During this thesis, a serpentine rectangular channel design was selected with
two-step thermal cycling for the PCR and RT-PCR chips.
Chip materials state-of-the-art
For microfluidic lab-on-a-chip (LOAC) devices the selection of materials plays a key
role. It determines the chip physical properties, the microfabrication technique,
and the chip cost. The evolution of materials for LOAC devices reflects the main
requirements of the major user of microfluidic technologies: research laboratories
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and commercialization. In general, research laboratories are concerned about ease
of prototyping and reliability of use; while for commercialization purposes, low
production costs and reliability in use are the main driving forces.43
The most common materials used for biological microfluidic chip fabrication
are glass/silicon, elastomers, thermoplastics, thermosets, hydrogels, and paper. In
Figure 4.6 it is shown the materials for microfluidic devices versus fabrication cost
and usage in commercial and research applications.43,44
Figure 4.6: Materials for LOAC microfluidic devices versus fabrication cost and
usage in commercial and research applications. Figure adapted from Ren et al.43
The advantages and disadvantages of the different materials for LOAC are
application oriented. For the selection of an appropriate substrate material for
on-chip qPCR assays, several requirements should be considered. Firstly, the ma-
terial should exhibit high heat stability since temperatures up to 95 ◦C are required
during the PCR assay. Secondly, to sensitively measure nucleic acid amplification
via fluorescence signals, substrate materials with low-autofluorescence and high
optical transparency should be selected. For biological assays that require expen-
sive enzymatic reagents, chemical inertness, and low protein substrate adhesion
of the material are important factors. Additionally, for commercialization of a
disposable chip, inexpensive substrate materials that can be rapidly manufactured
at a low-cost with high reproducibility are preferred. A table with the application
oriented advantages and disadvantages of the different materials can be found in
Appendix C.43
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Considering all the requirements for on-chip qPCR, thermoplastics materials
stand as the best option as they fulfill most of the requisites. Poly(methyl)-
methacrylate (PMMA), polycarbonate (PC), and cyclic olefin polymer and copoly-
mer (COP/COC) are the main thermoplastic materials for used for microfluidic
applications. COP/COC present the lowest water absorption (<0.01 % in 24 h)
when comparing with other materials. When looking at the glass transition tem-
perature, the glass transition temperature of COC/COP is the highest, it can be
up to 180 ◦C, higher than for other thermoplastic materials. Additionally, the tem-
peratures at which COC/COP deforms under a specified load is high (140/170 ◦C)
and is significantly superior to PMMA or PC. In terms of thermal conductivity, all
the different thermoplastic materials have similar low conductivity values, which
is highly desirable for PCR chip applications since different temperatures are re-
quired at different parts of the chip. Regarding the optical properties, the light
transmittance of COP/COC and PMMA is as high as glass (92 %) and the usable
transmission range for the three thermoplastic materials is very wide and similar
for all of them. Additionally, fluorescence measurements of some commercial ther-
moplastic polymers were performed and are presented in Section 4.4.1. Due to the
advantageous characteristics of COP/COC, this material was selected as substrate
for chip production in this thesis. A table with the relevant physical properties of
COC/COP, PMMA and PC is provided in Appendix D, in which the properties
of Polydimethylsiloxane (PDMS) and glass are also presented for comparison.
Chip production state-of-the-art
Due to the large variety of substrate materials for microfluidic chip applications,
numerous manufacturing methods for producing such devices are available.45 The
manufacturing method for lab-on-a-chip (LOAC) devices plays a key role for pro-
ducing quality, replicable, and especially low-cost chips. During this thesis, special
importance was given to the production aspect to assure easy translation to the
industrial scale and thus facilitate introduction to the market.
As previously described, thermoplastic polymers allow fast and cheap pro-
duction. Prototyping can primarily be achieved by direct milling of the positive
microstructures. A major drawback of such manufacturing is the significant time
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consumption of the setup and machining process. Larger volumes justify the use of
replicative manufacturing methods, such as injection molding or embossing, which
use complex negative master molds and are characterized by shorter cycle times
and higher throughput.45
Embossing of thermoplastics is the process by which a metal mold containing
the negative image of the devices desired features is pressed into the final de-
vice material. Embossing is a preferred technique for nano/micro fabrication as it
provides excellent replication accuracy and it is more economic than other micro-
machining techniques such as injection molding, glass etching, or milling machin-
ing.46 Typical embossing procedures involve either hot embossing47,48 where the
material is heated to a plastic state before applying the mold or by ultraviolet
(UV) embossing49 where the mold is pressed into a semi-solid resin before a final
UV cure solidifies the features. For large-scale production, UV embossing is pre-
ferred over hot embossing since it can be performed at room temperature at higher
speed than hot embossing due to its lower temperature and pressure requirements.
A schematic drawing of UV embossing techniques is presented in Figure 4.7.
Figure 4.7: Steps for UV embossing technique. a) Mold and cover for UV emboss-
ing (shown in grey). b) A semi-solid resin (shown in blue) attached to a polymeric
substrate (in pink) is placed between the mold and the cover. c) Pressure is ap-
plied to the resin which adopts the mold shape. d) Ultraviolet light is applied to
the resin, curing and solidifying it. d) At the end of the process the resin with the
mold features is solidified.
However, embossing (either hot or UV) with a flat mold has limited capability
for large-scale production as it is difficult to imprint consistently and accurately
over a large area with a uniform pressure over the entire surface. Roll-to-roll
embossing is a better technique for economic mass production of micro-machined
structures as it is a continuous and high-throughput process that can rapidly
manufacture large areas at ambient temperatures.46,50,51 A schematic drawing of a
typical roll-to-roll UV embossing system is presented in Figure 4.8.
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Figure 4.8: Schematic drawing of roll-to-roll ultraviolet (UV) embossing fabrica-
tion setup. The numbers indicate the different components of the system. 1)
Unwinding module. 2) Polymeric substrate material. 3) Slot die coating unit. 4)
Semi-solid resin showed in pink. 5) UV lamp. 6) Embossing mold. 7) Pressure
applied to the embossing mold. 8) Rewinding module.
Due to the advantageous characteristics of the embossing technique, and espe-
cially ultraviolet roll-to-roll embossing for economical large scale production, this
manufacturing technique was selected for chip production in this thesis.
Bonding state-of-the-art
The fabrication of microfluidic chips usually involves a bonding step to seal the
microfluidic channels at the microstructured substrate to the non-structured one.
The bonding step is a challenging step in which clogging the channels, changing
their physical parameters, or altering their dimensions should be avoided.
Gluing is one of the bonding techniques for thermoplastic polymers, commonly
used to join two different polymeric parts.52 However, a common risk of this tech-
nique is blockage of the microfluidic channels if the glue layer flows into them.
UV adhesives have been used to successfully bond COP parts of a lab-on-a-chip
systems.53,54
A more frequent technique to bond thermoplastic polymers, such as COP/COC,
is thermal bonding. This technique involves heating the substrates to the glass
transition temperature (Tg) of the polymers and pressing them together.
54,55 Us-
ing this physical bonding technique, the polymer chains in-between the polymeric
parts entangle and adhere to each other. An annealing step after the bonding
step (in which the pressure is removed but high temperatures are maintained) is
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usually performed to release tension due to entangled polymers which results in
stronger bonds.
A common variant of this thermal bonding technique is solvent bonding. Sol-
vent bonding method uses a solvent which dissolves the surface of the polymers
and enables a better entanglement of the polymer chains, since these become more
mobile across the bonding interface.54 This technique can achieve a higher bond
strength at lower temperatures than regular thermal bonding. The time inside the
solvent, and the bonding temperature and time are crucial for this process and need
to be optimized. As a solvent, decalin:ethanol solution is commonly used. Wallow
et al. sealed microfluidic channels which withstood pressures up to 13–16 MPa by
immersing COP pieces in a decalin:ethanol solution at room temperature prior to
thermal bonding.54,56 Other solvent mixtures have been used, such as hexadecane
and isopropanol.54,57
Plasma activation thermal bonding is another technique to increase the bonding
strength of standard thermal bonding. Plasma activates and creates radicals on
the surface of the polymeric substrates. When plasma-activated substrates are
pressed together at high temperatures, the radicals form strong covalent chemical
bonds in addition to the physical entanglement of the polymer chain. Plasma
activation is probably the most common surface activation method. O2 plasma
has been proven to be more effective than either N2 or a mix of both gases.
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Although there are other techniques for bonding thermoplastic lab-on-a-chip
devices, plasma-assisted thermal bonding and solvent bonding are the most com-
mon ones and are the ones used and optimized during this thesis.54
4.3.2 Surrounding instrumentation
Surrounding instrumentation state-of-the-art
Systems for continuous-flow PCR are usually designed around the microfluidic
chip. Heaters, thermal sensors and controllers, and pumps are common elements
for most of the systems. The most differentiating features between the systems
described in the literature relates to the detection system. Detection can be per-
formed either off-line or on-line. Off-line detection is usually performed by gel
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electrophoresis and thus, detection is not integrated to the PCR system.27,40,41 In
this case, post sample processing time should be taken into consideration. On-line
detection systems incorporate the detection element into the system. Within the
on-line systems, the detection can be performed either at the end of the PCR (end-
point detection) or while the PCR takes place (real-time PCR). Probably the most
common end-point detection techniques is laser-induced fluorescence (LIF).32,39
Regarding real-time detection techniques used for PCR microfluidic applications,
optical detection and especially fluorescence-based is the most common technique
due to its advantageous characteristics in terms of sensitivity, selectivity, and avail-
ability.18 However, other techniques such as electrochemical, or microgravimetric
have been used.18
As previously anticipated, due to the advantages of real-time fluorescence based
detection, the focus of this thesis is in this type of detection. In Figure 4.9, a
schematic drawing of a standard continuous-flow and real-time system is shown.
The nucleic acid sample (DNA/RNA) with other PCR reagents are introduced to
the chip through an inlet port generally by using a microfluidic pump. Below the
chip, there are heaters that control the chip temperature in two or three zones.
By thermally cycling the sample, the nucleic acids are amplified and detected in
real-time via fluorescence measurements. This type of system was used for this
work.
Figure 4.9: Schematic drawing of a standard continuous-flow PCR platform with
optical detection. 1) Inlet port to the microfluidic chip. 2) Microfluidic chip. 3)
Heaters. 4) Outlet port of the microfluidic chip. 5) Optical detection system.
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4.3.3 Reagents
In addition to the sample, the PCR and RT-PCR reaction mixtures involves mul-
tiple components with very diverse properties –oligonucleotide primers, dNTPs,
enzymes, metal ions, buffers. The optimization of these reagents is crucial for the
success of the amplification. Additionally, it should be taken into account that the
possibility for one or more of the PCR reaction components to bind to the internal
surface is significant, especially for microfluidic devices. Next, the approaches to
prevent unspecific binding of the PCR reagents to the chip surface are discussed.
Surface passivation state-of-the-art
The possibility of adverse interactions between the internal surface of a microchip
and/or the sample is critical for microdevices in which the surface area/volume
ratio is 20-fold or greater than for conventional PCR tubes.59 Therefore, several
passivation procedures for the inner surface of microdevices have been proposed.
They are usually classified into static and dynamic passivation. Static passivation
consists in pre-coating the inner walls of the microchip prior to the biological
process and usually during microchip fabrication. In dynamic passivation, a passi-
vating agent is added to the reaction mix itself to prevent nonspecific surface
binding.59 Common passivation agents for both static and dynamic passivation
include proteins and polymers. The inexpensive globular protein bovine serum
albumin (BSA) and polymers such as polyethylene glycol (PEG) have been success-
fully used for microfluidic applications. These substances bind preferentially to the
inner surface of the microchip and prevent binding by components of the sample
or reagent mixture.59,60
Another approach for static passivation and/or addition of an extra functiona-
lity is the use of plasma treatment to functionalize the surface. Plasma treatment is
a powerful method to efficiently and flexibly functionalize the surface of materials
by making nanometer thick films of tailored functional group densities.61 Although
surface functionalization using vacuum plasma is well documented in the literature;
there are few studies regarding plasma functionalization in a roll-to-roll process. A
corona system, which uses atmospheric plasma, is a more appropriate method for
roll-to-roll surface functionalization. In-line slot die coating or direct immersion
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in a solution with the target molecule are commonly used to deposit molecules on
the corona-activated surface. An approach to generate a surface which prevents
the attachment of oligonucleotides or enzymes consists of surface activation using
corona treatment to generate radicals on the surface which then are allowed to react
with other molecules with hydrophobic/hydrophilic character. By controlling the
hydrophobic/hydrophilic character of the surface, it is possible to prevent/control
molecules attachment.
During this thesis, the process conditions using dynamic and static passivation
techniques including plasma methods were studied.
Summarizing, this section provided an overview of the state-of-the-art of the
current technology used for microfluidic lab-on-a-chip applications. The next sec-
tion is focused on the improvement of the chip, system, and reagents for nucleic
acid amplification.
4.4 System Improvement
In this section the development and improvements in the PCR and RT-PCR sys-
tems are described. The system was design around a disposable and low-cost chip,
which is surrounded by heaters, thermal sensors, and an optical system. As a
starting point, a chip and system designed by Fraunhofer Center for Manufac-
turing Innovation (CMI) were used. Fraunhofer CMI has extensive experience
on-chip manufacturing for diagnostic purposes.62 In September 2012, as part of
the international research project Multilayer MicroLab (ML2) funded by the Eu-
ropean Commission within the Seventh Framework Programme, the development
of a chip and a system for nucleic acid amplification was initiated. During this
thesis, the chip was improved for a more economic chip production and less reagent
consumption, the system was enhanced to allow real-time detection with high sen-
sitivity, and different biological reagents were as well tested for faster and more
specific nucleic acid amplification for the different target pathogens. This section is
subdivided into the three main areas: chip improvements, the surrounding system,
and reagent improvements.
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4.4.1 Chip improvements
Chips have a long serpentine channel that connects the input to the output ports.
They work by introducing the pathogen sample along with nucleic acid reagents
into the microfluidic channel that travel first along a 95 ◦C heated area, where
the polymerase is activated and DNA double strands are melted. Afterwards the
reagents are thermally cycled between the 95 ◦C and 62 ◦C heated areas where
annealing, DNA synthesis, and denaturation take place every cycle.
In this section, the optimization of PCR and RT-PCR chips that were designed
for amplification of DNA and RNA respectively are described. Chips were opti-
mized in terms of chip dimensions (internal and external), materials, production
method, and bonding protocol to seal the channels. The chip optimization was
conducted with the chip to amplify DNA and the improvements were later applied
to the design and fabrication of the chip for RNA amplification.
Chip generations
Chip features and dimensions were modified through the course of this thesis.
Figure 4.10 shows a schematic drawing indicating the different chip elements that
were subject to modification through the different chip generations.
Figure 4.10: Chip schematic drawing showing the different chip elements that were
subject to modification through the different chip generations. t: chip thickness;
m: mixer; d: channel depth.
PCR-chip generation 1 was developed and manufactured by milling machining
techniques at Fraunhofer CMI before the start of this thesis. PCR-chip generation
1’s outer dimensions are 47.4 mm x 46.0 mm x 2.2 mm. A 1486 mm long and
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350 µm deep thin channel connects the two input ports to the output. The total
volume of the chip is 135 µl. The channel has two different sections: a 325 mm
long activation section and an 1161 mm long thermal cycling section which has 40
repetitive serpentine channels. The chip has one input port and one output port
in the top section; both ports are connected to the microfluidic tubes through a
manifold homemade at Fraunhofer CMI. With chip generation 1 successful PCR
amplification was obtained. Figure 4.11 shows a schematic drawing of the first
generation PCR chip with the heaters superimposed and DNA-polymerase acti-
vation and thermal cycling zones marked. Additionally, PCR-chip generation 1 is
also shown in Figure 4.12A for comparison with the other PCR chip generations.
Figure 4.11: A: Schematic drawing of a PCR chip with heaters superimposed. 1)
DNA-polymerase activation zone. 2) Thermal cycling zone.
In the case of PCR-chip generation 2, the depth of the chip features was re-
duced to a mere 50 µm while keeping all other chip dimensions and elements the
same. This channel depth reduction was mainly dictated by the requirements in
the production methods that will be described later. The reduction in channel
depth resulted in a total chip volume of 20 µl instead of 135 µl (see Table 4.6)
which allowed lower reagent consumption and thus reduced costs. The reduction of
channel depth also had dramatic consequences regarding optical detection, the in-
crease of fluidic resistance, and the modification of the surface/volume ratio which
could affect the PCR master mix reagent composition. First, since fluorescence
optical measurements were taken from a small section of each PCR cycle, when the
channel depth was merely 50 µm, only approximately 50 nl were monitored within
the optical field of view, compared to approximately 350 nl for a 350 µm channel
depth (a 7-fold volume reduction). Secondly, the decrease of channel depth to
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Figure 4.12: PCR-chip generations. 1) 1st PCR-chip generation. The outer di-
mensions of this chip generation are 47.4 x 46.0 x 2.2 mm, and the chip feature
depth is 350 µm. 2) 2nd PCR-chip generation. The outer dimensions of this chip
generation are 47.4 x 46.0 x 2.2 mm, and the chip feature depth is 50 µm. 3) 3rd
PCR-chip generation. The outer dimensions of this chip generation are 46.0 x 30.9
x 2.2 mm, and the chip feature depth is 50 µm. This chip generation also includes
a mixing section. 4) 4th PCR-chip generation. The outer dimensions of this chip
generation are 46.0 x 30.9 x 0.4 mm, and the chip feature depth is 50 µm.
50 µm resulted in more than 300 times increase in fluidic resistance, making more
challenging achieving a constant flow rate inside the chip and increasing the risk
of leakages at the junctions. The fluidic resistances for chip generation 1 and 2
were 1.4 and 488.3 KPa·s/µl and were calculated using Equation 4.3; the viscosity
of the fluid was considered equal to 0.89 mPa·s as an average for buffer solutions.
R =
12Lµ
d3w
(4.3)
where R is the flow resistance for a rectangular channel; L is the length of the
channel; µ is the viscosity; d is the depth; and w is the width.
Thirdly, due to the modification of the surface/volume ratio, additional ex-
periments were performed to assure adequate master mix reagent composition.
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Despite these challenges, since the shallow channel design was necessary for eco-
nomic industrial scale production, we directed our energies into optimizing our
optical system and assay rather than just make deeper channels.
On-chip PCRs with PCR-chips generation 1 and 2 were performed to evaluate if
despite the challenges, similar amplification could be obtained with chip generation
2. In Figure 4.13 A and B the gel electrophoresis of on-chip amplification of E.
coli target amplicon (76 bp) using chip generation 1 and 2 respectively are shown.
The composition of the master mix and the initial DNA template was the same in
both cases. As can be observed, the amplification with both PCR-chip generations
provided comparable successful results.
Figure 4.13: Gel electrophoresis of on-chip E. coli O157:H7 amplicons (76 bp)
with 104 DNA copies/µl initial template concentration. Primer Design primers
were used. A) Chip generation 1. Lane L: ladder. Lane 1: On-chip positive
control. Off-chip PCR results are shown in Lane 2 (104 DNA copies/µl) and Lane
3 (0 DNA copies/µl) for comparison. B) Chip generation 2. Lane L: ladder.
Lane 1: On-chip positive control. Lane 2: Off-chip positive control. Lane 3:
On-chip negative control (0 DNA copies/µl). Lane 4: Off-chip negative control
(0 DNA copies/µl).
A new chip generation 3 was later designed, which incorporated a new inlet
port and a new feature: a mixer. The mixing section has large zig-zag turns for
achieving optimal mixing; its dimensions are included in Table 4.6. The mixer
allows the introduction of DNA sample and master mix through different inlet
ports and achieving mixing inside the chip. This option was not used for the
experiments described in this thesis but was incorporated in the design for future
iterations of the assay. This chip generation was also designed to facilitate the
microfluidic connection between the PCR chip and the microfluidic tubes. As
previously stated, both chip generation 1 and 2 used an in-house manifold as the
connector. However, microfluidic manufacturers are now developing standards for
microfluidic connections to facilitate the use of products from different providers.
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Dolomite Microfluidics is one of the main microfluidic manufacturers worldwide
and PCR chip generation 3 was adapted to fit one of their universal microfluidic
connectors. Figure 4.14 A and B show Fraunhofer CMI homemade microfluidic
connector manifold and Dolomite microfluidic connector respectively.
Figure 4.14: Microfluidic connectors between the PCR chip and microfluidic tubes.
A) Fraunhofer CMI homemade microfluidic connector manifold. 1) Inlet port. 2)
Exit port. 3) PCR chip. 4) Manifold. B) Dolomite microfluidic connector. 1)
Entrance port. 2) Outlet port. 3) PCR chip. 4) Manifold.
PCR-chip generation 4 has the same channel dimensions compared with the
3rd chip generation but it has a lower outer thickness. This reduction of the outer
thickness was possible due to the use of a different manufacturing method. While
chip generations 1, 2, and 3 were produced through milling machining, PCR-
chip generation 4 was produced through hot embossing, a preferred technique for
industrial scale manufacturing and one step closer to the target of ultraviolet roll-
to-roll manufacture. Hot embossing technique allowed microstructuring a thinner
substrate (0.2 mm), which was more difficult to achieve when using a milling
machine. Thus, this 4th chip generation has a mere 0.4 mm of thickness (see
Table 4.5). The use of a thinner substrate reduced the costs of materials and
more importantly, improved the sensitivity of the fluorescence measurements. The
thinner the substrate, the less background substrate autofluorescence and less
118
fluorescence dispersion through the substrate. A schematic drawing and picture
of the last PCR-chip generation, generation 4, is shown in Figure 4.15.
Figure 4.15: 4th generation PCR chip. A) Schematic drawing of 4th generation
PCR-chip. 1) Mixing zone. 2) DNA-polymerase activation zone. 3) Thermal
cycling zone. B) Picture of the chip.
After the successful fabrication by hot embossing and the amplification results
obtained with the 4th generation PCR-chip, new chip designs were proposed to
allow the amplification of RNA. In this case, in addition to the functionalities
present in the PCR chip, a new 50–55 ◦C heated area was incorporated to allow
reverse transcription (RT) to take place. Two RT-PCR chip designs were proposed.
The 1st RT-PCR chip design (Figure 4.16 1) uses only two heaters and requires
to be operated in two steps; the first step is stationary and the second continuous-
flow based. During the first step, the RT-PCR master mix is kept stationary at
50–55 ◦C at the RT section placed at the bottom of the chip using one of the
heaters. This section has the same volume as the polymerase activation and ther-
mal cycling section together. Once the RT step is completed, both heaters are set
to the temperatures required for thermal cycling. The PCR master mix is pushed
in a continuous-flow mode through the polymerase activation section and the ther-
mal cycling section. Both, the polymerase activation and the thermal cycling zones
are identical to those present in the 3rd and 4th PCR chip generation. This de-
sign presents several disadvantages. First, it prevents a continuous-flow system.
Second, it would increase the time to results since after the RT step is completed;
the temperature of both heaters need to be increased and approximately 15 min
are required to achieve stable temperatures before the RT-PCR can be continued.
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Third, only 16.1 µl (the volume of the RT section) of PCR master mix could be
amplified each time. As a consequence of all these operational disadvantages, this
chip design was discarded before being manufactured.
The 2nd RT-PCR chip design (Figure 4.16 2) includes a third heater. The RT
section is placed close to the inlet and outlet ports to avoid deactivation of the RT
polymerase when travelling close to the 95 ◦C area. The length and inner channel
dimensions of the RT section are equal to those of the polymerase activation zone.
Both, the polymerase activation and the thermal cycling zones are identical to
those present in the 3rd and 4th PCR chip generation. This 2nd generation RNA
chip was manufactured by hot embossing technique. Schematic drawings of both
RT-PCR chip designs are presented in Figure 4.16. In Figure 4.17, a frontal
schematic drawing of the 2nd RT-PCR chip and a picture of the chip are shown.
Figure 4.16: Schematic drawing of RNA chip design generations. A) 1st RNA chip
generation. B) 2nd RNA chip generation.
A summary of the chip outer dimensions for the different DNA and RNA chip
generations is presented in Table 4.5. For the same chips, the dimensions of the
inner chip features is shown in Table 4.6.
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Figure 4.17: 2nd generation RT-PCR chip. A) Schematic drawing of the RT-PCR
chip. 1) Mixing zone. 2) Reverse transcription zone. 3) Polymerase activation
zone. 4) Thermal cycling zone. B) Picture of the chip.
Table 4.5: Chip outer dimensions for the different DNA and RNA chip generations.
Chip generation Length (mm) Width (mm) Height (mm)
1st & 2nd PCR chip 47.4 46 2.2
3rd PCR chip 46 30.9 2.2
4th PCR chip 46 30.9 0.4
1st & 2nd RT-PCR chip 50 41 0.4
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Table 4.6: Inner dimensions of the chip features for the different DNA and RNA
chip generations.
Chip section Length (mm) Width (mm) Depth (mm) Volume (µl)
1st PCR chip generation
Polymerase activation 325 0.26 0.35 29.6
Cycles 1161 0.26 0.35 105.6
Total 1486 135.2
2nd PCR chip generation
Polymerase activation 325 0.26 0.05 4.2
Cycles 1161 0.26 0.05 15.1
Total 1486 19.3
3rd and 4th PCR chip generation
Mixing 80 0.18 0.05 0.7
Polymerase activation 325 0.26 0.05 4.2
Cycles 1161 0.26 0.05 15.1
Total 1566 20
1st RT-PCR chip generation
Mixing 87 0.18 0.05 0.8
RT section 547 0.59 0.05 16.1
Polymerase activation 329 0.26 0.05 4.3
Cycles 1134 0.26 0.05 14.7
Total 2099 36
2nd RT-PCR chip generation
Mixing 95 0.18 0.05 0.9
RT section 372 0.26 0.05 4.8
Polymerase activation 354 0.26 0.05 4.6
Cycles 1131 0.26 0.05 14.7
Total 1952 25
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Chip materials
In Section 4.3.1, the advantages/disadvantages and the relevant physical properties
of the materials commonly used for microfluidic chip applications were described.
To complement these physical properties, autofluorescence of several commercial
thermoplastic materials was measured. Autofluorescence values were measured
using the same settings and optical system as was used during experimental on-
chip measurements. The values are presented in Table 4.7. Zeonex 690 R and both
PMMA types show low autofluorescence values; however, other materials such as
polyethylene terephthalate (PET) or O-carboxyanhydride (OCA) present higher
autofluorescence and thus are less desirable for our microfluidic chip application.
Table 4.7: Autofluorescence of several commercial thermoplastics materials. Va-
lues taken using the same disposition and optical system as when recording experi-
mental fluorescence on-chip measurements.
Sample Mean fluorescence (W)
Air 1.77 ·10−11
Zeonex 690 R 2.00 ·10−11
PMMA 200 µm, Evonik Plexiglas 0F058 1.78 ·10−11
PMMA 250 µm, Microsharp 2.37 ·10−11
PET 100 µm, HiFi Films PMX17C 5.76 ·10−11
PET 50 µm, HiFi Films PMX17C 4.12 ·10−11
OCA 50 µm, Tesa 69402 2.99 ·10−11
OCA 50 µm, 3M 8172 3.90 ·10−10
Polyolefin sealing film 100 µm, HJ-Bioanalytik 900320 2.14 ·10−11
PET 140 µm, Novacentrix Novele IJ-220 8.11 ·10−11
PET 120 µm, DuPont Tejin Films Melinex STCH11/500 3.36 ·10−11
Considering the advantages/disadvantages, the relevant physical properties of
the materials commonly used for microfluidic chip applications, together with the
requirements for on-chip qPCR, COC/COP was selected as substrate material (see
also Section 4.3.1). Specifically, Zeonex, a brand name for COC, was chosen.
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Chip production
Chips produced during this thesis were specifically designed to be compatible with
roll-to-roll UV embossing production due to its advantageous characteristics for
large-scale production as previously described in Section 4.3.1. Due to the re-
quirements of this technique, the depth of the chip features was 50 µm, which
is an appropriate depth for the structure to be produced on a roll-to-roll ultra-
violet embossing process according to companies in this sector63,64 and a private
communication from Dr. Xin Li from Microsharp Innovation.
Initial chip prototypes were directly machined using a milling machine. Once
the prototype was successful, an embossing mold was produced and chips were hot
embossed. Most of the experiments presented in the following sections were per-
formed using hot embossed chips. Milled machined and hot embossed chips present
very different characteristics. While milled chips have sharp edges and controlling
the exact depth is difficult, embossed chips present smother surfaces and chip fea-
tures are almost identical when using the same mold for several chips. The high
chip replicability achieved through embossing is highly important for comparison
purposes between PCR runs conducted using different chips. Since the fluorescence
optical measurements are taken from a small section of each PCR cycle, differences
in channel depth affect the volume, and thus the absolute fluorescence monitored
within the optical field. When chips are identical among themselves, differences
in fluorescence are only dependent on the success of the PCR run. Figure 4.18
shows the channel depth profile of the measurement of 3 different milled chips and
3 different embossed chips. In all cases the target channel depth was 50 µm. It
can be observed how the depth of embossed chips is 50 µm ± 3 µm; however, in
the case of milled chips, they differ in more than 50 µm from the target. Because
of the smooth edges, the replicable depth profile, and the low-cost of embossing
versus milling, embossing was the selected technique for the manufacture of our
microfluidic chips.
The protocol for hot embossing Zeonex was previously studied at Fraunhofer
CMI.65 The procedure consisted in the application of a pressure of 12.6 MPa at
157 ◦C for 2 min in vacuum conditions. It should be noted that the emboss-
ing temperature was 20 degrees above Zeonex 690R glass transition temperature,
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Figure 4.18: Channel depth profile of different milled (A, B, and C) and embossed
chips (D, E, and F). Values in mm. In all cases the target channel depth was
50 µm.
136 ◦C.66 Nevertheless, this protocol failed to provide successful embossed chips
repetitively; in many cases the substrate did not fully fill the mold. As a result
the temperature and/or pressure were increased until good Zeonex chip embossing
was achieved constantly. 163 ◦C and 15.73 MPa for 2 min in vacuum conditions
provided repetitively sucessful chips (conditions summarized in Table 4.8).
Table 4.8: Hot embossing parameters for Zeonex 690R.
Temperature (◦C) 163
Embossing time (min) 2
Pressure (MPa) 15.73
Vacuum On
The improvement of this protocol allowed for the reliable manufacture of high-
quality hot embossed chips. It should be noted that the depth of the chip features
(50 µm) and the chip fabrication process –including imprinting, bonding, and
cutting steps– were designed to be compatible with ultraviolet roll-to-roll emboss-
ing production independently if they were fabricated by milling or hot embossing
techniques. Although no chips were produced through roll-to-roll embossing, we
anticipate using this technique for our chip manufacture in the near future.
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Chip bonding
During this thesis, to seal the microfluidic channels, both solvent bonding and
plasma-assisted thermal bonding were employed. At Fraunhofer CMI, solvent-
assisted bonding was previously used to bond microstructured Zeonex substrates
with 350 µm deep channel features. The microstructured part and the unstruc-
tured cover were immersed in a decalin:ethanol mixture (35:65 % v/v) for 1 min,
followed by 2 min immersion in denatured ethanol to remove excess decalin and
then dried with pressurized air. Afterwards, thermal bonding was applied in two
steps, the first step was carried at 110 ◦C and 12.27 MPa for 10 min followed by
a second step at 134 ◦C and 2.67 MPa for 2 min. While these conditions worked
successfully with chips with 350 µm deep channel features, when the channel depth
was decreased to 50 µm, channels began to clog. The harsh bonding conditions
caused an extreme compression of the microfluidic channels and loss of microfluidic
functionality. In Figure 4.19 some channel clogs are shown; in Figure 4.19 A and
B it can be observed how the channels are dissolved.
Figure 4.19: Clogged channels from a microfluidic chip with 50 µm chip features.
The protocol for solvent bonding was studied in order to achieve a sufficient
and reliable sealing of the microfluidic channels while maintaining, as much as
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possible, the channel integrity. In order to solve this problem, different strategies
were followed. First, an additional ultrasonic cleaning step was introduced prior
to solvent activation to remove any extra material from the channels that could
contribute to the clogs. The ultrasonic cleaning step included an initial ultrasonic
wash in water with detergent followed by several ultrasonic washes in distilled
water. The incorporation of this step reduced clogging, but it did not solve it
completely. A second approach was comprised of optimizing bonding tempera-
ture/pressure parameters. This optimization was conducted by Philipp Ganser
during his master thesis at Fraunhofer CMI.65 Philipp Ganser considered a wide
array of temperature, pressure, and time parameters. In contrast with the two
bonding steps previously used, a one-step thermal bonding at 130 ◦C and 3.93 MPa
for 2 min was considered optimal. Thirdly, a reduction in the immersion time of
microstructured substrate inside the solvent was attempted. Several combinations
of immersion times for the microstructured and the unstructured substrates were
tested. 30 s immersion time for both substrates was sufficient to achieve a reliable
sealing; lower immersion times resulted in unsuccessful bonding.
Solvent activation of polymeric surfaces is characterized by a significant swelling
of the top surface; however, the chemical inertness of the material is persistent.
In contrast, plasma-assisted thermal bonding leaves the gross surface topography
unaffected but modifies the chemical reactivity of the surface. Plasma-assisted
thermal bonding was also studied during this thesis. Different plasma conditions
were tested. In all the cases the optimized one-step thermal bonding process was
used after surface activation. Plasma machine variables included: power, gas flow
rate, process time, and maximum pressure allowed inside the vacuum chamber in
order to start the plasma process. Several parameter values were selected for each
variable. The testing conditions were: power 10, 50, 100 W; gas flow rate 0.1, 1, 10,
25 cm3/min at standard temperature and pressure (sccm) of O2 gas; process time
1, 2, 5, 10 min; base pressure 3.33, 4, 6.67, 13.33 Pa. Combinations of the previous
parameter conditions were tested for delamination using samples replicates of each
condition. The optimal results were obtained for 1 sccm, 100 W, 2 min process time
and 4 Pa of initial base pressure. Higher gas flow rates, increased power, longer
process times or lower initial base pressure did not improve the bonding strength.
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Additionally, corona treatment was test as a substitute of O2 plasma activation;
however, the bonding strength was lower and chip delamination occurred more
frequently.
An annealing step after either solvent bonding or plasma-assisted thermal
bonding was always performed (details described in Section 4.2.1). Annealing
at high temperatures close to the glass transition temperature of the material
enhances the degradation of any residual stresses within the material.
A summary of the optimized bonding protocols for Zeonex substrate is shown
in Table 4.9 and Table 4.10 for solvent and plasma activation respectively.
Table 4.9: Solvent activation parametes for Zeonex 690R bonding.
Chip
Immersion time in decalin/ethanol mix 30 s
Immersion time in ethanol 100 % 2 min
Cover slip
Immersion time in decalin/ethanol mix 30 s
Immersion time in ethanol 100 % 2 min
Table 4.10: Plasma activation parameters for Zeonex 690R bonding.
Parameters Values
Power (W) 100
O2 flow rate (sccm) 10
Process time (min) 2
Base pressure (Pa) 4
4.4.2 Surrounding instrumentation improvements
Temperature on the chip
As previously described, heaters below the chip control the chip temperature in
different zones. A programmable temperature controller regulates the temperature
on each heater. The temperature in the PCR and RT-PCR chip plays a key role for
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successful amplification, especially in the case of the lower temperature heater (50–
60 ◦C) compared to the high temperature one (95 ◦C). Stable annealing and reverse
transcription (in the case of RT-PCR) temperatures are essential for effective PCR
performance. However, the denaturing temperature allows higher temperature
variations (approximately 90–97 ◦C) without altering the amplification process.
Verifying the temperature in the area of interest is a difficult task in microfluidic
systems without altering the process in a substantial manner. To determine the
actual temperature inside the chip for a given heater temperature, a thermal mea-
surement chip was built for a previous chip generation which had the same shape
as chip generations 1 and 2. The chip is shown in Figure 4.20, it has equidistant
measurement channels located in a similar depth as the PCR microfluidic chan-
nel. A thermocouple is embedded in high temperature silicone in every channel.
The channels are sealed using a regular cover slip. Six thermocouples measure the
temperature in the middle area of the chip while the other six provide temperature
values of the outer area of the chip. Thermocouples were read out using a digital
thermometer. For different given temperatures, the temperatures of the thermo-
couples inside the measurement chip were recorded. Approximately, for the 60 ◦C
heater temperature, the temperature inside the chip was 2 ◦C below; while for a
heater temperature of 95 ◦C, the temperatures inside the chip were in the range
90–92 ◦C. Given these results, for on-chip experiments, the heaters were set 2 ◦C
above the target temperature. In the case of target temperature of 95 ◦C inside
the chip, heaters were set to 97–98 ◦C to prevent boiling effects.
Figure 4.20: Thermal measurement chip with 12 thermocouples. A) Schematic
drawing. Numbers 1–6 show the inner thermocuples and 7–12 the outer ther-
mocuples. B) Picture.
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Optical system
As previously stated, optical methods are the most common methods to detect am-
plification products in real-time. Among them, the fluorescence-based technique
is the most popular one due to its high sensitivity, high selectivity, and commer-
cial availability of fluorophores.18 Commercial real-time PCR machines monitor
fluorescence in approximately a total volume of 20 µl; however, for on-chip-PCRs,
only a small section of each PCR cycle was monitored. As previously described,
for the chip generations with 50 µm channel depth (PCR chip generations 2, 3,
4 and both RT-PCR chip generations) the approximate monitored volume within
the optical field of view was a scant 50 nl. In the case of the 1st PCR chip, the
monitored volume was 350 nl due to its higher channel depth (350 µm).
Fraunhofer CMI developed an optical detection system previous to the start
of this PhD thesis. The system was composed of a light-emitting diode (LED)
source which excited fluorescence through a standard microscope FITC fluores-
cence excitation and emission filter set. The excitation light was directed to the
sample and the fluorescence generated by the sample was collected and directed to
a charge-coupled device (CCD) camera placed into the sample image plane. Photo
images were taken with the camera, which were latter analyzed using Image J pro-
gram. Unfortunately, this system was not sensitive enough for monitoring on-chip
amplification, and post sample processing through gel electrophoresis was required
to determine the success of the amplification. A schematic drawing of the optical
system and a CAD drawing are shown in Figure 4.21 A and B respectively.
In order to increase the sensitivity of the system, a photodetector was incor-
porated. Collected light was split into two detection paths using a broadband
beam splitter with 30/70 intensity split ratio. In the first detection path, a CCD
camera was placed into the sample image plane. In the second detection path, a
photodetector surface to maximize intensity response was located. The changes
in the photodetector current were measured using an optical power meter. The
camera was used to pre-align the target channel onto the opening in the second
detection path. A schematic drawing of the optical system and a CAD drawing
are shown in Figure 4.22 A and B respectively.
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Figure 4.21: First version of the optical system. A) Schematic drawing. B) CAD
drawing. For both A and B figures numbers are as follows. 1) LED light. 2)
Excitation filter. 3) Sample. 4) Dichroic filter. 5) Emission filter. 6) Camera.
Figure 4.22: Second version of the optical system after the addition of a pho-
todetector. A) Schematic drawing. B) CAD drawing. For both A and B figures
numbers are as follows. 1) LED light. 2) Excitation filter. 3) Sample. 4) Dichroic
filter. 5) Emission filter. 6) Beam splitter. 7) Camera. 8) Photodetector.
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The use of the photodetector surface increased the sensitivity of the system
and allowed real-time on-chip measurements. Using this optical set up, several
additional improvements were made to enhance the sensitivity, improve data collec-
tion, and data accuracy. Initially, values were directly read out from the power
meter; however, the rapidly fluctuating values led to inaccurate data collection.
By connecting the output of the power meter to a computer this problem was
solved and fluorescence intensity was read-out through the computer. Moreover,
data collection was improved with the incorporation of a computer program. This
program allowed for a more consistent data acquisition by collecting a desired
number of data points in an established time interval. During the optical system
improvement process, an attenuating effect in the fluorescence values due to the
platform on top of the chip was discovered. The platform was reshaped to avoid
interferences in the fluorescence data collection. Additionally, the sensitivity of the
system was improved by placing in the photodetector path a rectangular-shaped
opening into the sample image plane limiting throughput of the fluorescence to a
single channel.
In Figure 4.23, the on-chip PCR graphs associated with different optical sys-
tem iteration are shown. It can be observed that the different iterations have very
similar profiles and the CT value is very similar for the second and third iterations.
The last iteration allows for consistent data collection and provides high quality
and sensitive fluorescence curves. It should be noted that since all the system im-
provement experiments –regarding the chip, system and reagents– were performed
at the same time as the improvements in the optical system, the on-chip PCR data
shown during the improvement of the different sections varies depending on the
available optical system.
The next steps to further improve the optical system should be focused in
reducing the overall costs. For example, the microscope stage could be removed if
the chip could be positioned in the same identical plane. In the case of the CCD
camera, it could also be eliminated if an integrated system that automatically
moves through the chip channels was available.
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Figure 4.23: Iterations to improve the optical system. Experiments conducted
with E. coli O157:H7 and initial template concentration 104 DNA copies/µl. IDT
primers used. Iteration 1: optical data were directly read out from the power
meter. No error bars were obtained. Iteration 2: optical data read out from the
power meter connected to a computer. Attenuating effect in the fluorescence values
due to interference with the chip platform can be observed. Iteration 3: optical
data collected through a computer program consistently.
4.4.3 Reagents improvements
Given the importance of the optimization of the components involved in the PCR
reaction as described in Section 4.3.3, during the following subsections the selection
of oligonucleotide primers, enzymes and passivation agents for the microfluidic chip
is described.
Passivation
At Fraunhofer CMI before the start of this thesis, both static and dynamic passi-
vation were routinely performed prior to the PCR process. Static passivation was
implemented with bovine serum albumin (BSA) protein for 2 h. Additionally, BSA
and polyethylene glycol (PEG) were used as dynamic passivation agents and were
added to the PCR mixture to avoid nonspecific binding to the channel walls. The
main drawback of static passivation with BSA is the incompatibility with roll-to-
roll processes. As previously described, another passivation method compatible
with roll-to-roll production line uses plasma treatment for surface biofunctional-
ization.
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Experiments intended to improve the process conditions using both dynamic
and passivation strategies were performed and are described in this section. Ex-
periments using plasma treatment are first described. A corona system (which
uses atmospheric plasma) was used to activate the surface of the polymers. To
deposit molecules on the activated surface, either in-line slot die coating or direct
immersion in a solution with the target molecule were used. Tests were performed
at Eurecat Technology Centre of Catalonia (Barcelona, Spain) using an in-line
roll-to-roll system. Power tests and experiments with molecules of different nature
were conducted. A full surface characterization was accomplished by measuring
contact angle values and performing time-of-flight secondary ion mass spectrome-
try (TOF-SIMS) analysis.
Polyethylene terephthalate (PET) and cyclic olefin copolymer (COC) were used
as substrate materials. The feeding speed was kept constant throughout all the
experiments and was equal to 0.2 m/min. When not specified otherwise, corona
power density was 1200 W·min/m2. This corona power density was selected based
on former experiments where almost no improvements were obtained when increas-
ing the power density more than 1200 W·min/m2. Figure 4.24 shows the contact
angles before and after corona treatment for PET and COC substrates. PET and
COC contact angles decreased until approximately 20◦, being very hydrophilic
after corona treatment.
Secondly, the contact angles of PET samples treated with corona were moni-
tored over time in order to follow its evolution stored in air. Contact angle can be
directly correlated with the number of radicals and reactivity. Results are shown
in Figure 4.25. Immediately after corona treatment the highest number of radi-
cals was found. Contact angle increased with time (until approximately 45◦) as
radicals stabilize with each other and with air oxygen and nitrogen.
Afterwards, corona activated substrate polymers were subsequently treated
with slot die coating or direct immersion for 5 s in aqueous solutions with different
hydrophilic/hydrophobic character in order to evaluate its surface adhesion. The
solutions used were: water, polyethylene glycol (PEG 6000) 200 µM (hydrophilic),
aminoethoxyethanol 10 mM (hydrophilic), and decylamine 1 mM (hydrophobic).
Afterwards, samples were dried with nitrogen gas and the contact angle was imme-
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Figure 4.24: Contact angles before and after corona treatment for PET and COC
substrates.
Figure 4.25: Contact angles of PET samples treated with corona and stored in air
over time.
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diately measured. Direct immersion experiments were only conducted with PET
substrate. Figure 4.26 shows the results obtained.
Figure 4.26: Contact angles of PET and COC substrates treated with corona and
slot die coating or direct immersion in water, polyethylene glycol (PEG 6000)
200 µM, aminoethoxyethanol 10 mM, and decylamine 1 mM.
As can be observed in Figure 4.26, both substrates present very similar be-
haviors. High contact angle differences between the tested solutions were observed
for both PET and COC polymers: water (22◦), PEG (15–20◦), aminoethoxyethanol
(16–20◦) and decylamine (60–70◦). Hydrophilic solutions created low contact an-
gles while hydrophobic solutions generated higher contact angle values, as was
expected. When comparing the effect of direct immersion and slot die coating for
each of the solutions, both mean values and standard deviations were very similar.
Both techniques seem equally adequate for biofunctionalization of corona-treated
surfaces. Based on these results, it seems that the molecules are well attached to
the surface confirming the feasibility of using a corona system for surface biofunc-
tionalization.
In order to accelerate the drying time after slot-die coating or immersion in the
different solutions, a subsequent washing step in ethanol was introduced. After
surface biofunctionalization and the ethanol washing step, samples were dried with
nitrogen gas and contact angles were measured. Figures 4.27, 4.28, and 4.29 show
the contact angle results for direct immersion with PET polymer and slot die
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coating with PET and COC respectively. For comparison purposes, the contact
angles of samples which did not undergo an ethanol washing step are also included.
Figure 4.27: Contact angles of biofunctionalized PET samples through corona
treatment and direct immersion in water, polyethylene glycol (PEG 6000) 200 µM,
aminoethoxyethanol 10 mM, and decylamine 1 mM. Shown with shading those
samples which underwent a subsequent washing step in ethanol.
Looking at figures 4.27, 4.28, and 4.29, ethanol seems to have a high influence
in the contact angle of the biofunctionalized samples. Although it is still possible
to see the differences between samples treated with hydrophilic and hydrophobic
solutions, contact angle values tended towards the ethanol contact angle (approxi-
mately 45◦). Based on these results, performing a washing step with ethanol seems
to be detrimental.
Time-of-flight secondary ion mass spectrometry (TOF-SIMS) analysis was used
to confirm contact angle results. Three samples were analyzed: PET substrate
after treatment with corona (sample 1), PET after corona treatment and addi-
tion of pentafluorophenol dissolved in water (sample 2), and in ethanol (sample
3). Pentafluorophenol was selected since it is easier to recognize its characteristic
mass-to-charge ratio (m/z) peaks generated by TOF-SIMS than the peaks gene-
rated by other biomolecules including PEG, decylamine, or aminoethoxy ethanol.
Samples were first activated with corona and pentafluorophenol was then deposited
by slot die coating. Table 4.11 shows the relative abundance for m/z peak 183,
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Figure 4.28: Contact angles of biofunctionalized PET samples through corona
treatment and slot die coating in water, polyethylene glycol (PEG 6000) 200 µM,
aminoethoxyethanol 10 mM, and decylamine 1 mM. Shown with shading those
samples which underwent a subsequent washing step in ethanol.
Figure 4.29: Contact angles of biofunctionalized COC samples through corona
treatment and slot die coating in water, polyethylene glycol (PEG 6000) 200 µM,
aminoethoxyethanol 10 mM, and decylamine 1 mM. Shown with shading those
samples which underwent a subsequent washing step in ethanol.
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which correspond to pentafluorophenol ion without a hydrogen atom and is one
of the typical mass fragments of pentafluorophenol. The molecular structures of
pentafluorophenol and its 183 m/z fragment are shown in Figure 4.30.
Table 4.11: Relative abundance of m/z 183 peak measured by TOF-SIMS analysis
of three samples: PET substrate after treatment with corona, PET after corona
treatment and addition of pentafluorophenol dissolved in water, and in ethanol.
The abundance of peak 183 was normalized with C-12 peak.
Sample Normalized abundance of m/z 183 peak
Corona 8.9
Corona+pentafluorophenol in water 16.7
Corona+pentafluorophenol in ethanol 13.7
Figure 4.30: Molecular structure of pentafluorophenol. A) Pentafluorophenol
molecule, m/z=184. B) Pentafluorophenol anion, m/z=183.
Comparing the three samples, it can be observed how the addition of pentafluoro-
phenol increases the 183 peak, both in water and ethanol. This is attributed to
pentafluorophenol attachment to the surface of the samples. The signal when the
solvent is water is slightly higher than with ethanol as a solvent. These results
agree with previous contact angle results. As it has been stated before, treating
the substrate with corona followed by treatment with the desired molecules seems
to provide adequate surface attachment. Better biomolecule attachment to the
substrate is obtained when water is used as solvent solution and no ethanol wash
is performed.
Finally, a drying step was considered at the end of the process (after corona
treatment and slot die coating/immersion in solutions with different biomolecules).
Different temperatures were tested. The original feeding speed was 0.2 m/min and
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the oven was 1 m long. A temperature of 100 ◦C with aqueous solution was not
enough to dry the samples, a longer oven or a slower feeding speed are required.
However, when samples were washed with ethanol before entering in the oven,
95 ◦C dried all the substrates well.
Summarizing, surface functionalization proof of concept was successfully per-
formed using a roll-to-roll plasma system. Molecules were well attached to the
surface based on contact angle results and TOF-SIMS analysis.
The next step was to statically passivate the surface of a PCR chip through
plasma biofunctionalization with PEG molecules and test its performance. A chip
and its cover slip were activated with corona treatment followed by direct immer-
sion in a 1 mg/ml PEG aqueous solution for 3 h. Next, the chip was solvent-assisted
thermally bonded following the protocol described in the Materials and Methods
section. On-chip qPCR was performed with E. coli target, 104 DNA copies/µl
initial template concentration, 25 min residence time and using the 3rd PCR chip
generation. Optical measurements were taken. Additionally, for comparison pur-
poses, an on-chip PCR was run in a chip statically passivated with BSA using a
previously validated protocol. In both cases, BSA and PEG were added to the
master mix as dynamic passivating agents. The results are shown in Figure 4.31.
As can be observed in Figure 4.31, amplification was obtained using the two
differently statically passivated chips. It should be remarked that BSA and PEG
were used as dynamic passivating agents. Both optical curves present similar cycle
thresholds (CT ) and shapes. Thus, these results confirm that static passivation
with BSA for 2 h can be substituted by static passivation using a plasma system
and subsequent PEG attachment which allows chip biofunctionalization in a roll-
to-roll system.
The next experiments were focused on investigating if any of the static and
dynamic passivating agents was unnecessary and could be eliminated from the
passivation protocol. As previously described, static passivation is more time con-
suming and costly than dynamic passivation (especially when static passivation is
performed with BSA) and consequently dynamic passivation is usually preferable
than any type of static passivation. On-chip PCR experiments were conducted
with different combinations of dynamic blocking agents (BSA and PEG) and with
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Figure 4.31: Static passivation experiments. E. coli O157:H7 25 min residence
time on-chip qPCR results with 104 DNA copies/µl initial template concentra-
tion. Milled chips and IDT primers were used. BSA and PEG were added to the
master mixes for dynamic passivation. A) On-chip qPCR optical detection data
for different passivated conditions. The passivation conditions of each run are in-
dicated in the legend. Static passivation with BSA was performed for 2 h. Plasma
static passivation was performed with corona treatment followed by immersion in a
PEG solution. NC is the negative control performed with a BSA static passivated
chip. Each data curve was normalized with its average baseline from cycles 4 to
16. B) Gel electrophoresis of on-chip amplicons (69 bp) with varying passivation
conditions as shown in figure (A). Lane L indicates the ladder. Lane 1 and 3 cor-
responds to the passivation conditions shown in the legend of figure (A) following
the same order. Off-chip PCR results are shown in Lane 4 (104 DNA copies/µl)
and Lane 5 (0 DNA copies/µl) for comparison.
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and without prior static blocking with BSA. Static passivation was performed with
BSA instead of plasma due to simplicity reasons; however, as previously demon-
strated, experiments performed with BSA static passivation can be substituted
with static passivation with plasma biofunctionalization. Experiments were per-
formed under the same optical system conditions and with the 3rd chip generation,
using E. coli DNA as target with 104 DNA copies/µl initial template concentra-
tion, and for 25 min residence time. In Figure 4.32 the qPCR results are shown.
Figure 4.32: Static and dynamic passivation experiments. E. coli O157:H7 25 min
residence time on-chip qPCR results with 104 DNA copies/µl initial template con-
centration. A) On-chip qPCR optical detection data for different passivated con-
ditions. The passivation conditions of each run are indicated in the legend. BSA,
and PEG refers to dynamic passivation with those reagents while BSA blocking
refers to static passivation with BSA. Each data curve was normalized with its
average baseline from cycles 4 to 16. B) Gel electrophoresis of on-chip amplicons
(69 bp) with varying passivation conditions as shown in figure (A). Lane L in-
dicates the ladder. Lane 1 to Lane 5 corresponds to the passivation conditions
shown in the legend of figure (A) following the same order.
From the amplification curves (Figure 4.32 A) and gel electrophoresis results
(Figure 4.32 B), it is observed that three of the curves achieved comparable levels of
amplification: (1) static passivation with BSA and dynamic passivation with BSA
and PEG (green curve); (2) no static passivation and dynamic passivation with
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BSA and PEG (blue curve); (3) no static passivation and dynamic passivation
with BSA (pink curve). Based on these result, it can be concluded that static
passivation with BSA is unnecessary and that the addition of BSA to the PCR
mix as dynamic passivation agent is enough to prevent non-specific binding of
the PCR components to the internal microfluidic channel surface. Within the
chip, BSA in the PCR master mix binds to the channel surface and prevents PCR
components from potentially absorbing to the channel walls.59 When neither static
nor dynamic passivation was performed or when passivation was implemented with
only PEG as dynamic agent, no amplification was observed (brown and light green
curves respectively).
These findings allowed for chip passivation using only BSA as dynamic agent
during the subsequent experiments with our PCR chips. The elimination of the
static passivation step (either with a BSA pre-coating step or using plasma bio-
functionalization) facilitates chip manufacture and decreases its costs. Dispensing
with PEG contributes to the reduction of the PCR reagents costs and thus the
assay costs.
Primer/probe optimization for E. coli O157:H7
Specific primer and probe sets for each of the pathogen targets were designed to
be detected through the FAM channel and exploit the TaqMan principle. High
quality primers and probes are essential for the success of the PCR. In the case of
E. coli O157:H7 target, 3 sets of primers/probes were tested, one primer/probe set
from Primer Design Ltd. and two sets of primer/probe purchased from Integrated
DNA Technologies, Inc. (IDT). The sequences of the primers and probes are
specified in Section 4.2.3. Initial experiments were performed using Primer Design
primer/probe set with successful results. However, the 6 times higher price of
Primer Design primer/probe set compared to custom made primers/probes by
IDT, led us to test other IDT primer/probe sets. To assess its performance, off-
chip and on-chip experiments were performed using E. coli DNA as target with
initial template concentration of 104 DNA copies/µl. Off-chip qPCR experiments
are shown in figures 4.33 and 4.34 for Primer Design and IDT respectively.
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Figure 4.33: Off-chip qPCR results using Primer Design primer/probe set and E.
coli DNA as target. Initial template concentration of 104 DNA copies/µl was used
for the positive control.
Figure 4.34: Off-chip qPCR results using Primer Design primer/probe set and E.
coli DNA as target. Initial template concentration of 104 DNA copies/µl was used
for the positive controls.
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On-chip experiments were performed with the 3rd generation PCR chip for
25 min residence time. The optical system was not sensitive enough at the time
these experiments were perform and gel electrophoresis was used to analyze the
success of the on-chip runs. Figures 4.35 and 4.36 show the results for Primer
Design and IDT primer/probe sets respectively.
Figure 4.35: Gel electrophoresis of on-chip amplicons (76 bp) using Primer De-
sign primer/probe set and E. coli DNA as target. Initial template concentra-
tion of 104 DNA copies/µl were used for the positive controls. On-chip PCR
results are shown in Lane 1 (104 DNA copies/µL) and Lane 3 (0 DNA copies/µL).
Off-chip PCR results are shown in Lane 2 (104 DNA copies/µL) and Lane 4
(0 DNA copies/µL) for comparison.
Figure 4.36: Gel electrophoresis on-chip amplicons using IDT primer/probe set 1
(69 bp) and 2 (99 bp). 104 DNA copies/µl of E. coli target were used as initial
template concentration for the positive controls. Amplicons in Lane 1 and 2 were
obtained through on-chip PCR performed with primer/probe set 1 and 2 respec-
tively. The on-chip negative control (0 DNA copies/µL) is shown in Lane 5. For
comparison, off-chip PCR results are shown in Lanes 3 and 4 (104 DNA copies/µL)
for primer/probe set 1 and 2 respectively, and Lane 6 (0 DNA copies/µL).
Based on both off-chip and on-chip PCR results, the tree primer/probe sets
seem to perform similarly. Looking at the CT values of off-chip PCR curves, Primer
Design and IDT set 2 show a very similar CT , which are slightly lower than the
CT of IDT set 1. Comparing the gel electrophoresis bands of on-chip amplicons no
significant differences were observed between the three primer/probe sets. Given
the slight differences in terms of performance, other selection criteria were con-
sidered. Price was an important factor contemplated. Due to the higher price
of Primer Design primer/probe set compared to IDT, the latter were preferred.
IDT primer/probe set 1 was selected over set 2 due to the smaller amplicon size
since small amplicons have higher possibilities to be fully amplified during on-chip
145
PCR. Thus, IDT primer/probe set 1 was selected for PCR chip characterization
experiments (Section 4.5.1) when E. coli was used as target.
During this section we described the improvements in different aspects of the
PCR and RT-PCR. Significant consideration was given to the disposable chip
to assure rapid and economic production at industrial scale. The price of both
PCR and RT-PCR chips is expected to be under $0.4. In addition to disposable
components, in any POC system, considerable attention needs to be given to the
surrounding instrumentation. Components within the instrument must likewise be
robust and the biological assays should be optimized around instrumentation cost
constraints rather than vice versa. For our prototype instrument, the components
were limited to two heaters, the optical system including a detector, a pump, and
a computer for data processing. A picture of the prototype system is shown in
Figure 4.37. This instrument was assembled with simple off-the-shelf components
and the approximate cost was below $9,000. The cost of such instrumentation is
driven lower when producing in larger quantities and components are able to be
purchased in bulk. While satisfied with the costs of the first prototype, we are in
the process of incorporating even smaller and lower-cost components. Currently,
this work involves incorporating lower-cost optics, and miniaturizing the pump
and heaters. When the system improvements are incorporated, the price of the
instrument is expected to be below $2,000.
During next section, the function of the chip and surround instrumentation is
demonstrated with three infectious pathogens.
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Figure 4.37: Picture of the instrumentation used for qPCR experiments.67 1) Sy-
ringe pump. 2) Chip baseplate. Two block heaters are placed below the chip. 3)
Microscope objective. 4) LED source. 5) Camera. 6) Photodetector. 7) Power
source. 8) Optical power meter.
4.5 Characterization
At the end of the previous section, a PCR system that allows for amplifying
DNA and RNA-based pathogens and detecting them in real-time was achieved.
This section is focused on the characterization of both PCR and RT-PCR chips
using three infectious pathogens. Escherichia coli and Chlamydia trachomatis
were selected to characterize the PCR chip, and Ebola virus (EBOV) Zaire to test
the RT-PCR chip.
Infection with C. trachomatis, when untreated or if treatment is delayed, can
lead to ocular infection, pelvic inflammatory disease, or infertility.1,3 Infections
with E. coli O157:H7 can lead to hemorrhagic diarrhea and hemolytic uremic syn-
drome.7,8 Ebola virus disease (EVD), formerly known as Ebola haemorrhagic fever,
is a severe illness in humans, with an average case fatality rate around 50 %.14 EVD
early symptoms are non-specific (fever, sore throat, muscular pain, headaches). As
the disease progress, vomiting, diarrhea, decreased function of liver and kidneys,
and in some cases bleeding internally and/or externally follows.14 A rapid diagnosis
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of these pathogens would be crucial for prompt initiation of the right treatment, in-
creased treatment success, avoidance of the spread of the infections, and reduction
in the rise of antibiotic resistances due to broad prophylactic antibiotic use.
For both bacteria and virus, different flow velocities were tested for determin-
ing the maximum speed at which DNA amplification could occur and the limit of
detection (LOD) of the system was identified. First we describe the characteriza-
tion experiments regarding the PCR chip and later the tests performed with the
RT-PCR chip.
4.5.1 PCR Chip
The influence of the residence time in the on-chip PCR system was tested to
explore how quickly we could run each assay and to determine the optimal flow-
rate. The same initial template concentration, 104 DNA copies/µl, was used for
all the residence time experiments. On-chip amplifications were conducted for
40, 30, 20 and 10 min residence times. The optical data and the corresponding
gel electrophoresis amplicons are presented in Figure 4.38 and Figure 4.39 for C.
trachomatis and E. coli O157:H7, respectively. The cycle threshold (CT ) for 30 and
40 min residence times was almost identical suggesting that both reactions achieve
the maximum total amplification possible. At these low speeds, the enzymes likely
have sufficient time to complete polymerization of all targets. When the residence
time is 20 min the CT shifts to the right a couple of units.
For 10 min residence time, although no optical signals were measured above
the threshold for either bacteria, the fluorescence is slightly higher at the last
PCR cycles indicating some DNA amplification. Shown below each set of curves,
is the gel electrophoresis results for each amplification. Note that while we did
not optically detect product for the 10 min samples, faint bands were detected for
these conditions by gel electrophoresis for C. trachomatis and E. coli O157:H7 (see
Figure 4.38 B Lane 4 and Figure 4.39 B Lane 4 respectively). 20 min residence
time is probably the best tradeoff between sensitivity and speed; it allows achieving
high sensitivity while keeping the time to result low.
To further explore the limit of detection (LOD) of the system, determinations
were done by a DNA dilution series ranging from 105 to 1 DNA copies/µl by
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Figure 4.38: C. trachomatis on-chip qPCR results with 104 DNA copies/µl initial
template concentration.67 A) On-chip qPCR optical detection data for different
on-chip residence time. Each data curve was normalized with its average baseline
from cycles 4 to 16. Independent trials were run for 40, 30, 20, and 10 minutes total
on-chip residence times as indicated. B) Gel electrophoresis of on-chip amplicons
(85 bp). Amplicons in Lane 1 had a total on-chip time of 40 min and times
decreased by 10 minutes until a final on-chip time of 10 min as shown in Lane 4.
The negative control (0 DNA copies/µl for 25 min) is shown in Lane 5. Off-chip
PCR for 1 h with 104 DNA copies/µl (Lane 6) and 0 DNA copies/µl (Lane 7) are
shown for comparison purposes.
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Figure 4.39: E. coli O157:H7 on-chip qPCR results with 104 DNA copies/µl initial
template concentration.67 A) On-chip qPCR optical detection data for different on-
chip residence time. Each data curve was normalized with its average baseline from
cycles 4 to 16. Independent trials were run for 40, 30, 20, and 10 minutes total
on-chip residence times as indicated. B) Gel electrophoresis of on-chip amplicons
(69 bp). Amplicons in Lane 1 had a total on-chip time of 40 min and times
decreased by 10 minutes until a final on-chip time of 10 min as shown in Lane 4.
The negative control (0 DNA copies/µl for 25 min) is shown in Lane 5. Off-chip
PCR for 1 h with 104 DNA copies/µl (Lane 6) and 0 DNA copies/µl (Lane 7) are
shown for comparison purposes.
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factors of 10. On-chip qPCR of serially diluted DNA is presented in Figure 4.40
for C. trachomatis and Figure 4.41 for E. coli O157:H7 for 25 min residence time.
The limit of detection for our on-chip qPCR system for both C. trachomatis and
E. coli O157:H7 is 10 DNA copies/µl. It should be considered that for very low
DNA concentrations, stochastic sampling (the probability of retrieving a single
copy of DNA in the microliter) can lead to variations in the optical signals. For
large devices that process larger sample volumes, this effect of stochastic sampling
is obviously minimized. However, for all microfluidic approaches with small volu-
mes, these probabilistic limits need to be kept in mind when discussing LOD
measurements.
When doing 1 h-long qPCR experiments off-chip with a commercial thermocy-
cler, the LOD was 1 DNA copy/µl, an order of magnitude below our on-chip data.
However, it is remarkable that the on-chip PCR was done in less than half of the
time than that of the off-chip thermocycler. In addition, it should be pointed out
that the off-chip cycler measures the fluorescence from 20 µl, while in our on-chip
system the optical data is taken from a small section of each PCR cycle, which is
approximate 50 nl. This makes the comparison between on- and off-chip difficult
regarding PCR sensitivity or in terms of the total number of template copies.
The PCR efficiencies, calculated as described in the Materials and Methods
section, are 93±3 % and 95±5 % for C. trachomatis and E. coli O157:H7 respec-
tively. These PCR efficiencies are equivalent to those obtained from benchtop
thermocyclers. It can be observed how a 10-fold increase in the initial template
concentration produced a 3.3 threshold cycle shift. The data obtained matched
classic quantitative PCR amplification curves. Off-chip amplification results are
presented for comparison in Appendix E (figures E.1 and E.2). Gel electrophoresis
data (Figure 4.40 C and Figure 4.41 C for C. trachomatis and E. coli O157:H7)
confirm the successful on-chip amplifications and shows the same detection limit
(10 DNA copies/µl) as the on-chip optical detection system.
When comparing the data from C. trachomatis and E. coli O157:H7 (Fig-
ure 4.40 and Figure 4.41), it can be observed that optimized assays yielded similar
results in terms of the on-chip fluorescence curves, the limit of detection, the PCR
efficiency, and gel electrophoresis results for both bacteria. As each assay tar-
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Figure 4.40: C. trachomatis 25 min residence time on-chip qPCR results.67 A)
On-chip qPCR optical detection data for serially diluted DNA template. Each
data curve was normalized with its average baseline from cycles 4 to 16. Tem-
plate concentrations begin at 105 DNA copies/µl and are reduced by one order of
magnitude until the final trial of 1 DNA copy/µl. Also included is the negative
control (0 DNA copies/µl). B) On-chip qPCR efficiency graph representing the
cycle threshold versus the initial template concentrations in a logarithmic scale.
Dotted lines represent 95 % confidence interval. The slope is 3.50±0.19 which
correspond to a PCR efficiency of 93±3 %. C) Gel electrophoresis of on-chip am-
plicons (85 bp) with varying levels of template as shown in (A). Lane 1 has an
initial template of 105 DNA copies/µl and template concentrations are reduced by
one order of magnitude until the final trial of 1 DNA copy/µl in Lane 6 and the
negative control (0 DNA copies/µl) in Lane 7. Off-chip PCR results are shown in
Lane 8 (104 DNA copies/µl) and Lane 9 (0 DNA copies/µl) for comparison.
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Figure 4.41: E. coli O157:H7 25 min residence time on-chip qPCR results.67 A)
On-chip qPCR optical detection data for serially diluted DNA template. Each
data curve was normalized with its average baseline from cycles 4 to 16. Tem-
plate concentrations begin at 105 DNA copies/µl and are reduced by one order of
magnitude until the final trial of 1 DNA copy/µl. Also included is the negative
control (0 DNA copies/µl). B) On-chip qPCR efficiency graph representing the
cycle threshold versus the initial template concentrations in a logarithmic scale.
Dotted lines represent 95 % confidence interval. The slope is 3.45±0.25 which
correspond to a PCR efficiency of 95±5 %. C) Gel electrophoresis of on-chip am-
plicons (69 bp) with varying levels of template as shown in (A). Lane 1 has an
initial template of 105 DNA copies/µl and template concentrations are reduced by
one order of magnitude until the final trial of 1 DNA copy/µl in Lane 6 and the
negative control (0 DNA copies/µl) in Lane 7. Off-chip PCR results are shown in
Lane 8 (104 DNA copies/µl) and Lane 9 (0 DNA copies/µl) for comparison.
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geted a similar length amplicon (85 bp versus 69 bp for C. trachomatis and E. coli
O157:H7, respectively), the similarity in results may indicate that the conditions
were optimized for this amplicon range. Assays targeting longer amplicons could
require more residence time to achieve similar optimal detection while shorter am-
plicons would be predicted to require less residence time. Short amplicons are
limited by the requirement for specificity (shorter amplicons are less specific) and
room on the template for two primers and a probe. Sensitivity can also be in-
creased by monitoring multi-copy, rather than single copy genes.
4.5.2 RT-PCR Chip
The function of the RT-PCR chip was assessed with Ebola virus (EBOV). An in
vitro transcribed fragment of the L gene, one of the best conserved and most gene-
tically stable EBOV gene, was targeted.68,69 L gene codes for the RNA-dependent
RNA polymerase (RdRp), which are highly conserved in RNA-viruses with no
DNA stage.68 Assays targeting well-conserved genomic regions have higher possi-
bilities to be valid for different outbreaks with evolved EBOV variants.
For the characterization of the RT-PCR chip, two one-step RT-qPCR master
mixes, a ‘commercial’ and a ‘custom’ mix, were tested at various flow rates. Both
contain the same reverse transcriptase enzyme but different DNA-polymerases.
To determine the influence of the flow rate and the sensitivity for each master
mix, off-chip and on-chip experiments were performed. In the case of the off-
chip experiments, the steps of the thermal profile protocol recommended by the
manufacturer were modified and performed more rapidly. For both master mixes,
the protocol recommended by the manufacturer is referenced as ‘slow’ (see Ta-
ble 4.4). The ‘rapid’ protocol was selected based on the protocol recommended for
Affymetrix VeriQuest R© Fast qPCR Probe, which contains the DNA-polymerase
used in the ‘custom’ mix (see Table 4.4). Additionally, for the ‘commercial’ mix,
a ‘mid’ speed protocol was performed varying only the reverse transcription time
respect to the ‘slow’ protocol. Figure 4.42 shows the performance of each mas-
ter mix with the different thermal profile protocols for the same initial template
concentrations (105 and 102 RNA copies/µl).
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Figure 4.42: EBOV off-chip qPCR results. A) Off-chip RT-qPCR optical de-
tection data performed using the ‘commercial’ one-step RT-qPCR master mix.
Data were normalized by the internal thermocycler software. Template concen-
trations were 105 and 102 RNA copies/µl. ‘Slow’, ‘mid’, and ‘rapid’ thermal pro-
file protocols were performed (information about the protocols can be found in
Table 4.4). B) Off-chip RT-qPCR optical detection data performed using the
‘custom’ one-step RT-qPCR master mix. Data were normalized by the internal
thermocycler software. Template concentrations were 105 and 102 RNA copies/µl.
‘slow’ and ‘rapid’ thermal profile protocols were performed (information about
the protocols can be found in Table 4.4). C) Gel electrophoresis of off-chip am-
plicons (120 bp). Amplicons in Lane 1 (‘slow’, 105 RNA copies/µl), 2 (‘slow’,
102 RNA copies/µl), 5 (‘mid’, 105 RNA copies/µl), 6 (‘mid’, 102 RNA copies/µl),
7 (‘rapid’, 105 RNA copies/µl), 8 (‘rapid’, 102 RNA copies/µl) correspond to off-
chip RT-qPCR runs presented in Figure A with the ‘commercial’ mix. Amplicons
in Lane 3 (‘slow’, 105 RNA copies/µl), 4 (‘slow’, 102 RNA copies/µl), 9 (‘rapid’,
105 RNA copies/µl), and 10 (‘rapid’, 102 RNA copies/µl) correspond to off-chip
RT-qPCR runs presented in Figure B with the ‘custom’ mix.
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From the results shown in Figure 4.42 A, the ‘commercial’ master mix does
not lose efficacy by reducing the RT time from 15 to 5 minutes (from the rec-
ommended ‘slow’ protocol to the ‘mid’ speed protocol). However, reducing the
thermal cycling time increases the CT values: from 24.7 and 33.2 (‘slow’ proto-
col) to 30.3 and undetermined (‘rapid’ protocol) for 105 and 102 RNA copies/µl
respectively. This suggests that the standard DNA-polymerase contained in the
mix does not achieve full amplification of the cDNA target at such high thermal
cycling speed. In the case of the ‘custom’ mix, the ‘slow’ and ‘rapid’ protocols are
equally effective (Figure 4.42 B). The CT values are the same as those obtained
with the ‘commercial’ mix, using the ‘slow’ and ‘mid’ protocols. These results
indicate that the DNA-polymerase contained in the ‘custom’ mix functions well at
rapid thermal cycling speed. Overall, the ‘custom’ mix allows for faster RT-PCR
runs than the ‘commercial’ mix for the same sensitivity. Gel electrophoresis results
(Figure 4.42 C) confirm the optical data shown in Figure 4.42 A and B.
Next, on-chip experiments were performed varying the residence time inside
the chip. The same initial template concentration, 106 RNA copies/µl, was used
for all the residence time experiments. The optical data for the ‘commercial’ mix,
and ‘custom’ mix are presented in Figure 4.43 A and B respectively. In Figure 4.43
C, a gel electrophoresis including the on-chip RT-qPCR amplicons is shown.
Comparing the amplification curves for 50 min residence time for the two mas-
ter mixes, the CT for the ‘commercial’ and ‘custom’ mixes are identical. When
decreasing the residence time to 40 min, the CT for the ‘custom’ mix does not vary
respect to the CT at 50 min residence time; however, in the case of the ‘commer-
cial’ mix, the CT increases considerably. For the ‘custom’ mix at 50 and 40 min
residence time, the DNA-polymerase enzyme performs a full amplification of the
cDNA created by the RT-enzyme. However, for ‘commercial’ mix, the CT shift
can be attributed to insufficient time for the DNA polymerase to achieve full am-
plification (given that the RT-enzyme is the same in both mixes). Thus, for the
‘commercial’ mix, probably the best tradeoff between rapidity and sensitivity is
50 min residence time. These results confirm off-chip results: the ‘commercial’ mix
is unable to perform as well as the ‘custom’ mix in terms of rapid thermal cycling.
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Figure 4.43: EBOV on-chip qPCR results with 106 RNA copies/µl initial template
concentration. Each data curve was normalized with its average baseline from
cycles 4 to 16. A) On-chip qPCR optical detection data for different on-chip
residence time using the ‘commercial’ one-step RT-qPCR master mix. Independent
trials were run for 50 and 40 minutes total on-chip residence times as indicated.
Additionally, a negative control (0 RNA copies/µl) was run for 50 minute residence
time. B) On-chip qPCR optical detection data for different on-chip residence
time using the ‘custom’ one-step qRT-qPCR master mix. Independent trials were
run for 50, 40, 30, 20, and 15 minutes total on-chip residence times as indicated.
Additionally, a negative control (0 RNA copies/µl) was run for 50 minute residence
time. C) Gel electrophoresis of on-chip amplicons (120 bp). Amplicons in Lanes
1 (50 min), 2 (40 min), and 3 (negative control) correspond to on-chip PCR runs
presented in Figure A. Amplicons in Lanes 4 (50 min), 5 (40 min), 6 (30 min), 7
(20 min), 8 (15 min), and 9 (negative control) correspond to on-chip PCR runs
presented in Figure B. Off-chip PCR for 80 min with 104 RNA copies/µl (Lane
10) and 0 RNA copies/µl (Lane 11) are shown for comparison purposes.
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Based on both off-chip and on-chip results, for our application the most promis-
ing enzymatic combination appeared to be the ‘custom’ master mix. To further
explore the maximum speed at which amplification occurs and determine the op-
timal flow-rate for the ‘custom’ mix, more experiments were performed at lower
residence times. The CT for 50 to 30 min residence time curves are very similar
(see Figure 4.43 B), for 20 min residence time the CT shifts to the right by appro-
ximately 6 cycles, and for 15 min residence time no amplification was optically
detected on-chip. Thus, in the case of the ‘custom’ mix, 30 min residence time is
probably the best compromise of sensitivity and speed. Gel electrophoresis results
(Figure 4.43 C) confirm the optical data.
Although the ‘custom’ mix is the most promising master mix, due to its limi-
ted availability, we performed tests to determine the level of detection of the assay
using the ‘commercial’ mix which could be more quickly translated to the market.
LOD experiments were conducted at 50 min residence time to achieve full poly-
merization of all targets. LOD experiments were done with serially diluted EBOV
RNA ranging from 106 to 1 RNA copies/µl by factors of 10. On-chip RT-qPCR
results are presented in Figure 4.44.
The LOD for our on-chip RT-qPCR system using the ‘commercial’ mix and
EBOV as target was 10 RNA copies/µl. As previously commented, it should
be noted that for low template concentrations, such as 100 and especially 10
RNA copies/µl, fluctuations in the optical signal were observed due to stochastic
sampling. When comparing with 80 min-long off-chip RT-qPCR using a commer-
cial machine, the LOD was 10 RNA copies/µl. It is remarkable that our on-chip
RT-qPCR was performed faster than off-chip. Additionally, as previously men-
tioned regarding the PCR chip, the optical measures on-chip were taken from only
approximately 50 nl. The PCR efficiency was 99±6 % as shown if Figure 4.44. This
PCR efficiency is comparable to the efficiencies obtained with off-chip commercial
thermocyclers; a 3.3 threshold cycle shift is observed for 10 fold dilutions of initial
template. For comparison, off-chip LOD results with the same master mix are
presented in Appendix E (Figure E.3). Gel electrophoresis of on-chip amplicons
confirmed the results observed optically. For 100 RNA copies/µl, no band could be
distinguished by gel electrophoresis (Figure 4.44 C Lane 5) although amplification
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Figure 4.44: EBOV 50 min residence time on-chip RT-qPCR results performed
using the ‘commercial’ one-step RT-qPCR master mix. A) On-chip qPCR optical
detection data for serially diluted RNA template. Each data curve was normalized
with its average baseline from cycles 4 to 16. Template concentrations begin at
106 RNA copies/µl and are reduced by one order of magnitude until the final
trial of 1 RNA copy/L. Also included is the negative control (0 RNA copies/µl).
B) On-chip qPCR efficiency graph representing the cycle threshold versus the
initial template concentrations in a logarithmic scale. Dotted lines represent 95 %
confidence interval. The slope is 3.34±0.28 which correspond to a PCR efficiency of
99±6 %. C) Gel electrophoresis of on-chip amplicons (120 bp) with varying levels of
template as shown in (A). Lane 1 has an initial template of 106 RNA copies/µl and
template concentrations are reduced by one order of magnitude until the final trial
of 1 RNA copy/L in Lane 7 and the negative control (0 RNA copies/µl) in Lane 8.
Off-chip PCR results for 80 min are shown in Lane 9 (104 RNA copies/µl), Lane
10 (0 RNA copies/µl), and Lane 11 (104 RNA copies/µl and master mix without
RT-enzyme) for comparison.
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was optically measured; probably the amplicons obtained were under the limit of
detection of gel electrophoresis technique. For 10 RNA copies/µl (Figure 4.44 C
Lane 6) a faint band could be detected, confirming the limit of detection measured
optically on-chip for 50 min residence time using the ‘commercial’ master mix.
Given the equivalent sensitivity obtained for both ‘commercial’ and ‘custom’
mixes for 50 min and 30 min residence times respectively, we believe that a limit
of detection of 10 RNA copies/µl is likely to be achieved for 30 min residence time
using the ‘custom’ made master mix.
Along section 4.5, we demonstrated successful performance of both PCR and
RT-PCR chips. Both bacterial and viral targets were amplified and detected in
real-time with high sensitivity and rapidity.
4.6 Discussion
4.6.1 Comparison with other devices
In this chapter we presented a real-time, quantitative, and continuous-flow PCR
and RT-PCR systems for DNA and RNA-based pathogen detection. Our PCR de-
vice provides quantitative results with high sensitivity and efficiency: 10 copies/µl
were amplified within 20–25 min for both bacterial pathogens with PCR efficien-
cies between 90–100 %. RT-qPCR with a viral pathogen was performed faster
(30 min) than conventional benchtop thermocyclers, with the same sensitivity
(10 RNA copy/µl) and efficiencies between 90–110 %. Faster PCRs and RT-PCRs
were possible (10 min and 20 min respectively) although the sensitivity was re-
duced.
In relationship to other designs and approaches, very few publications describe
devices that combine quantitative detection and continuous-flow PCR. Frey et al.
have reported amplification in 3 min residence with an initial template concen-
tration of 2.2·108 molecules, which is more than 4 orders of magnitude more of
template DNA than we have used in our speed tests.37 Furutani et al. reported
8 min PCR with 4 copies/µl as input DNA.29
To the best of our knowledge, no continuous-flow RT-PCR systems that use
conventional microfluidics and allow real-time detection have been reported in the
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literature. On the one hand, some real-time RT-PCR systems reported use digital
microfluidic technology, which through modifications in the electrical field, trans-
port droplets with PCR reagents through different stations of the chip.70,71 These
assays are very similar to traditional benchtop thermocycler but with smaller vol-
umes; they differ considerably from conventional microfluidics.71,72 On the other
hand, several platforms were reported which rely on conventional microfluidics
to perform RT-PCR but present end-point detection either on-line38,39,73 and off-
line.40,41 Few of these platforms report the sensitivity and maximum flow rate at
which amplification is still observed. Li et al. reported a sensitivity of 6.4·104
copies/µl achieved in approximately 1 h RT-PCR;73 Yamanaka et al. stated a
limit of detection of 5.36·103 copies/µl completed in 15 min.38 Other reported
RT-PCR speeds are 100–120 min40 and 73 min41 (calculated from the published
data). To the best of our knowledge, the continuous-flow RT-PCR system based
on conventional microfluidics reported by Yamanaka et al. is the only one that
reported faster amplification than ours (by 5 min); however, the sensitivity re-
ported is lower and importantly only end-point detection was performed.38 Addi-
tionally, we believe that this is the first time that the PCR efficiency is reported
for continuous-flow PCR and RT-PCR.
It also worth mentioning the emerging isothermal techniques for RNA amplifi-
cation. In contrast with PCR, isothermal systems do not require thermal cycling
facilitating and reducing the costs of their designs, usually based in static chamber
format.74 There are a wide variety of isothermal techniques which differ in terms
of complexity, reaction speed (usually from 30–50 min)75, sensitivity, specificity,
incubation temperatures, etc.; making comparison with PCR challenging.76 When
comparing isothermal techniques to PCR, the main drawback of isothermal tech-
niques is that they are not quantitative, which limits their use in applications that
require quantifying the target such as in viral load determinations.77 Additionally,
isothermal techniques require complex assay optimization (difficult primer design
and buffer optimization, requirement of multiple enzymes, etc.).78
Regarding chip characteristics, our chip has the lowest channel depth (50 µm)
and overall thickness (410 µm) compared to other published chip designs.38–41 In
terms of chip manufacturing, most designs use injection molding which is less
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precise and more expensive than flat or roll-to-roll embossing. No articles were
found that reported prototype or chip cost.29,30,37 From the outset, we constrained
our biological assay by the demands of large-scale manufacturing methods. Mi-
crofluidic channel designs including the aspect ratio and dimensions of features
were selected to be compatible with ultra-precision machine manufacture of the
chip molds and ultimate UV embossing. Optimizing the assay within these pa-
rameters is critical for ultimate translation of any device to the market. As an
example of this process, the channel depth of our device is a mere 50 µm, which
is an appropriate depth for the structure to be produced on a roll-to-roll ultra-
violet embossing process according to companies in this sector63,64 and a private
communication from Dr. Xin Li from Microsharp Innovation. This means that
only 50 nl of sample are monitored within the optical field of view at any time,
which had the potential to make detection difficult. However, the shallow channel
design was necessary for high-fidelity embossing of features in the rapid roll-to-roll
manufacturing process and so we directed our energies into optimizing our optical
system and assay rather than just make deeper channels. Many prototypes of
POC devices developed without much regard for final production constraints fail
to make the translation to the market. The demonstration of a holistic approach
as described here underscores the ability to meet or exceed all the biological goals
of the assay while paving the way for industrial scale production. Some of the next
steps and future challenges include decreasing the size of the surrounding instru-
mentation and include sample pre-treatment to make the system more compact
and easier to operate as POC device, through a standard product development
process. Consequently, costs of the surrounding instrumentation would be sharply
reduced and portability and ease of use increased. We provide here this system as
an example of optimizing the biological task within the constraints and context of
large-scale manufacturing methods.
With respect to the mobile PCR and RT-PCR POC landscape, currently an
increasing number of suppliers of portable, low-cost, quantitative PCR and RT-
PCR systems are entering the market. Prices range from $3,000–$25,000 and most
provide results from 40–60 minutes. Cobas R© Liat (Roche), q16 (PrimerDesign),
and GeneXpertOmni (Cepheid) are just a few of these devices. All are based on
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static chamber models that optimize the heat transfer and portability of standard
thermal cycler design.
Regarding POC tests for Chlamydia trachomatis, most of the test currently
available in the market rely in immunoassays and few are nucleic acid based. Some
examples of antigen-based devices are Clearview R© Chlamydia (Alere), ACON
Chlamydia Rapid Test Device (Acon), Chlamydia Rapid Test (Diagnostics for
the Real World). Although these tests can be performed rapidly with high speci-
ficity (about 99 %), their poor sensitivity (between 20–60 % in most cases), limit
their applicability.79,80 Consequently, nucleic acid based test continue to be the
gold standard for C. trachomatis diagnosis. Some of the previously mentioned
manufacturers, such as Cepheid and Roche, commercialize specific tests for C.
trachomatis and report high sensitivity (90–100 %) and specificity (99–100 %),
although as previously mentioned, the times to results are approximately 1 h.79
The few, if any, POC devices available in the market that combine high sensitivity,
specificity, and rapidity converts these test into a high research priority.81
A similar scenario exists for POC diagnostic tests for diarrheal causative patho-
gens. Some of the previously mentioned manufacturers, such as PrimerDesign,
commercialize tests for E. coli O157:H7. We believe that more tests will be availa-
ble in market soon due to high importance of the identification of the responsible
pathogens to administer a correct treatment and importantly, to avoid the rise of
antibiotic resistant pathogens.
After the 2014–2015 Ebola outbreak, numerous suppliers (including the pre-
vious mentioned ones) developed assays for Ebola virus detection. Some exam-
ples of commercialized assays are FilmArray Biothreat-E (bioMe´rieux), RealStar R©
Filovirus Screen RT-PCR kit 1.0 (Altona Diagnostics), and DoD EZ1 Real-time
RT-PCR Assay (USA Department of Defense).82 The time-to-result for most of
the commercialized EBOV assays is 40–60 min. The usual genes targeted in these
assays encode for RNA-dependent RNA polymerase (L), nucleoprotein (NP), gly-
coprotein (GP), and matrix protein (VP24); with the L gene being one of the best
genetically conserved and the most likely to be valid for future outbreaks.68,69,82–85
Blood plasma is the most common sample used. Typical EBOV viral load in blood
for acutely ill infected patients ranges between 106–103 RNA copies/µl and then
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decreases during the recovering phase until approximately 1 RNA copy/µl,86,87
which is the reported lowest limit of detection of viral RNA in plasma on RT-
PCR assays.87 Most suppliers of Ebola assays reported sensitivities ranging from
10–103 copies/test.
We believe that our continuous-flow device, with its high sensitivity, PCR
efficiency, low price (we anticipate a price of $2,000),67 portability, and rapidity
is in good position to enter this competitive market. It would not only allow
diagnosis but also monitoring the coarse of the diseases. Additionally, the fact that
our platform is open and versatile would facilitate its adaptation to the diagnosis
of new bacterial and RNA viral threats such as Zika or chikungunya viruses.
We consider that the characteristics of our system make it ideal to be exploited
in developing countries. The few medical device industries in developing countries
together with the fact that industries in high-resource settings typical have little
interest in investing in proper need assessment for low-resource countries that
promise a low return on investment, contribute to the lack of appropriate devices
in poor nations. By contributing to better disease diagnosis in developing countries
and as a consequence to better health of their population, poverty is reduced,
economic productivity improved and inequalities between rich and poor countries
are decreased.
4.7 Concluding Remarks
During this chapter we presented a real-time, quantitative, and continuous-flow
PCR and RT-PCR systems for DNA and RNA-based pathogen detection demons-
trating a holistic approach for POC device design. The development of these
systems respond to health research priorities and fulfills several of the medical
device prioritization criteria (criteria 1, 5, 6, 8). These devices will help to reduce
the burden of infectious diseases (criterion 1), and since infectious diseases are
more prevalent in resource-limited settings, these devices will also contribute to
reduce the inequalities around the world (criterion 8). The few devices with similar
characteristics in the market, even though the individual technologies required to
conform the system are well developed, increase the priority of our research (crite-
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ria 5 and 6). Additionally, considering the pathogens selected to demonstrate the
function the system –Chlamydia trachomatis, E. coli O157:H7, and EBOV– crite-
ria 2 and 4, which consider the expected impact of a new test and the availability,
expense, and toxicity of a treatment respectively, are also fulfilled.
We described the development and the improvements made in the PCR and RT-
PCR systems regarding the chip, surrounding instrumentation, and PCR reagents.
More specifically, the chip was improved in terms of materials, chip production,
bonding, and dimensions to achieve a faster and more economic chip production,
and less reagent consumption. The surrounding instrumentation was improved
regarding the microfluidic connections, optical system, and data acquisition in or-
der to allow real-time detection with high sensitivity, accurately, and consistently.
Biological reagents were tested in terms of primers/probe, polymerases, and chip
channel passivation to increase the specificity and speed of the enzymatic reaction
and avoid attachment to the channel walls and thus loss of reagents or nucleic
acids.
The function of the PCR chip was demonstrated with two infectious bacteria,
C. trachomatis and E. coli O157:H7, for which rapid diagnosis would be crucial
for reducing patient morbidity. Successful amplification was obtained for 20 min
residence time with high sensitivity (10 copies/µl) and PCR efficiencies between
90 and 100 % for both pathogens. Faster PCRs were possible although sensitivity
was reduced.
The performance of our RT-PCR system was tested with EBOV. Two one-
step master mixes with different DNA-polymerases were tested and the limit of
detection was determined. Our system performs RT-qPCR faster, with the same
sensitivity (10 RNA copy/µl) and efficiency (90–110 %) compared to conventional
benchtop thermocyclers. Depending on the master mix used, amplification with
high sensitivity was achieved in 30 to 50 min. Faster amplifications were possible
(20 min) with lower sensitivities. Thus, our system achieves faster amplification
than most commercial RT-qPCR platforms and commercialized Ebolavirus detec-
tion assays which typically require 40–60 min.
These successful results with C. trachomatis, E. coli, and EBOV make our
system promising to be used with other DNA and RNA pathogens such as Zika
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or chikungunya viruses. The portability, versatility, rapidity, sensitivity, and low-
cost of our POC diagnostic device make it ideal for remote settings with low
medical infrastructure and for outbreak control in which rapid identification of the
causative pathogen is key to avoid the spread of the infection, and it might save
many lives and aid to reduce inequalities around world.
Bibliography
1. Mabey, D. C. W., Solomon, A. W. & Foster, A. Trachoma. Lancet 362, 223–
9. issn: 1474-547X (2003).
2. Patel, A. L. et al. Prevalence of Chlamydia infection among women visiting
a gynaecology outpatient department: evaluation of an in-house PCR assay
for detection of Chlamydia trachomatis. Annals of clinical microbiology and
antimicrobials 9, 24. issn: 1476-0711 (2010).
3. Manavi, K. A review on infection with Chlamydia trachomatis. Best Practice
& Research Clinical Obstetrics & Gynaecology 20, 941–951. issn: 15216934
(2006).
4. Baud, D. et al. Role of Chlamydia trachomatis in miscarriage. Emerging
Infectious Diseases 17, 1630–1635. issn: 10806040 (2011).
5. World Health Organization. Prevention of Blindness and Visual Impairment:
Trachoma 2016. <http://www.who.int/blindness/causes/trachoma/en/>
(2016).
6. Clerc, O & Greub, G. Routine use of point-of-care tests: usefulness and appli-
cation in clinical microbiology. Clinical Microbiology and Infection 16, 1054–
1061. issn: 1198743X (2010).
7. Nguyen, Y & Sperandio, V. Enterohemorrhagic E. coli (EHEC) pathogene-
sis. Frontiers in Cellular and Infection Microbiology 2, 1–7. issn: 2235-2988
(2012).
8. Tarr, P. I., Gordon, C. a. & Chandler, W. L. Shiga-toxin-producing Es-
cherichia coli and haemolytic uraemic syndrome. Lancet 365, 1073–86. issn:
1474-547X (2005).
166
9. Lanata, C. F. et al. Global causes of diarrheal disease mortality in children
<5 years of age: a systematic review. PloS one 8 (ed Sestak, K.) e72788.
issn: 1932-6203 (2013).
10. Walker, C. L. F., Aryee, M. J., Boschi-Pinto, C. & Black, R. E. Estimating
diarrhea mortality among young children in low and middle income countries.
PloS one 7, e29151. issn: 1932-6203 (2012).
11. World Health Organization. Cause-specific mortality estimates for 2000-2012
2014. <http://www.who.int/healthinfo/global burden disease/estimates/
en/index1.html> (2016).
12. Bissonnette, L & Bergeron, M. Diagnosing infectionscurrent and anticipated
technologies for point-of-care diagnostics and home-based testing. Clinical
Microbiology and Infection 16, 1044–1053. issn: 1198743X (2010).
13. Goldwater, P. N. & Bettelheim, K. a. Treatment of enterohemorrhagic Es-
cherichia coli (EHEC) infection and hemolytic uremic syndrome (HUS). BMC
Medicine 10, 12. issn: 1741-7015 (2012).
14. World Health Organization. Ebola virus disease Fact sheet N103 2016. <http:
//www.who.int/mediacentre/factsheets/fs103/en/> (2016).
15. Centers for Disease Control and Prevention. About Ebola Virus Disease 2016.
<http://www.cdc.gov/vhf/ebola/about.html> (2016).
16. Kucharski, A. J. & Edmunds, W. J. Case fatality rate for Ebola virus disease
in West Africa. The Lancet 384, 1260. issn: 1474547X (2014).
17. Park, S., Zhang, Y., Lin, S., Wang, T.-H. & Yang, S. Advances in microfluidic
PCR for point-of-care infectious disease diagnostics. Biotechnology Advances
29, 830–839 (2012).
18. Lee, T. M. H. & Hsing, I. M. DNA-based bioanalytical microsystems for hand-
held device applications. Analytica Chimica Acta 556, 26–37. issn: 00032670
(2006).
19. Mullis, K. et al. Specific enzymatic amplification of DNA in vitro: the poly-
merase chain reaction. 1986. Biotechnology (Reading, Mass.) 24, 17–27. issn:
0740-7378 (1992).
167
20. Zhang, C., Xu, J., Ma, W. & Zheng, W. PCR microfluidic devices for DNA
amplification. Biotechnology Advances 24, 243–284. issn: 07349750 (2006).
21. Northrup, M., Ching, M., White, R. & Watson, R. DNA Amplification in
a Microfabricated Reaction Chamber in Proceedings of the Seventh Interna-
tional Conference on Solid-State Sensors and Actuators (Transducers 93)
(IEEE Proceedings, Yokohama, Japan, 1993), 924–926.
22. Kopp, M. U., Mello, A. J. & Manz, A. Chemical amplification: continuous-
flow PCR on a chip. Science 280, 1046–8. issn: 0036-8075 (1998).
23. Zhang, C. & Xing, D. Miniaturized PCR chips for nucleic acid amplification
and analysis: Latest advances and future trends. Nucleic Acids Research 35,
4223–4237. issn: 03051048 (2007).
24. Heid, C. a., Stevens, J, Livak, K. J. & Williams, P. M. Real time quantitative
PCR. Genome research 6, 986–994. issn: 1088-9051 (1996).
25. Mackay, I. Real-time PCR in the microbiology laboratory. Clinical Microbi-
ology and Infection 10, 190–212. issn: 1198743X (2004).
26. Benson, D. A., Karsch-Mizrachi, I., Lipman, D. J., Ostell, J. & Wheeler, D. L.
GenBank. Nucleic Acids Research 33, 34–38. issn: 03051048 (2005).
27. Obeid, P. J., Christopoulos, T. K., Crabtree, H. J. & Backhouse, C. J. Mi-
crofabricated device for DNA and RNA amplification by continuous-flow
polymerase chain reaction and reverse transcription-polymerase chain reac-
tion with cycle number selection. Analytical Chemistry 75, 288–295. issn:
00032700 (2003).
28. Fukuba, T., Yamamoto, T., Naganuma, T. & Fujii, T. Microfabricated flow-
through device for DNA amplification - Towards in situ gene analysis. Chem-
ical Engineering Journal 101, 151–156. issn: 13858947 (2004).
29. Furutani, S et al. Rapid and highly sensitive detection by a real-time poly-
merase chain reaction using a chip coated with its reagents. Analytical Sci-
ences 30, 569–74 (2014).
168
30. Tachibana, H. et al. On-chip quantitative detection of pathogen genes by
autonomous microfluidic PCR platform. Biosensors and Bioelectronics 74,
725–730. issn: 09565663 (2015).
31. Park, N., Kim, S. & Hahn, J. H. Cylindrical Compact Thermal-Cycling De-
vice for Continuous-Flow Polymerase Chain Reaction. Analytical Chemistry
75, 6029–6033. issn: 00032700 (2003).
32. Curcio, M. & Roeraade, J. Continuous segmented-flow polymerase chain reac-
tion for high-throughput miniaturized DNA amplification. Analytical chem-
istry 75, 1–7. issn: 0003-2700 (2003).
33. West, J et al. Application of magnetohydrodynamic actuation to continuous
flow chemistry. Lab Chip 2, 224–230. issn: 1473-0197 (2002).
34. Liu, J., Enzelberger, M. & Quake, S. A nanoliter rotary device for polymerase
chain reaction. Electrophoresis 23, 1531–1536. issn: 01730835 (2002).
35. Chiou, J., Matsudaira, P., Sonin, A. & Ehrlich, D. A closed-cycle capillary
polymerase chain reaction machine. Analytical Chemistry 73, 2018–2021.
issn: 00032700 (2001).
36. Belgrader, P. et al. A reusable flow-through polymerase chain reaction instru-
ment for the continuous monitoring of infectious biological agents. Analytical
Chemistry 75, 3446–3450. issn: 00032700 (2003).
37. Frey, O., Bonneick, S., Hierlemann, A. & Lichtenberg, J. Autonomous mi-
crofluidic multi-channel chip for real-time PCR with integrated liquid han-
dling. Biomedical Microdevices 9, 711–718. issn: 1387-2176 (2007).
38. Yamanaka, K. et al. Rapid detection for primary screening of influenza A
virus: microfluidic RT-PCR chip and electrochemical DNA sensor. The Ana-
lyst 136, 2064–2068. issn: 0003-2654 (2011).
39. Obeid, P. J. & Christopoulos, T. K. Continuous-flow DNA and RNA ampli-
fication chip combined with laser-induced fluorescence detection. Analytica
Chimica Acta 494, 1–9. issn: 00032670 (2003).
169
40. Hartung, R. et al. Application of an asymmetric helical tube reactor for fast
identification of gene transcripts of pathogenic viruses by micro flow-through
PCR. Biomedical Microdevices 11, 685–692. issn: 1387-2176 (2009).
41. Felbel, J. et al. Technical Concept of a Flow-through Microreactor for In-situ
RT-PCR. Engineering in Life Sciences 8, 68–72. issn: 16180240 (2008).
42. Li, Y., Zhang, C. & Xing, D. Integrated microfluidic reverse transcription-
polymerase chain reaction for rapid detection of food- or waterborne pathogenic
rotavirus. Analytical Biochemistry 415, 87–96. issn: 00032697 (2011).
43. Ren, K., Zhou, J. & Wu, H. Materials for microfluidic chip fabrication. Ac-
counts of Chemical Research 46, 2396–2406. issn: 00014842 (2013).
44. Ren, K., Chen, Y. & Wu, H. New materials for microfluidics in biology.
Current Opinion in Biotechnology 25, 78–85. issn: 09581669 (2014).
45. Worgull, M. Hot Embossing: Theory and Technology of Microreplication (ed
Ramsden, J.) isbn: 9780815515791 (Elsevier, 2009).
46. Shan, X. C. et al. Process study on roll-to-roll ultraviolet (UV) embossing
in 2010 12th Electronics Packaging Technology Conference (2010), 231–235.
isbn: 978-1-4244-8560-4. doi:10.1109/EPTC.2010.5702638.
47. Becker, H. & Heim, U. Hot embossing as a method for the fabrication of
polymer high aspect ratio structures. Sensors and Actuators 83, 130–135.
issn: 09244247 (2000).
48. He, Y., Fu, J.-Z. & Chen, Z.-C. Research on optimization of the hot embossing
process. Journal of Micromechanics and Microengineering 17, 2420–2425.
issn: 0960-1317 (2007).
49. Lee, H. S., Kim, D. S. & Kwon, T. H. UV nano embossing for polymer nano
structures with non-transparent mold insert. Microsystem Technologies 13,
593–599. issn: 0946-7076 (2006).
50. Brecher, C., Baum, C. & Bastuck, T. Comparison of roll-to-roll replication
approaches for microfluidic and optical functions in lab-on-a-chip diagnostic
devices in Proc. SPIE 9320, Microfluidics, BioMEMS, and Medical Microsys-
170
tems XIII (eds Gray, B. L. & Becker, H.) 9320 (2015), 932008. doi:10.1117/
12.2077592.
51. Nezuka, O., Yao, D. & Kim, B. H. Replication of Microstructures by Roll-
to-Roll UV-Curing Embossing. Polymer-Plastics Technology and Engineering
47, 865–873. issn: 0360-2559 (2008).
52. Becker, H & Ga¨rtner, C. Polymer microfabrication methods for microfluidic
analytical applications. Electrophoresis 21, 12–26. issn: 0173-0835 (2000).
53. Do, J. & Ahn, C. H. A polymer lab-on-a-chip for magnetic immunoassay with
on-chip sampling and detection capabilities. Lab on a chip 8, 542–549. issn:
1473-0197 (2008).
54. Nunes, P. S., Ohlsson, P. D., Ordeig, O. & Kutter, J. P. Cyclic olefin poly-
mers: Emerging materials for lab-on-a-chip applications. Microfluidics and
Nanofluidics 9, 145–161. issn: 16134982 (2010).
55. Bhattacharyya, A. & Klapperich, C. M. Thermoplastic microfluidic device
for on-chip purification of nucleic acids for disposable diagnostics. Analytical
Chemistry 78, 788–792. issn: 00032700 (2006).
56. Wallow, T. I. et al. Low-distortion, high-strength bonding of thermoplastic
microfluidic devices employing case-II diffusion-mediated permeant activa-
tion. Lab on a chip 7, 1825–31. issn: 1473-0197 (2007).
57. Paul, D., Pallandre, A., Miserere, S., Weber, J. & Viovy, J. L. Lamination-
based rapid prototyping of microfluidic devices using flexible thermoplastic
substrates. Electrophoresis 28, 1115–1122. issn: 01730835 (2007).
58. Kettner, P, Pelzer, L, Glinsner, T, Farrens, S & Lee, D. New results on plasma
activated bonding of imprinted polymer features for bio MEMS applications.
Journal of Physics: Conference Series 34, 65–71. issn: 1742-6588 (2006).
59. Kricka, L. J. & Wilding, P. Microchip PCR. Analytical and Bioanalytical
Chemistry 377, 820–825. issn: 1618-2642 (2003).
171
60. Jeyachandran, Y. L., Mielczarski, E, Rai, B & Mielczarski, J. A. Quantitative
and Qualitative Evaluation of Adsorption/Desorption of Bovine Serum Albu-
min on Hydrophilic and Hydrophobic Surfaces. Langmuir 25, 11614–11620.
issn: 0743-7463 (2009).
61. Duque, L. et al. Reactions of Plasma-Polymerised Pentafluorophenyl Methacry-
late with Simple Amines. Plasma Processes and Polymers 7, 915–925. issn:
16128850 (2010).
62. Sauer-Budge, A. F. et al. Low cost and manufacturable complete microTAS
for detecting bacteria. Lab on a chip 9, 2803–2810. issn: 1473-0197 (2009).
63. Epigem Ltd. UV embossing 2016. <http://epigem.co.uk/technology/uv-
embossing> (2016).
64. SVG Optronics Co. Ltd. R2R UV nanoimprinting 2016. <http : / / www .
svgoptronics.com> (2016).
65. Ganser, P. Optimization of polymer fabrication techniques for the production
of Lab-on-a-Chip devices PhD thesis (RWTH Aachen University, 2014), 163.
66. Zeon Chemicals. Zeonex: The Gold Standard of High-Purity Plastic 2016.
<http://www.zeonex.com/pharmaceuticals.aspx> (2006).
67. Ferna´ndez-Carballo, B. L. et al. Low-cost, real-time, continuous flow PCR
system for pathogen detection. Biomedical Microdevices 18, 34. issn: 1387-
2176 (2016).
68. Jun, S. R. et al. Ebolavirus comparative genomics. FEMS Microbiology Re-
views 39, 764–778. issn: 15746976 (2015).
69. Silva, R. M., Pratas, D., Castro, L., Pinho, A. J. & Ferreira, P. J.S. G. Three
minimal sequences found in Ebola virus genomes and absent from human
DNA. Bioinformatics 31, 2421–2425. issn: 14602059 (2015).
70. Prakash, R. et al. Multiplex, Quantitative, Reverse Transcription PCR De-
tection of Influenza Viruses Using Droplet Microfluidic Technology. Micro-
machines 6, 63–79. issn: 2072-666X (2014).
71. Kaler, K. & Prakash, R. Droplet Microfluidics for Chip-Based Diagnostics.
Sensors 14, 23283–23306. issn: 1424-8220 (2014).
172
72. Beer, N. R. et al. On-Chip Single-Copy Real-Time Reverse-Transcription
PCR in Isolated Picoliter Droplets. Analytical Chemistry 80, 1854–1858.
issn: 0003-2700 (2008).
73. Li, Y., Zhang, C. & Xing, D. Fast identification of foodborne pathogenic
viruses using continuous-flow reverse transcription-PCR with fluorescence de-
tection. Microfluidics and Nanofluidics 10, 367–380. issn: 16134982 (2011).
74. Asiello, P. J. & Baeumner, A. J. Miniaturized isothermal nucleic acid ampli-
fication, a review. Lab on a chip 11, 1420–1430. issn: 1473-0197 (2011).
75. Ahmad, F. & Hashsham, S. a. Miniaturized nucleic acid amplification systems
for rapid and point-of-care diagnostics: A review. Analytica Chimica Acta
733, 1–15. issn: 00032670 (2012).
76. Niemz, A., Ferguson, T. M. & Boyle, D. S. Point-of-care nucleic acid testing
for infectious diseases. Trends in biotechnology 29, 240–50. issn: 1879-3096
(2011).
77. Tang, Y.-W. & Ou, C.-Y. Past, present and future molecular diagnosis and
characterization of human immunodeficiency virus infections. Emerging Mi-
crobes & Infections 1, e19. issn: 2222-1751 (2012).
78. Yan, L. et al. Isothermal amplified detection of DNA and RNA. Molecular
bioSystems 10, 970–1003. issn: 1742-2051 (2014).
79. Herbst De Cortina, S., Bristow, C. C., Joseph Davey, D. & Klausner, J. D.
A Systematic Review of Point of Care Testing for Chlamydia trachomatis,
Neisseria gonorrhoeae, and Trichomonas vaginalis. Infectious Diseases in Ob-
stetrics and Gynecology 2016. issn: 10980997. doi:10.1155/2016/4386127
(2016).
80. Van der Helm, J. J. et al. Point-of-care test for detection of urogenital chlamy-
dia in women shows low sensitivity. a performance evaluation study in two
clinics in suriname. PLoS ONE 7, 1–7. issn: 19326203 (2012).
81. Mohd Hanafiah, K., Garcia, M. & Anderson, D. Point-of-care testing and
the control of infectious diseases. Biomarkers in medicine 7, 333–47. issn:
1752-0371 (2013).
173
82. Foundation for Innovative New Diagnostics. Situational review of Ebola diag-
nostics and opportunities for rapid improvement tech. rep. (Geneva, 2014).
83. Towner, J. S., Sealy, T. K., Ksiazek, T. G. & Nichol, S. T. HighThroughput
Molecular Detection of Hemorrhagic Fever Virus Threats with Applications
for Outbreak Settings. The Journal of Infectious Diseases 196, S205–S212.
issn: 0022-1899 (2007).
84. Trombley, A. R. et al. Comprehensive panel of real-time TaqMan polymerase
chain reaction assays for detection and absolute quantification of filoviruses,
arenaviruses, and New World hantaviruses. The American journal of tropical
medicine and hygiene 82, 954–60. issn: 1476-1645 (2010).
85. Weidmann, M., Mu¨hlberger, E. & Hufert, F. T. Rapid detection protocol for
filoviruses. Journal of Clinical Virology 30, 94–99. issn: 13866532 (2004).
86. Towner, J. S. et al. Rapid Diagnosis of Ebola Hemorrhagic Fever by Reverse
Transcription-PCR in an Outbreak Setting and Assessment of Patient Viral
Load as a Predictor of Outcome Rapid Diagnosis of Ebola Hemorrhagic Fever
by Reverse Transcription-PCR in an Outbreak Setting an. Journal of Virology
78, 4330–4341. issn: 0022-538X (2004).
87. Kreuels, B. et al. A Case of Severe Ebola Virus Infection Complicated by
Gram-Negative Septicemia. New England Journal of Medicine 371, 2394–
2401. issn: 0028-4793 (2014).
174
Chapter 5
Conclusions
• A holistic approach for Point-of-care (POC) device development, which con-
siders the context, the end-users, the prevalent diseases, and the end goal of
production and implementation of the device, was applied to the develop-
ment of POC diagnostic devices appropriate for low-resource countries.
• Prioritization criteria for POC device development were developed. The
criteria for prioritization considered the impact of a new test on the burden of
disease, the availability and expense of disease treatments, the technological
investment to develop a new device, and the bioethical principles giving
particular attention to the principle of justice.
• A paper chemical dipstick assay was developed which responds to the prioriti-
zation criteria and fulfills the holistic approach for POC device development.
This low-cost diagnostic assay allows detecting biomarkers present in biolo-
gical fluids and was fully produced with domestic inkjet printers and simple
ink preparation recipes.
• The fabrication technique for dipstick assays was tested for the detection of
iodine deficiency. Chemical inks were successfully prepared by adjusting the
physico-chemical properties of the chemical solutions to make them resemble
those of commercial inks and by performing corrosion inhibition studies in
case of potentially corrosive inks. Chemical inks were effectively printed
on paper, and iodine in the same concentrations present in the urine was
detected (20–300 µgI/L). Semi-quantification of the iodine concentration was
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possible and differences between deficient, adequate, and excessive iodine
intake groups were unambiguously discriminated.
• A nucleic acid test was developed which responds to the prioritization crite-
ria and fulfills the holistic approach for POC device development. Low-cost,
continuous-flow, real-time, POC PCR and RT-PCR systems for quantita-
tive detection of DNA and RNA-based pathogens were developed. Both
systems were built around disposable microfluidic chips designed to be pro-
duced industrially by roll-to-roll embossing methods. The improvement of
the system in terms of the chip, surrounding instrumentation, and reagents
for nucleic acid amplification was described. More specifically, the improve-
ments included: (1) the chip in terms of materials, chip production, bonding,
and dimensions to achieve a faster and more economic chip production with
lower reagent consumption; (2) the surrounding instrumentation including
the microfluidic connections, optical system, and data acquisition in order to
allow real-time detection with high sensitivity, accurately, and consistently;
and (3) the biological reagents in terms of primers/probes, polymerases, and
chip channel passivation to increase the specificity and speed of the enzy-
matic reaction and avoid loss of reagents or nucleic acids to the channel
walls.
• The qPCR and RT-qPCR systems were characterized with two infectious
bacteria and one viral target: Chlamydia trachomatis, Escherichia coli O157:-
H7, and Ebola virus (EBOV). Our PCR device provided quantitative results
with high sensitivity and efficiency: 10 DNA copies/µl were amplified within
20–25 min for both bacterial pathogens with PCR efficiencies between 90–
100 %. RT-qPCR with EBOV was performed faster (30 min) than conven-
tional benchtop thermocyclers, with the same sensitivity (10 RNA copy/µl)
and efficiencies between 90–110 %. Faster PCRs and RT-PCRs were possible
(10 min and 20 min respectively) although the sensitivity was reduced.
• Both POC diagnostic assays developed during this thesis are very versatile
and can be applied to a wide variety of biomarkers and infectious pathogens.
They are simple, inexpensive, rapid, sensitive, user-friendly and are appro-
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priate to be used at health clinics in low-resource settings. Both POC assays
presented here have the potential to save many lives and help to reduce
worldwide inequalities.
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Appendix A
Current diagnosis methods used
for the detection of various
infectious diseases
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Table A.1: Current diagnosis methods used for the detection of various infectious
diseases. Adapted from Mabey et al.1
Disease Diagnostic test
Acute respiratory infections Blood/sputum culture
Microscopy
Diarrohoeal diseases
Stool culture
Blood film
Antigen detection (dipstick)Malaria
Antibody detection
Serology (antibody detection)
HIV
CD4+ cell counts and viral load
Sputum microscopy (and culture)
Tuberculosis
Tuberculin skin test
DAT serological field test
Microscopy of spleen or bone marrowVisceral leishmaniasis
Culture of spleen or bone marrow
CATT serological field test
African trypanosomiasis
Blood/CSF microcopy and examination
Onchocerciasis Skin-snip microscopy
Syphilis Serology (antibody detection)
Microscopy
Gonorrhea
Culture
Leprosy Skin smears
Blood film
Lymphatic filariasis
Antigen detection
Schistosomiasis Microscopy of stool/urine
Chagas’ disease Serology (antibody detection)
Dengue Serology (antibody detection)
DAT: Direct agglutination test; CATT: Card agglutination trypanosomiasis test.
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Appendix B
Inkjet printed antibodies
preliminary experiments
Table B.1: Reagents, equipment and software for conducting prelimiary experi-
ments regarding inkjet printed antibodies.
Name Reference Vendor
Reagents
‘Capture’ ab
Rabbit anti-ferritin Ab7332 Abcam
‘Detection’ ab
Goat anti-rabbit Alexa Fluor R© 488 Ab150077 Abcam
Nitrocellulose membrane High-FlowTMPlus 135 Merck Millipore
Equipment
Desktop printer SX420W Seiko Epson
Drop Shape Analysis System DSA100 KRU¨SS GmbH
The methodology and main results obtained regarding printing antibodies on
nitrocellulose paper are described as follows. An antibody ink was prepared con-
taining a low concentration of ‘capture’ antibody to reduce the cost of the test.
2 µg/ml of ‘capture’ antibody in phosphate-buffered saline (PBS) was prepared.
PBS has very similar viscosity and surface tension compared to water. The visco-
sity of the solution was not modified since, as previously stated, viscosities in the
range of water present good jetting performance without adjustments. Regarding
surface tension, Tween-20 was selected to adjust the surface tension instead of
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Triton X-100 because the later could compromise the folding stability of the anti-
body. Different concentrations of Tween-20 were tested (0.05 %, 0.1 %, 1 %, 2 %,
and 10 %(v/v)) and in all cases the superficial tension achieved was 38–40 mN/m.
Given the insignificant differences in surface tension reached with the different
concentrations of surfactant tested, 0.05 %(v/v) Tween-20 was selected and added
to the antibody solution.
Once the ink solution was prepared, it was introduced into a refillable car-
tridge which was previously blocked with blocking buffer (1 % BSA in PBS) for
4 h and then washed with PBS. The antibody ink was printed on nitrocellulose
paper. Since the concentration of antibody ink was low and to ensure that enough
‘capture’ antibody was deposited, the same area of nitrocellulose was printed seve-
ral times (approximately 20 times). Afterwards, printed nitrocellulose paper was
blocked with 0.05 %(w/w) Tween-20 in blocking buffer for 30 min and then dried
out for 3 h.
To test the functionality of the printed antibody, a 0.2 µg/ml in blocking
buffer:PBS 1:1 secondary antibody conjugated to Alexa Fluor R© was used. One
side of nitrocellulose paper was immersed into the ‘detection’ antibody, which
flowed through the nitrocellulose paper through to the other end, where an ab-
sorbent pad was placed. When the fluid with ‘detection’ antibody reached the test
line, where ‘capture’ antibody was immobilized, the ‘detection’ antibody bound.
The rest of the fluid was collected at the absorbent pad. In Figure B.1, the dis-
position of membrane and the components of the assay are shown. By observing
the nitrocellulose paper under a microscope fluorescence filter set, the test line
was detected which confirmed the functionality of the printed antibody. In this
case, ‘IQS’ was printed with ‘capture’ antibody ink and in Figure B.2, fluorescence
detail pictures of the letter ‘Q’ are shown.
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Figure B.1: Schematic drawing of the disposition of the nitrocellulose membrane
and other components of the assay.
Figure B.2: Fluorescence picture detail of the test line of an immunoassay printed
with ‘capture’ antibody and detected with a fluorescent-labeled ‘detection’ anti-
body. ‘IQS’ was printed as capture line and details of the letter ‘Q’ are shown in
the pictures.
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Appendix C
Application oriented advantages
and disadvantages of the different
materials for lab-on-a-chip
microfluidic devices
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Table C.1: Main application oriented advantages and disadvantages of the different
materials for lab-on-a-chip (LOAC) microfluidic devices.1–3
Advantages Disadvantages
Glass/silicon
High thermal stability and conductivity Expensive manufacture
High optical transparency High materials cost
High chemical inertness Impermeability to gases
High solvent compatibility High brittleness
Good mechanical strength
Elastomers (silicon-based elastomers: PDMS)
Enable low-cost prototyping Time consuming manufacture
High optical transparency Inappropriate for mass production
Good chemical inertness Low melting point
Good gas permeability Low solvent compatibility
High elasticity
Thermoplastics
Rapid and inexpensive microfabrication May exhibit autofluorescence
Excellent for commercial production May absorb water
Can be reshaped multiple times May absorb light in the UV range
Broad variety of types May adsorb proteins
Medium-high optical transparency Expensive for prototypic use
Medium-high thermostability Barely permeable to gases
Medium-high solvent compatibility
Good mechanical resistance
Lightweight and disposable
Thermosets
High optical transparency Expensive manufacture
High thermostability Cannot be reshaped once cured
High solvent compatibility
High strength
Hydrogels
Good for cell-culture research Low optical transparency
Biocompatible Low thermostability
High gas permeability
Paper
Simple and economical manufacture Inability to perform in continuous flow
Inexpensive and easy to use Restricted to low temperature
Sensitivity is usually unsatisfactory
Low optical transparency
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Appendix D
Relevant physical properties for
on-chip qPCR assays for the main
thermoplastic materials for
microfluidic applications
Table D.1: Relevant physical properties for on-chip qPCR assays for the main
thermoplastic materials for microfluidic applications (PMMA, PC, COC/COP).
PDMS and glass physical properties are also presented for comparison.1–5
Propertiy Glass PDMS PMMA PC COP/COC
General
Aw [% in 24 h] - >1 0.1–0.5 0.04–0.15 <0.01
Tg [
◦C] 560–1215 -120 110 148 70–180
Thd [
◦C] - 200 90 125 140/170
k [W m−1 K−1] 0.27–5.1 0.15 0.19–0.22 0.19–0.23 0.12–0.15
α [10−6 K−1] 3.3 310 59–101 70 60–70
Optical
τL [%] 92 - 92 88 92
λu [nm] 160–3500 220–1580 430–1600 380–1550 280–1650
Aw = water absorption; Tg = glass transition temperature; Thd = Heat distortion
temperature; k = thermal conductivity; α = thermal expansion coefficient; τL =
light transmittance; λu = usable transmission range.
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Appendix E
Off-chip limit of detection qPCR
amplification results for
C. trachomatis, E. coli O157:H7,
and Ebola virus
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Figure E.1: C. trachomatis off-chip qPCR results.1 A) Off-chip qPCR optical de-
tection data for serially diluted DNA template. Data were normalized by the inter-
nal thermocycler software. Template concentrations begin at 105 DNA copies/µl
and are reduced by one order of magnitude until the final trial of 1 DNA copy/µl.
Also included is the negative control (0 DNA copies/µl). B) Off-chip qPCR effi-
ciency graph representing the cycle threshold versus the initial template concen-
trations in a logarithmic scale. Dotted lines represent 95 % confidence interval.
The slope is 3.38±0.11 which corresponds to a PCR efficiency of 98±2 %. C)
Gel electrophoresis of off-chip amplicons (85 bp) with varying levels of template
as shown in (A). Lane 1 has an initial template of 105 DNA copies/µl and tem-
plate concentrations are reduced by one order of magnitude until the final trial of
1 DNA copy/µl in Lane 6 and the negative control (0 DNA copies/µl) in Lane 7.
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Figure E.2: E. coli O157:H7 off-chip qPCR results.1 A) Off-chip qPCR optical de-
tection data for serially diluted DNA template. Data were normalized by the inter-
nal thermocycler software. Template concentrations begin at 105 DNA copies/µl
and are reduced by one order of magnitude until the final trial of 1 DNA copy/µl.
Also included is the negative control (0 DNA copies/µl). B) Off-chip qPCR effi-
ciency graph representing the cycle threshold versus the initial template concen-
trations in a logarithmic scale. Dotted lines represent 95 % confidence interval.
The slope is 3.56±0.19 which corresponds to a PCR efficiency of 91±3 %. C)
Gel electrophoresis of off-chip amplicons (69 bp) with varying levels of template
as shown in (A). Lane 1 has an initial template of 105 DNA copies/µl and tem-
plate concentrations are reduced by one order of magnitude until the final trial of
1 DNA copy/µl in Lane 6 and the negative control (0 DNA copies/µl) in Lane 7.
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Figure E.3: EBOV 80 minutes off-chip qPCR results performed using the ‘com-
mercial’ one-step qRT-PCR master mix. A) Off-chip RT-qPCR optical detection
data for serially diluted RNA template. Data were normalized by the internal
thermocycler software. Template concentrations begin at 106 RNA copies/µl and
are reduced by one order of magnitude until the final trial of 1 RNA copy/µl.
Also included is a negative control with 0 RNA copies/µl and a negative control
with 104 RNA copies/µl and no RT-enzyme. B) Off-chip qPCR efficiency graph
representing the cycle threshold versus the initial template concentrations in a
logarithmic scale. Dotted lines represent 95 % confidence interval. The slope is
3.18±0.12 which corresponds to a PCR efficiency of 106±3 %. C) Gel electrophore-
sis of off-chip amplicons (120 bp) with varying levels of template as shown in (A).
Lane 1 has an initial template of 106 RNA copies/µl and template concentrations
are reduced by one order of magnitude until the final trial of 1 RNA copy/µl in
Lane 7. Two negative controls with 0 RNA copies/µl and 104 RNA copies/µl and
master mix without RT-enzyme are included in Lanes 8 and 9 respectively.
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